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Lung cancer is the leading cause of cancer-related deaths in the United States with 
a 5-year survival rate of only 18%. Differences in access to care and treatment utilization 
may play a role in observed survival disparities among rural patient populations. This 
dissertation aimed to examine rural disparities in all-cause and lung-cancer specific 
survival, time to treatment initiation, and utilization of surgical treatment among non-
small cell lung cancer cases.  
 
We utilized comprehensive cancer registry data from the Surveillance, 
Epidemiology, and End Results program linked with Medicare billing claims (SEER-
Medicare) for non-small cell lung cancer (NSCLC) patients diagnosed between 2003-
2011. We compared differences in all-cause survival and lung cancer-specific survival 
based on urban and rural residence while controlling for demographic and clinical 
characteristics of patients. We examined differences in the time between diagnosis and 
treatment initiation for urban and rural NSCLC patients and furthermore the impact of 
time to treatment on survival. We also implemented multilevel modeling techniques to 
assess the associations of county-level neighborhood and patient-level demographic and 




Our results showed that rural NSCLC patients had worse all-cause and lung 
cancer-specific survival than their urban counterparts. Our adjusted Cox PH model results 
found that differences in the time between diagnosis and treatment initiation may not 
contribute to rural disparities in lung cancer survival. However, utilization of surgical 
treatment at any time point was related with high survival probability. More than 50% of 
the patients who received surgery survived longer than 5 years following diagnosis. 
When examining differences in surgical utilization, factors related to decreased 
likelihood of surgical treatment for lung cancer included living in higher poverty 
counties, enrollment in Medicaid, and black race. When controlling for county-level 
poverty and patient characteristics, rurality was not significantly related to differences in 
surgical utilization among NSCLC patients.  
 
This dissertation identified persisting rural disparities in all-cause and lung 
cancer-specific survival in the United States. Observed rural disparities may be due to 
sociodemographic factors more common among rural cancer patients such as public 
insurance or being uninsured, and low incomes. In concordance with previous research, 
black NSCLC patients were also less likely than white patients to receive surgical 
treatment. Targeted interventions are needed to improve lung cancer survival in rural, low 
income, and black patient populations, particularly focusing on improving utilization of 
surgical treatment in early-stage cases among these groups.  
 
Keywords: Non-small cell lung cancer, lung cancer survival, survival analysis, multilevel 
modeling, health disparities  
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Among all cancer types, lung cancer is the leading cause of cancer-related death 
in the United States (U.S.), for both men and women, killing approximately 156,000 
people in 2017.1 In comparison, an estimated 134,000 people died from the next three 
deadliest cancers combined (colorectal, pancreatic, breast) in the same year.1 The 
American Cancer Society estimates that there will be 234,030 newly diagnosed cases of 
lung cancer in 2018, making up 13% of the total cancer cases in the U.S.,2 creating a 
financial burden of over $12.12 billion for treatment costs.3 Lung cancer survival varies 
depending on patient and environmental factors such as stage at diagnosis, smoking 
history, treatment approaches, and access to care. Such factors differ by racial and ethnic 
groups, sex, rurality, and geographic region, creating observed disparities in lung cancer 
survival.  
 
Black and Native American populations have the highest lung cancer-specific 
mortality rates when compared to all other racial and ethnic groups.4–7 The causes of 
these racial disparities are complex and multifactorial, including differences in access to 
care and risk factors for lung cancer. Existing data points to distrust of the medical 
community, perceived discrimination, and a predominately white medical workforce as 
possible contributing factors.4,8,9 Black lung cancer cases are also diagnosed at later 
stages and less likely to receive surgery than white cases (even in early stages).4–6,10–13 
2 
Similarly, black and Native American cases are less likely to receive smoking cessation 
counseling (a crucial component of lung cancer prevention) and more likely to be 
diagnosed with lung cancer at late stages than whites.7,14–18 In contrast, Hispanic and 
Asian American lung cancer patients have longer survival times that whites.4   
 
A sex disparity in survival from lung cancer has been observed with men having 
shorter survival than women.19–22 Historically, the population of lung cancer patients in 
the US has been predominately male, though the proportion of female cases has increased 
in recent years with incident cases in 2017 being 52.5% male and 47.5% female.2,12 
While the incidence of large cell and squamous cell lung cancers has decreased over time 
for both men and women, adenocarcinoma incidence rates in men have remained steady 
and increased among women.12 In fact, higher overall lung cancer incidence rates among 
women than men were observed for those born between 1965-1980.23 The smoking 
prevalence among women in this age group was higher than their predecessors but lower 
than the smoking prevalence in men of the same age and does not fully account for the 
observed increase in the incidence rates.23 Sex differences in lung cancer incidence and 
survival need to be examined continuously in the future.  
 
In the U.S., rural residents have a higher smoking prevalence, higher overall 
incidence rates of lung cancer, and higher rates of late-stage lung cancer diagnoses than 
urban residents.24–27 When examining lung cancer mortality rates from 1999-2016 by 
region and rurality, the highest mortality rates existed in the rural South at 63.0 per 
100,000 population.28 Rural residents with lung cancer are also less likely to receive 
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treatment than urban residents with lung cancer.29 Late-stage diagnoses and limited 
treatment options for late-stage cases are contributing factors to the higher observed 
mortality rates for rural Americans with lung cancer.29 Combined with the sheer disease 
burden, rural residents also face higher poverty rates, lower education, and a higher 
proportion of uninsured and elderly adults than urban residents.30,31   
 
Early detection is integral in improving survival from lung cancer.32 Over 65% of 
lung cancer cases are diagnosed in stage III or IV.33 When detected at stages I and II, the 
survival rate for lung cancer is 54%, and when detected after metastasis to other organs, 
the survival rate drops to 4%.2,34 Annual screening by low-dose computed tomography 
(LDCT) for patients deemed high risk for lung cancer began being covered by most 
private health insurance providers and Medicare in 2015.35 In randomized clinical trials, 
LDCT screening among high-risk individuals was shown to reduce the risk of lung 
cancer death by 20-40%, providing a promising avenue to improving survival rates for 
smoking-related lung cancers in the future.36–38 Equal access to LDCT screening centers 
among rural residents of the screening-eligible population needs to be prioritized to close 
the gaps in disparities in early detection of lung cancer.39,40  
 
Regional differences in lung cancer survival exist as well.41–44 Southeastern states 
have the highest mortality-to-incidence ratios for lung cancer.42 Disparities in accessing 
care for rural and black populations are most pronounced in the South where smoking 
prevalence, lung cancer incidence rates, and poverty are also the highest in the nation.31,45 
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The largest proportion of the lung cancer screening-eligible population also resides in the 
South.39  
 
1.1 Statement of the Problem  
First, the goal of this research was to identify existing disparities in lung cancer 
outcomes (i.e., survival and treatment utilization) among persons of different racial/ethnic 
backgrounds, sex, rurality, and geographic locations. Identifying persistent (or 
increasing) disparities may aid in the development of targeted public health interventions 
and policies for at-risk populations or regions. While lung cancer incidence and mortality 
rates among black and Native American races and rural residents are higher in 
comparison to their white and urban counterparts, estimates of these disparities need 
updating. The available data is largely based on non-generalizable datasets (e.g., single 
state cancer registries, single health care system), restricted to rare types of lung cancer 
(e.g., small cell lung cancer), data from the early 1990s to early 2000s, or survival not 
adjusted by race, sex, and/or rurality in modeling approaches.11,46 Lung cancer survival 
data is highly cited in the field but is based on data from as far back as 1991 with the 
most recent publications utilizing data on non-small cell lung cancer only up to 2006.6,47–
53 We anticipate that our results will be highly cited data on lung cancer survival.  
 
Second, significant changes have been made in the prevention and control of lung 
cancer in recent years with respect to lung cancer screening guidelines, tobacco control 
policies, declining smoking rates, genetic testing availability, oncology telemedicine 
(teleoncology), pharmaceutical development, and personalized/precision medicine. 
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Screening reduces mortality via early detection, while tobacco control and declining 
smoking prevalence have driven down lung cancer incidence.54–56 Enhanced treatment 
approaches including genetic testing, teleoncology, evolving first-line drugs, and 
personalized medicine improve survival and expansion of these treatment approaches 
have the potential to change the disease progression.57–59 Improved health insurance 
coverage through the Affordable Care Act (ACA) may also play a role in closing gaps in 
survival disparities between black and white populations. The percentage of black adults 
without health insurance decreased from 21% to 11% from 2010 to 2015.60 A reference 
point for lung cancer survival among different racial groups is needed as we move into 
this new era to measure the impact, if any, that new screening and treatment efforts may 
have on the survival of lung cancer patients at the population-level. 
 
Third, continuing expansion of rural oncology providers and early detection of 
lung cancer via annual LDCT screening provide possible avenues for reducing rural and 
racial disparities. The results of this project allow for monitoring of temporal changes in 
disparities when compared with results from earlier cohorts from SEER-Medicare data. 
Additionally, the National Cancer Institute’s (NCI) stated research emphasis areas 
currently includes a focus on health disparities and rural cancer control current research.61 
This work contributes to their research agenda61 by identifying geographic areas of high 
need or disparities among rural populations, providing formative data needed to develop 




1.2 Aims and Hypotheses  
To address these known gaps in the field, we implemented a comprehensive 
registry and claims-based analysis of lung cancer patients in the U.S. using the existing 
2003-2011 SEER-Medicare database for all aims. Specifically, we: 
 
Aim 1: Investigated disparities in lung cancer-specific and all cause survival by 
race/ethnicity, sex, and geography and identify patient-level and county-level factors 
associated with survival 
Hypothesis 1a: We hypothesized that lung cancer survival and overall survival would be 
lower among black and Native American races vs. whites, men vs. women, and rural vs. 
urban residence.  
Hypothesis 1b: We further hypothesized that these disparities would be most pronounced 
in the South Census region (SEER locations in Louisiana, Kentucky, Georgia). 
Methods: We used Cox Proportional Hazards models for primary lung cancer cases  
  
Aim 2:  Examined differences in lung cancer-specific survival at differing thresholds 
of treatment initiation  
Hypothesis 2: We hypothesized that lung cancer survival would be highest among those 
initiating treatment within 4 weeks of diagnosis.  
Methods: We used three time dependent and stratified Cox Proportional Hazards models, 
one for each treatment type (surgery, chemotherapy, radiation), comparing survival of 
those (with the same stage at diagnosis) initiating treatment after diagnosis at five 
7 
differing thresholds: 4 weeks or less, 5-6 weeks, 7-9 weeks, 9-12 weeks, greater than 12 
weeks. 
 
Aim 3: Explored disparities in utilization of lung cancer surgical treatment and 
related patient and county predictors among lung cancer patients  
Hypothesis 3a: We hypothesized that county-level factors would impact surgical 
treatment utilization among lung cancer patients 
Hypothesis 3b: We further hypothesized that Medicaid enrollees (low income) and black 
patients would be less likely to receive surgery when compared to those not on Medicaid 
and white patients 
Methods: We performed a multilevel logistic regression examining patient factors nested 
within counties (and county-level factors) associated with utilization of surgical treatment 
for lung cancer  
 
1.3 Significance and Rationale  
The goals of this project were to identify potential disparities in lung cancer 
survival along with access, utilization, and timely receipt of treatment for lung cancer. 
There is currently no standard guideline for appropriate time intervals between the data of 
diagnosis and treatment initiation for the of lung cancer. Time may play a role in lung 
cancer survival as lung cancer is an aggressive disease that metastasizes to other organs. 
Differences in time to treatment initiation may be an important mechanism driving 
observed disparities in lung cancer mortality, especially among black and Native 
American races, and rural residents. Empirically based guidelines for timeliness of 
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treatment could provide a valuable measure for patients interested in seeking second 
opinions or for those concerned about time delays in scheduling required appointments 
following initial diagnosis.   
 
A better understanding of disparities in survival and access to surgical cancer 
treatment is a crucial step in improving lung cancer survival. Patient race/ethnicity, sex, 
and residential location impacts the course of cancer treatment received.4–6,11,13,62 Our 
results provide insight necessary to develop targeted interventions aimed at improving 
access to treatment and survival of lung cancer by identifying areas with the greatest need 
of expanded healthcare services, including but not limited to teleoncology, mobile LDCT 
screening units, and hospital partnerships (e.g., local tumor boards, physician sharing 
arrangements). This also lays the groundwork for potential interventions aimed at 
advancing patient navigation for racial minorities or rural patients, patient education 
initiatives improving surgical acceptance among black and Native American patients, as 
well as physician education on discrimination, bias, and cultivating trusting relationships 
with patients.  
 
Race and ethnicity, rurality, and region may be social determinants of patient 
experience in navigating cancer care, influencing potential differences in survival rates. 
Residents of rural counties may have longer travel times to cancer treatment facilities and 
decreased likelihood of receiving care from specialist physicians, such as thoracic 
surgeons. This could contribute to differences observed in urban and rural outcomes as 
utilization of surgical treatment can greatly improve survival among early stage cases. 
9 
Our examination of urban-rural differences in timely treatment and lung cancer survival 
also provides insight into how space and place impact receipt of healthcare. Examining 
factors for potential intervention is imperative in addressing the multifaceted mechanisms 
driving healthcare decisions. The growing focus by federal agencies on multilevel 
intervention research points to the importance of researching various sources of impact 
on patient outcomes. Projects such as ours, which help pinpoint predictors of survival, the 
timeliness of cancer treatment, and the utilization of surgical treatment open the door for 
future changes to health care policy and interventions aimed at improving equity to 







This chapter provides a brief overview of the existing data related to lung cancer 
survival including environmental exposures, histology, disease staging, treatment types 
and timeliness, cancer treatment centers and patient characteristics (e.g., race/ethnicity, 
sex, rurality, and residential location). An understanding of lung cancer history, causes, 
treatment, and related disparities is crucial to comprehension of the evolving landscape of 
the disease. 
 
2.1 Epidemiology of Lung Cancer 
Several environmental exposures have been directly linked to lung cancer through 
epidemiologic research dating back to the 1950s.56 Lung cancer incidence in the U.S. 
began increasing in the 20th century with increased popularity and mass production of 
cigarettes containing addictive materials, particularly nicotine. In the 1950s, U.S. and 
British researchers published numerous studies demonstrating a probable link between 
cigarette smoking and lung cancer.63–73 Subsequently in 1964, the U.S. Surgeon 
General’s Advisory committee released a report compiling the existing evidence warning 
that smoking causes lung cancer, citing retrospective studies with relative risks ranging in 
magnitude from 2.0 to 25.5 for the relationship of smoking and lung cancer. Since that 
report, tobacco smoke has emerged as the most profound factor impacting lung cancer 
incidence and premature death, with an estimated 80-90% of cases directly attributed to 
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active smoking and second-hand smoke exposure.74 Despite this, approximately 40 
million Americans currently smoke.75 Time trends in the occurrence of lung cancer 
closely follow smoking prevalence rates. Lung cancer mortality peaked among men in 
approximately 1990 at 70 cases per 100,000 population and has since decreased every 
year, closely tracking with declining smoking prevalence.55,56,76,77 Relatively high 
smoking prevalence among black adults, men, residents of rural areas, and in the South 
drive high lung cancer incidence and mortality in these populations.60,75,78  
 
Approximately 10-20% of lung cancer cases are not linked to smoking.79,80 
Chemical exposures such as radon, asbestos, nickel, and chromates are also strongly 
linked to lung cancer.56,81,82 In 1970, asbestos was recognized as a hazardous chemical 
and thus began being regulated by the Environmental Protection Agency (EPA). Radon, 
the second leading cause of lung cancer, was first linked to lung cancer in mine workers 
in 1989, the same year that the EPA issued a full ban on asbestos use.56,82 Moreover, high 
levels of arsenic exposure are established as causing lung, liver, kidney, prostate, and 
bladder cancer.82 Additional lung cancer risk factors include outdoor air pollution, 
occupational smoke inhalation (e.g., firefighters) and smoke inhalation from cooking on 
an open fire.56,83 Rarely, lung cancer occurs in those with no smoking history and no 
known exposures to chemicals or smoke. These cases are often attributed to genetic 
mutations or possibly unidentified environmental exposures.56,79,80  
 
2.2 Low Dose Computed Tomography (LDCT) Screening 
Annual LDCT screening significantly reduces lung cancer mortality by 20-40%.54 
Following the National Lung Screening Trial in 2011, national organizations including 
12 
 
the U.S. Preventive Services Task Force (USPSTF) and the American Cancer Society 
released recommendations for annual LDCT screening to individuals at high risk for lung 
cancer.54,84–86 Although eligibility criteria vary by organization, the USPSTF classifies 
high risk individuals as current and former smokers who quit within the last 15 years, 
persons aged 55 to 80 years, and those with 30+ pack-years smoking history.35,84,87 
Medicare began covering LDCT screening for high risk individuals (including a shared 
decision-making visit with a qualified health care provider) in 2015.35 Although LDCT 
screening for lung cancer increased from 3.3% in 2010 to 3.9% in 2015 following the 
publication of the NLST results in 2011 and updated USPSTF recommendations in 2013, 
national LDCT screening rates remain very low.88,89 Screening utilization significantly 
varies by region with the highest utilization in Northeast (10.1%) compared to the 
Midwest (2.2%), the South (3.5%), and the West (1.6%).39  Utilization does not mirror 
the size of the LDCT screening eligible population, as the largest proportion of those 
eligible (40.3%) resides in the South.39 
 
Many factors contribute to low screening rates. Screening eligible smokers are 
less likely to have a usual source of care than the general population and therefore less 
likely to be referred for LDCT screening.90 However, eligible individuals who are 
identified as smokers and have a usual health care provider appear to miss opportunities 
to learn about LDCT screening from their healthcare providers. Previous research has 
reported both physician barriers,91–93 and patient factors contribute to these missed 
opportunities. For example, patients who smoke have reported barriers in discussing lung 
cancer screening with their health care providers due to feelings of discrimination based 
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on their smoking history.94,95 Furthermore, patients eligible for screening with 
comorbidities may experience more harm than benefit, thus motivating the patient and 
physician to decide against screening during a shared decision-making counseling 
session.94 Screening among high-risk populations provides an opportunity to diagnosis 
more cases at early stages. More research is needed to understand and improve low 
screening utilization in an effort to further improve lung cancer survival.  
 
2.3 Histology and Staging 
Lung cancer histology and staging are associated with survival, as both play 
prominent roles in defining the clinical characteristics of a case and choosing the 
appropriate treatment approach following a lung cancer diagnosis. Lung cancer histology 
is divided into two categories: non-small cell lung cancer (NSCLC) and small cell lung 
cancer (SCLC). NSCLC accounts for 85-90% of all cases and includes three subtypes: 
large cell, adenocarcinomas and squamous cell carcinomas.12 Adenocarcinoma is the 
most common histologic type and is the most common type among never smokers.96 The 
remaining 10-15% are SCLC, which is almost exclusively observed among smokers and 
former smokers. SCLC is considered the most aggressive form of lung cancer since it is 
the least responsive to chemotherapy.97 Small cell, squamous cell, and large cell 
incidence rates have decreased over time while the incidence of adenocarcinomas has 
increased in women and remained constant among men.12,98  
 
The American Joint Committee on Cancer defines lung cancer stages 0-IV by 
three combined categories, referred to as TNM classifications, including: primary tumor 
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size (TX, T0-T4), regional lymph node involvement (NX, N0-N3), and distant metastasis 
(M0, M1, M1a, M1b).99 Tumor size (T score) defines the greatest dimension in 
centimeters and the physical location of the primary tumor.99 Determining the 
involvement of lymph nodes (N score) has been cited as the most important piece to 
staging the disease and determining the proper course of treatment.100 Conversely, 
improper nodal detection can lead to treatment failure and decreased survival.101 Nodal 
involvement can be determined through various methods (invasive/surgical approaches or 
non-invasive scans: CT or PET).100 Surgical systematic nodal sampling is preferred by 
the American College of Chest Physicians, with a detection rate almost twice that of 
surgical selective sampling of lymph nodes and non-invasive scans.102 Cases with 
metastasis (M1, M1a, M1b) are defined as Stage IV. Approximately 40% of lung cancer 
cases are diagnosed with stage IV disease, with a 5-year survival rate between 0-
10%.99,103   
 
2.4 Treatment Options 
Treatment approaches for lung cancer are highly variable depending on histologic 
type, stage at diagnosis, genetic profile, overall health of a patient, and location of 
cancerous nodule(s). Cancer-directed treatment is defined as any treatment approach 
intended to control, remove, or destroy cancer cells in the body.104 Cancer-directed 
treatment approaches may include surgery to resect the tumor, chemotherapy, radiation, 
immunotherapy, or a combination of all four. Non-cancer-directed therapies are given for 
clinical reasons such as pain management, nutrition supplementation, and diagnostic 
tests. Cancer registries are required to differentiate between cancer-directed and non-
15 
 
cancer-directed treatments in patient records. For this project, we only considered the use 
of cancer-directed treatment.  
 
In otherwise healthy adults diagnosed with lung cancer before metastasis, surgery 
is the most effective treatment approach to improve survival.100 Staging, tumor size, 
tumor location(s), and patient comorbidities (i.e., medical operability) are collectively 
considered when determining if surgical resection is appropriate and is often reserved for 
patients diagnosed in early stages.100,105 Surgery to remove tumors from the lungs can be 
complex, depending on the location of the nodules in proximity to crucial blood vessels 
and surrounding organs.100   
 
Lung resection for the treatment of lung cancer may be performed in various ways 
(e.g., lobectomy, sleeve lobectomy, or pneumonectomy) through a traditional open 
approach or via minimally invasive thoracic surgery (MITS), which includes video-
assisted thoracic surgery (VATS) or robotic VATS (RVATS).100,106 Lobectomy (removal 
of a lobe of the lung) is the preferred surgical approach for the surgical management of 
lung cancer, recommended by the American College of Surgeons due to the lower rates 
of tumor recurrence and longer survival in comparison to the use of segmentectomy 
(removal of a segment of a lung lobe).100 Patient outcomes further improve when 
lobectomy is performed by MITS rather than by an open surgical approach.106–108 In fact, 
research has demonstrated increased 5-year survival, shorter hospital stays, better post-
operative pulmonary function, and lower reported levels of pain in comparison to open 
surgical approaches.106–108 Despite these advantages, MITS approaches have not been 
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adopted uniformly as the standard approach to lung resection.109 Thoracic surgeons have 
been shown to adopt recommended surgical guidelines more readily than general 
surgeons and have better patient outcomes including improved survival.110,111 However, 
thoracic surgeons are not widely accessible in rural areas, potentially resulting in unequal 
access to high-quality surgery for early-stage lung cancer cases.112,113 
 
In late-stage cases and/or people with poor health, surgery may not be an option. 
Hence, chemotherapy and/or radiation is the next best treatment approach. Depending on 
the stage at diagnosis, chemotherapy for lung cancer can be given prior to surgery, after 
surgery (adjuvant therapy), or at the same time as radiation treatment (concurrent 
therapy). Most patients receive a combination of two chemotherapy drugs given in cycles 
lasting one to three days, with breaks in between over a three to four-week period.87 All 
chemotherapy drugs recommended for use in the treatment of NSCLC are included in 
Appendix A of this document.114  
 
In the same way as chemotherapy, radiation may be given before surgery, after 
surgery, and in some cases alone.87 Radiation prior to surgery is often an attempt to 
shrink tumors to make them easier to remove. Radiation alone may be recommended for 
late-stage patients as a palliative care approach. The two main types of radiation for the 
treatment of NSCLC are external beam radiation therapy and brachytherapy (also 
referred to as internal radiation therapy). Subtypes of external beam radiation therapy are 
three-dimensional conformal radiation therapy (3D-CRT), intensity modulated radiation 
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therapy (IMRT), and stereotactic body radiation therapy (SBRT).87,115 Radiation therapy 
is often given five days a week for up to seven weeks.  
 
Lung cancer treatment is constantly evolving through the development of new 
medications, novel genetic testing techniques, and advanced treatment protocols from 
clinical trials. Immunotherapy drugs work to stimulate the immune system to destroy 
cancer cells and can be given along with, after, or in place of chemotherapy. The first 
immunotherapy drug for NSCLC, Opdivo, was approved in 2015 followed by Keytruda, 
Tecentriq, and Imfinzi.116 Targeted therapy drugs are commonly used for late-stage 
patients and are coupled with genetic testing to pinpoint when they are appropriate for 
each patient. These drugs work to inhibit tumor development differently than 
chemotherapy drugs through processes such as altering proteins, hindering chemical 
signals, and blocking blood vessel production in tumors. In 2018 there were ten FDA 
approved targeted treatments.114,117 Epidermal growth factor receptor (EGFR) mutation 
testing was the first approved in 2013 following recommendations by the National 
Comprehensive Cancer Network for EGRF testing for late-stage NSCLC patients in 
2007.118 However, disparities may exist in the use of targeted therapies. An examination 
of utilization of EGFR testing from 2011-2013 found it was being underutilized in all 
practice settings and most commonly performed in urban areas and among Asians. On the 
contrary, Medicaid recipients, Hispanics and black cases were the least likely groups to 
be tested, potentially leading to missed opportunities for use of targeted therapies and 
improved treatment outcomes for these populations.118  
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Clinical trials provide opportunities to understand the efficacy of new treatment 
approaches. Clinical trials are sometimes considered a last option in survival for late-
stage lung cancer patients when approved treatment options have failed or are not 
considered appropriate. In December 2018, there were 149 NIH funded clinical trials 
active in the U.S. focusing on innovative approaches to lung cancer treatment.119 
However, it may be difficult for all eligible patients to access clinical trial locations. The 
NCI and FDA have acknowledged the underrepresentation of racial minorities and rural 
residents in past clinical trials.120,121 New initiatives such as the National Community 
Oncology Research Program sponsored by NCI focus on bringing more clinical and 
intervention trials to diverse communities serving minority and rural patients at local 
community-based hospitals.121  
 
2.5 Time to treatment initiation 
Choosing the appropriate treatment approach varies depending on patient 
characteristics and provider tendencies, which can impact the time between diagnosis and 
treatment initiation. An appropriate time interval between diagnosis and treatment 
initiation is defined as timely treatment and is one of six domains of health care quality 
recommended by the Institute of Medicine.122 However, optimal timing of treatment 
initiation and the impact of timely treatment on lung cancer survival is not well 
defined.123–126 Recommendations from agencies such as the American Cancer Society 
and American Lung Association suggest starting treatment “very soon” or “within a few 
weeks” after a cancer diagnosis. These vague recommendations ideally could be more 
precise.123 Because a cancer diagnosis can cause anxiety and depression that delay patient 
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action to seek immediate follow-up care and plan a course of treatment, clearly defined 
recommendations for timely treatment are needed to encourage prompt delivery of 
guideline-concordant treatment. 
 
2.6 Factors driving treatment delays 
Previous research has reported multiple factors driving delays in treatment 
including medical system processes, patient comorbidities, stage at diagnosis, and 
diagnostic testing approaches. Medical system processes, including long referral periods, 
have contributed to treatment delays in early-stage patients diagnosed in community 
settings127 and time spent scheduling PET scans contributed to treatment delays in a 
diverse population of Medicare patients.124 In a single health system in Texas, patients 
treated at public hospitals experienced longer delays in treatment than those treated in 
private hospitals (76 days vs. 45 days, p<0.01.128 Among a sample of veterans, the 
median time to surgery was 98 days and waiting for smoking cessation significantly 
delayed treatment for almost a third of the study sample (29%).125 In this same 
population, time spent on evaluation and staging (a median wait time of 71 days for 
scans) also contributed to delays in treatment.125 Missed diagnoses was reported as 
causing delays in patient interviews from cancer centers, outpatient settings, and 
community treatment centers.125,127,129 Late-stage diagnosis (versus early-stage) and 
treatment in non-academic settings versus a VA hospital have been associated with 
improved timely treatment in some studies.130,131 However, treatment for late-stage 
disease at academic centers was associated with delays in a diverse population of patients 
from the National Cancer Data Base as were urban location, having an income less than 
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$35,000 and increasing Charlson comorbidity scores were all associated with delays in 
treatment.132  
 
2.7 Timely treatment and survival  
Timely treatment and its association with lung cancer survival is not well 
understood. Publications on the topic have used a range of definitions for treatment itself 
(surgery, chemotherapy, or radiation) and timely treatment (e.g., median time from study 
sample, arbitrarily 6 weeks). Few studies have identified a positive association between 
timely treatment and improved survival in lung cancer patients. A study of early-stage 
lung cancer patients at John Hopkins cancer center reported an average referral time of 
61.2 days following diagnosis. They found that increasing weeks from diagnosis to first 
surgery (measured continuously) predicted worse survival (HR=1.04, 95%CI:1.00-
1.09).127 However, these results were not statistically significant after adjusting for 
patient demographics and clinical factors. Findings from a 12-year sample of stage I 
patients from the National Cancer Database found that surgery initiation before 8 weeks 
post-diagnosis resulted in significantly higher survival rates.132 Similarly, a review among 
Medicare patients found a median time-to-treatment of 27 days. In early-stage cases, 
treatment initiation within 35 days was associated with improved survival. There was no 
association between treatment time and survival for distant-stage cases.124 
 
Others have reported conflicting findings, showing worse survival or no 
association between timely treatment and lung cancer. In a small sample of veterans 
(n=129) from a single health care system, the median time to treatment was longer than 
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that reported in other settings at 84 days.133 They defined timely treatment as less than the 
median, 84 days, and found that patients receiving timely treatment were more likely to 
die than patients receiving care after 84 days (HR=1.6, 95%CI: 1.3-1.9). After stratifying 
by severity, the results were not significantly different.133 A study of privately insured 
lung cancer patients in South Carolina found patients who received treatment within 6 
weeks of diagnosis had shorter median survival at all stages (36.9, 27.1, 12.4 months for 
localized, regional, and distant) when compared to cases who received treatment in more 
than 6 weeks (39.4, 33.8, 25.2 months for localized, regional, distant).134 Likewise, an 
investigation of 482 stage I-III NSCLC patients in a single medical network in Texas 
from 2000-2005 found a median diagnosis to treatment time of 33 days.128 They defined 
timely treatment as less than the median 33 days and reported no association between 
timely treatment and survival using Kaplan Meier survival analysis (p=0.42).128 An 
examination of SEER-Medicare records from 2002-2007 showed a substantial proportion 
of patients waiting over 300 days to initiate treatment.126 Timely treatment was defined 
using guidelines published by the RAND corporation and the British Thoracic Society: 
less than 8 weeks for surgery, 7 weeks for radiation, and 4 weeks for chemotherapy.126,135 
In their survival analysis among 16,747 patients diagnosed in 2003 or 2004, they found 
lower mortality risk for patients receiving delayed care (HR=0.68, 95%CI:0.66-0.71) 
compared to patients receiving more rapid care.126   
 
2.8 Disparities in timely treatment 
There are also conflicting findings related to disparities in the time to treatment 
initiation for lung cancer; however, overall studies found disparities relating to race, sex 
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and rurality. A study of the association between race and time to treatment initiation for 
lung cancer among veterans found only slight racial differences in time to treatment 
between black and white patients (72 days vs. 65 days, p=0.80).53 Using a Cox PH model 
adjusting for patient and disease characteristics, black cases had significantly better 
survival than whites (HR=0.30, p<0.01).53 A SEER-Medicare analysis of lung cancer 
patients from 2000-2002 reported black patients had 1.4 times the odds of treatment 
delays when compared with white patients (p<0.01).136 Other factors associated with 
delays in treatment were Medicaid and Medicare dual enrollment (vs. Medicare alone), 
being divorced or widowed (vs. married), and late-stage diagnosis (vs. early stage).136 A 
SEER analysis using records from 2002-2007 reported differences in timely treatment by 
race and sex where females were 25% less likely to receive timely treatment compared to 
men and black patients were 66% less likely to receive timely treatment compared to 
white patients.47  
 
2.9 National Cancer Institute and Commission on Cancer Treatment Centers 
Treatment center type is related to patient outcomes including survival.137–140 
National Cancer Institute (NCI) designation and Commission on Cancer (CoC) 
accreditation are two of the highest standards for cancer treatment centers. Patients 
treated at these centers have better survival than those treated at non-accredited 
centers.137–140 A study of 69,579 cancer patients in Los Angeles County found lung 
cancer patients who did not receive their first treatment at a NCI-designated 
comprehensive cancer center had worse survival than those treated at other cancer centers 
after adjusting for demographic and clinical factors (HR=1.4, 95% CI, 1.3-1.6).137 More 
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research is needed to understand the factors associated with patient utilization of these 
centers in comparison to non-accredited treatment centers. NCI designation results from a 
peer-review process through the National Cancer Institute. There are currently 14 NCI-
Designated Cancer Centers and 49 NCI Comprehensive Cancer Centers located in 36 
states, primarily in urban areas.141 Most NCI centers are part of high-volume university 
medical centers. High patient volume and academic settings have been shown to have 
better survival in lung cancer patients where post operation morality was 3.2% in high-
volume settings (more than 90 operations per year) compared to 4.8% in low-volume 
settings (p < 0.01)142 and are the primary locations of clinical trials testing new cancer 
treatments.141  
 
The Commission on Cancer (CoC), an accreditation program from the American 
College of Surgeons, provides accreditation to high-quality treatment centers. The 
proportion of hospitals with CoC accreditation changes per year and varies widely across 
states. For example, in 2009 the proportion of CoC-accredited hospitals in Wyoming was 
0% and 100% in Delaware.143 CoC accreditation requires treatment centers to meet 
standards on prevention, research, education, and quality care aimed at improving 
survival.144 When compared with non-CoC-accredited hospitals, CoC hospitals are larger, 
more commonly in urban areas, and have more available services for cancer patients such 




2.10 Race and Ethnicity 
Racial disparities in lung cancer incidence, treatment, and thus survival, 
particularly among black vs. white race, are well documented.2,12,49,50,146–151 Observed 
racial disparities in lung cancer survival may be a complex function of socioeconomic 
differences, access to care, treatment disparities, comorbidities, smoking behavior, or 
other factors. Statistically controlling for covariates such as socioeconomic status (SES), 
stage at diagnosis, and comorbidities has been shown to reduce or remove survival 
differences in survival observed between black and white lung cancer patients.146–149  
 
2.11 Racial Differences in Incidence and Survival 
Lung cancer incidence is higher in black adults than any other racial/ethnic group 
in the U.S.2,12,50,150,151 Smoking functions as major contributor to the observed incidence 
of lung cancer in black adults.150 The 2017 smoking prevalence for black adults in the US 
was 14.9% compared to 15.2% among whites.152 Furthermore, black smokers are less 
likely to use smoking cessation assistance and less likely to stop smoking than 
whites.153,154 Even among never smokers, lung cancer incidence is higher in blacks than 
whites.96,155 Black lung cancer patients also tend to be younger and diagnosed at a later 
stage than their white counterparts.6,148  
 
Like the overall U.S. population, cancer is the second leading cause of death 
among Native Americans.156 Lung cancer mortality from 2009-2013 for Native American 
men was lower than the incidence for white and black men but higher than Asian men.77 
However, Native Americans in Oklahoma experience higher lung cancer incidence rates 
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than whites.157 Native American women had the highest lung cancer incidence as 
compared to white, black, and Asian women. Despite the higher incidence rates, Native 
American women had lower mortality rates than white and black women.77  
 
Lung cancer mortality rates are also highest among black men, followed by white 
men, white women and black women, respectively.2 Research on racial differences in 
lung cancer survival using small cohorts, state cancer registries, and SEER data similarly 
report worse survival among black lung cancer cases than all other race 
categories.4,5,146,149,158,159 Conversely, Asians have better survival than whites.4,155  
 
Lung cancer survival among Hispanics is not well understood. In some 
populations, the survival of Hispanics is cited as better than whites.4,155,160 Researchers 
point to potential differences in histologic type, social support, or exposures (e.g., wood 
burning smoke) as reasons for better survival in Hispanics, while others argue that 
detection bias and diversity among Hispanics may play a role.161–163 An examination of 
Florida and Texas cancer cases from 1995-2003 reported high missingness among 
foreign-born Hispanics in the sample that can explain the previous observed rates of high 
survival.162,163  In a study among stage I SEER registry patients from 1991-2000, 
Hispanics had worse survival than whites.164 However, after adjusting for surgery and 
stage at diagnosis, the difference was not statistically significant suggesting that 
differences in surgical resection by race may explain observed survival differences 




The data related to Native American disparities in lung cancer mortality and 
survival is sparse and presents conflicting results. An analysis of lung cancer cases 
between 1999-2009 recorded by Indian Health Services found death rates among Native 
Americans living in Contract Health Service Delivery Area (CHSDA) counties higher 
than whites in the same CHSDA counties, citing disparities in tobacco control and 
interventions as contributing factors.165 Kaiser Permanente Northern California reported 
significantly higher comorbidities among Native American lung, breast, colorectal, and 
prostate cancer patients compared to whites.156 However, after adjusting for 
comorbidities and disease characteristics, all-cause mortality and cancer-specific 
mortality were not significantly higher in Native Americans than whites.156 Similarly, 
Indian Health Services records in Florida spanning 1996-2007 examining 148,140 
patients found no difference in lung cancer survival between whites and Native 
Americans.166  
 
2.12 Racial differences in treatment  
Racial differences in lung cancer treatment are also well documented. Black lung 
cancer patients are less likely than white patients to receive timely treatment (within 6 
weeks of diagnosis), receive radiation therapy, undergo surgical staging, and receive 
surgical resection.8,10,11,13,47,155,164 When choosing to undergo surgical resection, black 
patients are less likely than white patients to use high-volume hospitals, a metric 
associated with better surgical outcomes such as survival.167 Black patients are also more 
likely to refuse treatment all together, even when diagnosed at an early stage.8 Treatment 
delays among Medicare beneficiaries were reported where Native Americans experienced 
27 
 
significantly longer treatment delays and lower receipt of treatment than whites.168 Native 
Americans were less likely to receive guideline concordant treatment, less likely to have 
surgical resection, and had lower rates of follow-up surveillance than whites.168 Survival 
was significantly lower among those who did not receive optimal treatment and surgery. 
Minority groups’ potential distrust in medical providers, fatalism, and negative surgical 




More lung cancer cases are male than female, as the smoking prevalence among 
men has historically been much higher than that of females. However, the gap between 
males and females in lung cancer incidence is narrowing at 52.2% male and 47.5% 
female in 2017.12,60,171,172 Of note, more lung cancer cases among never smokers are 
female than male.22,23 and a higher proportion of adenocarcinoma lung cancer cases are 
female than male.173–175 There is concern over biological differences, specifically higher 
susceptibility to cigarette carcinogens in women than in men.173,176–178 Additionally, 
women have a harder time quitting smoking compared to men.179   
 
Female lung cancer cases tend to be younger and have better survival than men 
even after controlling for age, stage, and treatment type.19,21,23,173,180,181 A meta-analysis 
reported sex differences in targeted therapy and immunotherapy, where females benefited 
more than males from EGFR inhibitors.182 Sex differences in histology and treatment 
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response may need to be considered with greater magnitude when choosing the treatment 
approach for lung cancer.22,182  
 
2.14 Rurality 
At least 46 million people live in rural areas of the U.S. and often face higher 
rates of poverty, smoking, and overall poor access to healthcare in comparison to urban 
areas.48,183 Most rural areas have a smoking prevalence twice that of large urban areas 
contributing to higher lung cancer incidence and mortality rates in rural areas.24,48,184 
Rural areas also have 1.15 (95%CI: 1.15-1.16) times the risk of lung cancer diagnosed at 
late-stage compared to those in urban areas, making treatment decisions more 
complicated and limiting.185 Even among stage I patients, rural residents have higher 
odds of receiving no treatment than their urban counterparts (RUCA 9 vs. RUCA 1 
OR=1.40, 95%CI: 1.09-1.80).48 
 
The rural population is dispersed over 97% of the nation’s land area, often making 
it difficult for rural residents to access healthcare resources needed to diagnosis and treat 
lung cancer.186 Rural residents must travel farther to access care, specifically to access 
specialty physicians.187 Access to specialists is important as treatment by specialists is 
associated with receipt of cancer-directed therapy even among late-stage lung cancer 
patients and improved survival.110,111,188,189 In a geographic analysis of drive times to 
cancer treatment centers, researchers found that 45.2% of the population live less than a 
one-hour drive to an NCI-designated center and 69.4% live within a one-hour drive to 
academic centers.187 However, Native Americans, rural residents, and those living in the 
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South had the longest drive times to any cancer treatment centers.187 When examining the 
association of the interaction between race and rurality on access to cancer care, urban 
black cancer patients had shorter travel times than urban white patients,190 yet rural black 
patients had longer travel times than rural whites to NCI-designated Cancer Centers. 
Rural black patients were also 58% less likely than rural whites to receive care at an NCI-
designated cancer center.191 On the other hand, in an analysis of self-reported quality of 
care among rural breast, lung, colorectal, and prostate cancer patients, the rural cancer 
patients reported getting cancer care quickly more so than urban cancer patients.192  
 
2.15 Regional differences 
The South bears the burden of the highest smoking rates and lung cancer 
incidence in the country.50,193 Kentucky has the highest incidence rate of lung cancer 
cases for both men and women.193 In 2015, the age-adjusted lung cancer incidence rates 
in for men was 105.6 per 100,000 and 77.5 per 100,000 for women in Kentucky. In 
comparison, Utah had the lowest age-adjusted cancer incidence rates at 29.6 per 100,000 
for men and 22.1 per 100,000 for women. In Kentucky, 24.5% of adults currently smoke, 
placing them the second highest in the nation in 2016 behind West Virginia at 24.8% of 
adults.193 An examination of regional differences in racial disparities of lung cancer 
incidence in 2016 reported that lung cancer incidence among black men in Kentucky is 
twice that of Colorado, further illustrating the differences in the burden of lung cancer 
between the two populations.150 A review of SEER and National Program of Cancer 
Registries (NPCR) lung cancer data from 2004-2006 also reported differences in lung 
cancer incidence by region where those living in the South had the highest lung cancer 
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incidence.50 They also described racial differences in incidence by region; the highest 
lung cancer incidence rates among whites were in the South, among Asians in the West, 
among Hispanics in the Northeast and among blacks and Native Americans in the 
Midwest.50 Based on these results, the authors recommended tailoring prevention 
messages to fit regional culture.50   
 
2.16 Socioeconomic Status 
Socioeconomic status (SES) is an important factors influencing survival, 
potentially working through mechanisms of low smoking rates, better access to care, 
improved health literacy, and overall better health among high SES populations when 
compared to low SES populations.51,146,194–196 Among lung cancer patients, low SES is 
linked to lower likelihood of surgical resection, guideline-concordant treatment, and 
lower survival.6,51,195,197,198 Even after adjusting for comorbidities, patients of the lowest 
SES continue to have worse survival outcomes compared to those of higher SES 
(HR=1.05, p<0.01).6 Differences in SES may be a contributing factor to the observed 
cancer disparities among rural and black populations. While some have shown that 
adjusting for SES eliminates rural and racial disparities,53,195 others have demonstrated 
that these disparities are reduced, but not eliminated, after adjusting for SES.146,195,196   
 
2.17 Martial Status 
Marital status has also been associated with cancer survival, perhaps functioning 
through improved SES and social support.146,195,196 Married individuals are less likely to 
have late stage at diagnosis (OR=0.83, 95%CI:0.82-0.84), more likely to undergo cancer-
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directed treatment (OR=1.53, 95%CI: 1.51-1.56), and experience improved survival 
when compared to non-married individuals (single, divorced, widowed) (HR=0.80, 
95%CI: 0.79-0.80).196 The protective result of marital status may be stronger for men 
than women.146  
 
2.18 Summary 
An understanding of disparities in survival and access/utilization of high-quality 
lung cancer treatment facilities is a crucial step in reducing lung cancer mortality. Patient 
race/ethnicity, sex, and location impacts cancer treatment and thus survival. The results 
of our proposed project add to existing data on lung cancer disparities and our results 
identifying barriers in surgical utilization among low income and black patient 
populations provide necessary insight for the development of future interventions. 
Further research aimed at improving surgical utilization among early stage cases may 





To address the aforementioned gaps in the literature, we used the National Cancer 
Institute’s Surveillance, Epidemiology and Ends Results (SEER) cancer registry data 
linked with fee-for-service Medicare billing data from the Centers for Medicare and 
Medicaid Services (CMS), referred to as SEER-Medicare.199 We used the SEER-
Medicare linked database to address all three of our research aims.  
 
3.1 Description of SEER-Medicare Dataset 
The SEER-Medicare data set provides population-based cancer registry data from 
the SEER program and comprehensive Medicare billing data for fee-for-service (FFS) 
Medicare beneficiaries. We utilized twelve years of linked SEER-Medicare claims data 
from 2003-2014. SEER-Medicare data is fitting for our population of interest because it 
covers nearly 26% of the U.S. population and two-thirds of lung cancer patients in the 
U.S. are over the age of 65 (the age at which most individuals qualify for Medicare 
coverage).200 SEER provides cancer registry information on patient disease 
characteristics such as primary cancer site, stage at diagnosis, and tumor behavior. 
Medicare FFS billing data provides information on all procedures and visits billed to 
Medicare including the treatment(s) received and the associated dates and locations of 
treatment receipt.  
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The geographic coverage of the SEER-Medicare linked dataset is limited to that 
of SEER registry sites in the United States: New Jersey, Connecticut, Iowa, Wisconsin, 
Detroit, Michigan, Louisiana, Kentucky, Georgia, Seattle (Washington), California, 
Hawaii, Utah, Idaho, New Mexico,  Alaska Natives.  
 
3.2 Description of the SEER Program 
The main objective of SEER is to reduce the mortality of morbidity of cancer in 
the US through research using cancer registry data. SEER began collecting cancer 
registry data in 1973 in Connecticut, Hawaii, Iowa, New Mexico, Utah, Detroit, and San 
Francisco/Oakland and has since expanded to include twenty registries representing a 
diverse population of US residents.201 In addition to clinical data, SEER also provides 
information on the cause of death, survival time, demographics, and county-level urban 
versus rural designation. To address generalizability, NCI has shown that the 
characteristics of the geographic areas covered by SEER registries are similar to that of 
the overall US population in terms of education and poverty. The SEER registry 
population does, however, have a higher proportion of foreign-born residents that the 
general US population (17.9% vs. 13.2%). The racial coverage of the registry is 31.9% of 
whites, 30.0% of blacks, 44.0% of Hispanics, 57.5% of Asians, 49.3% of American 
Indians or Alaskan Natives, and 68.5% of Hawaiians or Pacific Islanders.201  
 
3.3 Description of Medicare Fee for Service Claims 
The Medicare portion of the dataset provides health care billing claims for 
covered expenditures for enrollees in fee-for-service (FFS) Medicare. Those covered 
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under Medicare Advantage (MA) do not have detailed billing claims available in the data 
files, restricting analytic capabilities to the FFS population only. Medicare is limited to 
those age 65 and older, those with disabilities, and patients with End Stage Renal 
Disease.202  
 
NCI and CMS perform the SEER-Medicare linkage process before releasing the 
data files to researchers. This process occurred every 4 years between 1991-2003, every 3 
years from 2006-2012, and now biennially since 2014 with the most recent linkage 
available from 2016. The most recent files released in 2016 cover SEER data for patients 
diagnosed with cancer through December 31, 2013 and their accompanying Medicare 
billing claims through December 31, 2014. The linkage itself includes matching SEER 
registry patient identifiers with corresponding identifying variables in Medicare master 
enrollment files with a reported successful match rate of 93%.200   
 
3.4 Study Sample 
Our sample included subjects identified with a first primary diagnosis of non-
small cell lung cancer lung cancer confirmed by a biopsy procedure on record. Receipt of 
treatment was identified in claims data using CPT and ICD9 codes for chemotherapy, 
radiation, and/or surgical resection. Our inclusion criteria are: 1) a first primary lung 
cancer tumor diagnosed between 2003-2011, 2) a diagnosis of non-small cell lung cancer 
(NSCLC) only, which accounts for approximately 85% of lung cancer cases, and 3) age 
66 years and older.  We excluded lung cancer patients who were diagnosed postmortem. 
Patients undergoing surgical resection of the lung for reasons not related to treatment of 
35 
 
lung cancer (e.g., to treat collapsed lung, removal of blood clots, removal of damaged 
tissue from emphysema) or with Kaposi’s sarcoma of the lung (this disease has a unique 
prognosis/associated complications) were also excluded (ICD-9 Codes in Figure 3.1 and 
Appendix). Patients eligible for Medicare due to a diagnosis of End Stage Renal Disease 
(ESRD) and/or disability were excluded from our study sample. These patients are often 
younger and coping with complex medical conditions as compared with Medicare 
beneficiaries who have aged into eligibility (65 and older). 
 
3.5 Independent Variables 
Patient-level variables were drawn from the SEER component of the data base 
and included age of patient (66-69, 70-74, 75-79, 80-84, 85+), sex (male vs female), and 
race with categories white, black, Asian and Pacific Islander, Native American/Alaskan 
Native. SEER provides four different variables for patient rurality, also a main exposure 
of interest. We used county-level U.S. Department of Agriculture defined Rural-Urban 
Continuum Codes (RUCC) for all three aims.203 RUCC codes are based on metropolitan 
population densities and adjacency to metro areas.203 We used primary RUCC codes, nine 
whole number categories indicating population sizes, with three metro classifications and 
six nonmetro classifications: 1) Metro county of over 1,000,000 population, 2) Metro 
county of 250,000-1,000,000 population, 3) Metro county of under 250,000 population, 
4)Nonmetro county of 20,000 or more population and adjacent to a metro area, 5) 
Nonmetro county of 20,000 or more population and not adjacent to a metro area 
6)Nonmetro county of 2,500 to 19,999 population and adjacent to a metro county, 7) 
Nonmetro county of 2,500 to 19,999 population and not adjacent to a metro county, 8) 
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Completely rural or less than 2,500 population and adjacent to a metro area, 9) 
Completely rural or less than 2,500 population and not adjacent to a metro area.203 We 
used SEER registry location to assign Census regions in the following four categories:  
1. Northeast: New Jersey, Connecticut 
2. Midwest: Iowa, Wisconsin, Detroit, Michigan  
3. South: Louisiana, Kentucky, Georgia 
4. West: Seattle, California, Utah, Idaho, New Mexico, Alaska Natives, Hawaii    
 
Covariates included marital status, year of diagnosis, and Medicaid enrollment (as 
a patient level measure of low income). We used clinical data from SEER on data of 
diagnosis, cause of death, date of death, survival time, stage at diagnosis, and histology 
type (with NSCLC as an inclusion criteria) 
 
All statistical analyses were conducted with SAS software, version 9.4 (SAS 
Institute Inc., Cary, NC). This research contained only deidentified secondary data 





3.6 Paper 1 Methods 
Investigate disparities in lung cancer-specific and overall survival by race/ethnicity, 
sex, and geography and identify patient and geographic factors associated with 
survival 
Hypothesis: We hypothesized that lung cancer survival would be lowest among black, 
rural, and male cases. We further hypothesized that these disparities would be most 
pronounced in the South Census region. 
 
3.6.1 Measures 
Lung cancer disease characteristics and patient demographics were derived from 
the SEER component of our SEER-Medicare data. Our main independent variable of 
interest was rurality. Patient residence at county-level at the time of diagnosis was used to 
assign levels of rurality using RUCC codes.203 The USDA 2003 RUCC designation, 
based on 2000 Census data, were used for cases diagnosed between 2003-2009. The 2013 
RUCC codes, based on 2010 Census data, were used to define rurality for cases 
diagnosed in 2010-2011. We collapsed RUCC codes into three categories as follows: 1) 
Large urban=Metro counties over 250,000 population, 2) Small urban =Metro counties 
under 250,000 population, 3) Rural=All Nonmetro counties 
 
We controlled for race (white, black, Asian, Native American, other), sex (male 
or female), Census region (Northeast, Midwest, South, West) and stage at diagnosis 
(localized, regional, distant) in our model. Cause of death was used to define lung cancer-
specific and overall survival. Our outcome variables, vital status and survival time in 
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months, are reported by SEER. The following covariates were also tested with the main 
variables of interest for model selection based on literature reviews: year of diagnosis, 
patient age at diagnosis, Charlson Comorbidity Index, treatment type (chemotherapy, 
radiation, surgery, combination, all of the above), marital status, and Medicaid enrollment 
(yes or no).  
 
3.6.2 Analyses 
We produced descriptive statistics for our study sample demographics and 
performed between-group comparisons by rurality and stage at diagnosis using t-tests for 
continuous variables and chi-square tests for categorical variables. We used the Kaplan 
Meier method and the Log-Rank test to examine the unadjusted differences of all-cause 
and lung cancer-specific survival by levels of rurality. We used the logrank trend test to 
investigate a possible trend in survival with increasing rurality. We implemented 
multivariable survival analyses through two Cox Proportional Hazards (PH) models, one 
for all-cause survival and one for lung cancer-specific survival, with rurality as our 
primary exposure of interest. Before performing model selection, we tested the 
Proportional Hazard (PH) assumption for our model variables using log-log plots and 
Schoenfeld residual plots across time with =0.05. Two of our variables violated the PH 
assumption, race and receipt of radiation therapy. Through Likelihood Ratio testing, we 
determined that the best approach was to use a stratified Cox PH model, stratified by 
race. After examining the interaction of time with the variable for radiation therapy, 
which also violated the proportional hazards assumption, we recognized a clear crossover 
in all-cause survival probability at 12 months post diagnosis. We implemented a time-
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dependent model using a heavy side function at 12 months post diagnosis for the all-
cause model. In the lung cancer-specific model, the crossover of survival curves occurred 
earlier at month 8, and a heavy side function was implemented at 8 months post 
diagnosis. We selected variables in our final model through backward selection with 
removal level of p≤0.05 and then examined potential significant interactions between 1) 
rurality and sex, 2) rurality and Census region by performing additional Likelihood Ratio 
Tests. Once our final models were selected, we produced hazard ratios with 95% 
confidence intervals. We produced Kaplan Meier curves for levels of rurality in each 
region since the use of time-dependent Cox Ph models does not allow for estimation of 
final adjusted survival curves. 
 
 









Table 3.1 Study Variable Definitions and Sources 
 
Study Variable Definition Source Aim(s) 
Patient characteristics 
Age at diagnosis 65-69, 70-74, 75-79, 80-84, 85+ SEER 1,2,3 
Race White, Black, Native American, Asian, Other SEER 1,2,3 
Sex Male or female SEER 1,2,3 
Marital status Married, not married, unknown SEER 1,2,3 
Comorbidity Charlson Index Medicare 1,2,3 
Income level  Low income (Yes or No) provided as Medicaid recipient or 
not  
Medicare 1,2,3 
End Stage Renal 
Disease 
Yes or No (exclusion criteria) ICD9 585.6 Medicare 1,2,3 
Kaposi sarcoma  Yes or No (exclusion criteria) ICD9 176.4 Medicare 1,2,3 
Date of diagnosis Month and year; first biopsy SEER, 
Medicare 
2 
Vital status  Dead or alive SEER 1,2,3 
Cause of death ICD codes SEER 1,2 
Date of death Date of death agreement  SEER, 
Medicare 
1,2 
Survival time Survival time in months (from date of diagnosis) SEER 1,2 
Tumor factors  
Stage at diagnosis I, II, III, IV SEER 1,2,3 








Patient location at 
diagnosis 
State and county FIPS code SEER 1,2,3 
Rurality  County level Rural Urban Continuum Codes 2003 and 2013 SEER 1,2,3 
Census region Northeast, South, Midwest, West (defined from patient 
registry location via SEER registry ID) 
SEER, GIS 1,2,3 
County Median 
Income 
Continuous measure of median income of a county to gauge 




County MUA designation (Yes or No) HRSA 3 
Treatment factors 
Surgery  Yes, No, Unknown SEER, 
Medicare 
1,2,3 
Radiation therapy Yes, No, Unknown SEER, 
Medicare 
1,2,3 
Chemotherapy Yes, No, Unknown Medicare 1,2,3 




other than removal of 
malignant neoplasms 
Benign neoplasms ICD9 211.0-235.8 
Cystic fibrosis IDC9 277.02 
Primary pulmonary hypertension ICD9 416.0 
Emphysema ICD9 492.0-494.1 
COPD ICD9 496 
Pneumonia ICD9 486, 513, 516 
Pleurisy ICD9 511.0-511.9 







3.7 Paper 2 Methods  
Examine differences in lung cancer-specific survival at differing thresholds of 
treatment initiation  
Hypothesis: We hypothesized that survival would be highest among those initiating 
treatment within 4 weeks of diagnosis  
 
 
Figure 3.2 Conceptual Framework of Paper 2 Survival Analysis  
 
3.7.1 Measures 
The outcome of lung cancer-specific survival time will be assessed from SEER 
data on vital status and survival time in months. Our main independent variable will be 
time from initial diagnosis to treatment defined at five differing thresholds: 4 weeks or 
less, 5-6 weeks, 7-9 weeks, 10-12 weeks, greater than 12 weeks. Time to treatment will 
be calculated by the weeks between the date of diagnosis (from SEER) to the time of the 
first treatment billing code in Medicare. Treatment is defined as first surgery, 




HCPCS and CPT codes. A full list of the CPT, HCPCS, and ICD-9 codes for surgery and 
radiation are listed in the appendix.204,205 To identify chemotherapy initiation, we will use 
codes associated with a comprehensive list of chemotherapy drugs approved by the Food 
and Drug Administration (FDA) for the treatment of NCSLC.204 HCPCS codes for this 
list of drugs is available from the National Cancer Institute.205 Since our data set does not 
include Medicare Part D (prescription drug billing codes), we will not be able to capture 
chemotherapy medications taken at home by prescription. We will control for age, stage 
at diagnosis, race/ethnicity, sex, rurality, and Census region. Rurality will be 
dichotomous (urban vs rural) based on rural urban continuum codes (RUCC). 
 
3.7.2 Analyses 
For each treatment type, we produced frequencies for all variables included in the 
model and performed between group comparisons by time to treatment using chi-square 
tests with =0.05. We tested the unadjusted relationship between time to treatment and 
lung cancer-specific survival with Kaplan Meier curves and the logrank test. We then 
tested the Proportional Hazards (PH) assumption using log-log of survival probability 
over time for all variables included in the model. We calculated univariate Hazards 
Ratios (HRs) for all variables tested for inclusion and performed a backwards selection 
with removal levels of 0.05 coupled with likelihood ratio tests to assess model fit. Using 
our final models, we produced hazards ratios with 95% confidence intervals for survival 





For surgical treatment, two variables of interest violated the PH assumption: time 
to surgery initiation and radiation treatment. Time to surgery initiation showed a clear 
crossover in survival probability at 16 months post diagnosis. To account for these 
violations in our model, we incorporated a variable for the interaction between time to 
surgery initiation and survival time at 16 months post diagnosis and stratified by radiation 
treatment.  
 
When stratifying by a radiation in survival analysis, the stratified Cox PH models 
constructs separate partial likelihood functions for each radiation group. The multiplies 
the two functions are multiplied together and use values of the coefficient that maximize 
the function. Therefore, the effect of radiation is absorbed into the time function and we 
can no longer make comparisons on this variable. Time-dependent Cox PH models allow 
us to account for the PH assumption of a variable, when deemed appropriate, and retain 
the ability to draw conclusions on that variable. Further explanations on time-dependent 
and stratified Cox PH models can be found elsewhere.206,207  
 
For our sample of patients who received chemotherapy treatment, the variable for 
radiation treatment also violated the PH assumption; thus, we applied a time-dependent 
PH model. Specifically, we created and incorporated a time dependent variable into the 
Cox PH model representing radiation 12 months post diagnosis or not.  
 
`For the model of time to radiation treatment initiation, Census region violated the 




described above, using a stratified Cox PH model accounts for the effect of region in the 
final model but does not allow for comparisons between regions.206  
 
3.8 Paper 3 Methods  
Explore disparities in utilization of surgical lung cancer treatment across county 
characteristics (urban/rural, medically underserved areas, and by percent of 
population 65 and over in poverty) and related patient and county predictors among 
lung cancer patients seeking treatment  
Hypothesis 3a: County-level factors would impact surgical treatment among early stage 
lung cancer patients 
Hypothesis 3b: Patients in rural counties, Medically Underserved Areas (MUAs), or in 
high poverty counties would be less likely to receive surgical treatment for early stage 
lung cancer 
 
This study design incorporated multilevel logistic regression modeling techniques 
to account for patient fixed effects nested within counties as well as county fixed effects. 
Multilevel modeling was performed to identify patient and county factors influencing the 
utilization of surgical treatment for lung cancer. We expected a clustering of 
characteristics within levels of our data by county. For example, patients from the same 
residential area (county) tend to be more alike than patients residing different counties in 
terms of access to care and income. Multilevel modeling allowed us to account for these 
















Conceptual multilevel model of patients nested within geographic factors associated with utilization of surgical 
treatment 
 
Figure 3.3 Conceptual Framework of Multilevel Model 
 
3.8.1 Measures 
The dependent variable in our model, utilization surgical treatment center 
(yes/no), was defined from SEER records on patient treatment type. The first level of our 
multilevel logistic regression contained patient demographics and clinical characteristics 
from SEER data: age at diagnosis, race/ethnicity, sex, marital status, Medicaid 
enrollment, stage at diagnosis, grade, and laterality. We used a binary definition for 
rurality in this model (urban versus rural) by collapsing RUCC codes into Metro/urban 
versus Nonmetro/rural categories. Level-one patient factors were nested within level-two 
county factors including rurality, percent of the population over 65 in poverty (as a 
measure of socioeconomic status of the county), and Medically Underserved Area 
designation (MUA). MUAs are county-level assignments for counties with too few 
primary care providers for the population in the county.208   
 
 













County: Rurality, Percent of Population over 65 
in Poverty, Medically Underserved Areas, 
Random Effect 
Patients Age, Race, Sex, Marital Status, Medicaid 










We employed a multilevel modeling approach for this aim, specifically a basic 
random intercept logistic regression. This model allows the intercept to vary randomly 
across clusters (counties) by incorporating cluster-specific (county) random effects. First, 
we calculated descriptive statistics for patient-level factors across counties and test for 
differences by chi-square tests (=0.05). We then estimated the null model predicting 
surgery utilization from only county-level random effects. We then calculated the median 
odds ratio (MOR) and intraclass correlation coefficient (ICC). The MOR explains the 
median magnitude of the odds ratio between a randomly chosen high-risk county (rural, 
low SES, MUA) versus a low-risk county (urban, high SES, not MUA), providing an 
estimate of the amount of individual probability of surgical utilization attributed to 
county characteristics.209 An MOR not equal to 1.0 indicates that the multilevel model is 
an appropriate statistical approach for the data being used.209 The ICC provides a measure 
of the total variation in the outcome that is attributed to clustering by groups (clustering 
by county in our analysis). A significant ICC indicates that a multilevel modelling 
approach should be used for the data.210 We then selected county-level predictors of 
surgical treatment for our level-two model also backward selection. After our level-two 
model was complete, we estimated our level-one model with patient characteristics 
predicting surgical utilization. Variable selection was based on coefficients with 
significant p-values less than or equal to 0.05 or deemed to be significant based on 
literature related to our research question. We assessed model fit using pseudo R-squared. 




random effects and odds ratios with 95% confidence intervals for predictors associated 







RURAL DISPARITIES IN ALL-CAUSE AND LUNG CANCER-





                                                          






Despite declining smoking rates nationwide, lung cancer remains the leading 
cause of cancer-related death among both men and women in the United States. When 
examining stage at diagnosis, those diagnosed at distant stage have the highest risk of 
death with a 5-year survival of 4% compared to 54% among localized cases. For all 
stages combined, the five-year survival is 18%. Lung cancer survival differs by race, sex, 
and stage at diagnosis. Black and Native American lung cancer cases have worse survival 
when compared to white cases while men have worse survival than women. However, 
research regarding lung cancer survival differences by rurality is limited. Our objective 
was to investigate the relationship of rurality with all-cause survival and lung cancer-
specific survival, adjusting for clinical and demographic factors. 
Methods 
We examined 135,627 cases of non-small cell lung cancer diagnosed between 
2003-2011 from SEER-Medicare and defined rurality using Rural Urban Continuum 
Codes from the US Department of Agriculture. We used the Kaplan Meier estimator and 
Log Rank test to examine the relationship of rurality with all-cause survival and lung 
cancer-specific survival. We used the trend test to investigate a possible trend in survival 
with increasing rurality. We implemented a stratified, time-dependent Cox Proportional 
Hazards (PH) model to examine the relationship of rurality, stratified by race, with all-
cause survival and lung cancer-specific survival controlling for patient and clinical 
characteristics. Based on our final models, we produced hazard ratios and 95% 





The log rank and trend test were significant for decreasing survival with 
increasing rurality for both all-cause and lung cancer-specific survival (p<0.01). The 
interaction of race and Census region was also significant in our final Cox PH model, 
stratified by race. In the South and West regions, small urban and rural areas had worse 
all-cause and lung cancer-specific survival than large urban areas, stratified by race. In 
the South, the all-cause hazard ratio was 1.07 (95%CI: 1.03-1.10) for small urban and 
1.10 (95%CI: 1.06-1.14) for rural, compared to large urban. The South lung cancer-
specific hazard ratio for small urban was 1.09 (95%CI: 1.05-1.15) and 1.10 (95%CI: 
1.06-1.15) for rural in comparison to large urban. The hazard ratios were slightly higher 
for the West small urban (All-cause HR:1.13, 95%CI: 1.10-1.16; Lung cancer-specific 
HR:1.12, 95%CI: 1.08-1.15) and rural (All-cause HR:1.11, 95%CI: 1.06-1.15; Lung 
cancer-specific HR:1.12, 95%CI: 1.07-1.18) as compared to large urban, stratified by 
race. In the Midwest, all-cause and lung cancer-specific survival was worse for only rural 
areas compared to large urban with marginal significance, stratified by race (All-cause 
HR: 1.07, 95%CI: 1.01-1.12; Lung cancer-specific HR: 1.07, 95%CI: 1.01-1.14).  In the 
Northeast, hazard ratios based on rurality were not significant for small urban (All-cause 
HR: 1.01, 95%CI: 0.97-1.05; Lung cancer-specific HR: 0.99, 95%CI: 0.95-1.03) or for 
rural (All-cause HR: 0.97, 95%CI: 0.87-1.08; Lung cancer-specific HR: 0.94, 95%CI: 
0.83-1.06) 
Conclusions 
Rural residence was associated with lower all-cause and lung cancer-specific 




health equity between urban and rural populations such as improvements in access to care 
and receipt of guideline-concordant lung cancer treatment.  
 




Lung cancer is the leading cause of cancer-related death among both men and 
women in the United States with a five-year survival of only 18%.2 However, survival 
improves dramatically if the cancer is detected at an early, localized stage, with an 
improved five-year survival rate of 54%, compared to 4% for distant stage at diagnosis.1,2 
Many factors are related to survival, including socioeconomic status and clinical 
characteristics such as comorbidities and histology type.103,181,43 Racial disparities are 
documented for survival with black and Native American cases having lower survival 
compared to whites, due in part to differences in comorbidities, increased likelihood of 
late-stage diagnosis, and lower utilization of surgical treatment.4,49,146,148,149,156,166  
Similarly, differences by sex have shown that women fare better than men with lung 
cancer in terms of survival.19,181  
 
Geographic variation in lung cancer survival by rurality and region needs to be 
further examined. Rural areas of the US have higher smoking prevalence, higher lung 
cancer incidence, and higher lung cancer mortality than their urban counterparts.27,78,211 




supply of health care providers, and experience longer drive times to providers.78,187,190 
These factors contribute to more late-stage diagnoses and lower utilization of surgical 
treatment in rural patients than urban patients, both determinants of cancer 
survival.185,190,211 Data from the Utah Cancer Registry showed that the 5-year survival of 
rural residents was 5.2% lower than for urban residents.212 However, a similar study 
using Georgia Comprehensive Cancer Registry data found no significant differences in 
urban and rural survival after controlling for treatment.213  Rural-urban differences in 
lung cancer survival may differ from across regions in the US, as many of the factors 
related to lung cancer survival differ by region (such as race/ethnicity, income, education, 
access to care, and smoking prevalence).78,214 In the context of lung cancer, the South has 
the longest drive times to reach medical providers and the largest population deemed 
high-risk for lung cancer (defined by LDCT screening eligibility)39,187as well as the states 
with the  highest lung cancer mortality-to-incidence ratios.42 Further research is needed to 
examine survival disparities by rurality and region. Our objective was to examine 
differences by rurality and region in all-cause and lung cancer-specific survival time in a 




We examined comprehensive cancer registry from the Surveillance, 
Epidemiology, and End Results program linked with Medicare billing data (SEER-
Medicare)199 to examine cases of non-small cell lung cancer with a first primary tumor 




months of Medicare billing claims prior to any cancer diagnosis. We also excluded cases 
diagnosed post-mortem and any Medicare receipts with end stage renal disease as this 
condition is associated with unique clinical challenges and short life expectancy. Lung 
cancer clinical characteristics, survival time, and patient demographics were taken from 
SEER. Our main independent variable of interest, patient rurality, was defined using the 
patient residence at county-level at the time of diagnosis using Rural Urban Continuum 
Codes (RUCC). RUCC codes, developed by the US Department of Agriculture (USDA) 
Economic Research Service (ERS), are based on metropolitan population densities and 
adjacency to metro areas.203 We collapsed the nine primary RUCC codes into the 
following 3 categories: 1) Large urban - Metro county of 1,000,000 population or higher, 
2) Small urban - Metro county under 1,000,000 population, 3) Rural – All nonmetro 
counties. We used 2003 RUCC designation (based on 2000 Census data) for cases 
diagnosed between 2003-2009 and 2013 RUCC codes (based on 2010 Census data) to 
define rurality for cases diagnosed in 2010-2011. We defined regions by SEER registry 
locations within 4 Census regions: Midwest (Iowa, Wisconsin, and Detroit, Michigan), 
Northeast (New Jersey, Connecticut), South (Louisiana, Kentucky, Georgia) West (Utah, 
Idaho, New Mexico, Alaska Natives, all California registries, and Seattle, Washington). 
Cause of death from SEER records was used to define all-cause and lung cancer-specific 
survival and has been previously assessed for validity.215 Our outcome variables, vital 
status and survival time in months, were taken also taken from SEER. We controlled for 
race/ethnicity (white, black, Asian, Native American, other). We did not include Hispanic 
ethnicity in our race/ethnicity categories as it is not self-reported in SEER, but rather 




region (Midwest, Northeast, South, West) and stage at diagnosis (localized, regional, 
distant) in our model. The following covariates were tested as main exposures of interest 
(rurality) for model selection: year of diagnosis, patient age at diagnosis, Charlson 
Comorbidity Index, marital status, Medicaid enrollment at the time of diagnosis (yes or 
no), and treatment types (chemotherapy, radiation, surgery). Receipt of radiation and 
surgery were reported by SEER. We used a validated SAS macro to pull chemotherapy 
use from linked Medicare billing codes.217  
 
Data Analyses 
We produced descriptive statistics for our study sample demographics and 
performed between-group comparisons by rurality and stage at diagnosis using t-tests for 
continuous variables and chi-square tests for categorical variables. We used the Kaplan 
Meier method and the Log-Rank test to examine the unadjusted differences of all-cause 
and lung cancer-specific survival by levels of rurality. We used the logrank trend test to 
investigate a possible trend in survival with increasing rurality. We implemented 
multivariable survival analyses through two Cox Proportional Hazards (PH) models, one 
for all-cause survival and one for lung cancer-specific survival, with rurality as our 
primary exposure of interest. Before performing model selection, we tested the 
Proportional Hazard (PH) assumption for our model variables using log-log plots and 
Schoenfeld residual plots across time with =0.05. Two of our variables violated the PH 
assumption, race and receipt of radiation therapy. Through Likelihood Ratio testing, we 
determined that the best approach was to use a stratified Cox PH model, stratified by 




which also violated the proportional hazards assumption, we recognized a clear crossover 
in all-cause survival probability at 12 months post diagnosis. We implemented a time-
dependent model using a heavy side function at 12 months post diagnosis for the all-
cause model. In the lung cancer-specific model, the crossover of survival curves occurred 
earlier at month 8, and a heavy side function was implemented at 8 months post 
diagnosis. We determined variables necessary to include in our final model to control for 
confounding based on significance in our literature review and through development of a 
Directed Acyclic Graph (DAG). We then examined potential significant interactions 
between 1) rurality and sex, 2) rurality and Census region by performing additional 
Likelihood Ratio Tests. Once our final models were selected, we produced hazard ratios 
with 95% confidence intervals. We produced Kaplan Meier curves for levels of rurality in 
each region since the use of time-dependent Cox PH models does not allow for 




Our final sample size included 135,627 NSCLC cases with over half (57.3%) 
living in large urban areas, 28% in small urban areas, and 14.8% in rural areas (Table 
4.1). All patient characteristics differed significantly by level of rurality (p<0.01). One-
third of the cases (31.2%) were 80 or more years old and the majority were white 
(85.0%), males (50.6%), married (50.1%), and diagnosed at a distant stage (52.7%). With 
respect to treatment, more than half (56.8%) received chemotherapy (defined from billing 




although recommended treatment varies depending on patient clinical factors (data not 
available). In the total sample 13.4% were enrolled in Medicaid, 44.7% were in the West 
Census region, and 30.2% had no comorbidities detected through billing data (i.e., 
Charlson comorbidity score=0). Missing or unknown responses were noted for race 
(0.2%), marital status (3.4%), and receipt of surgery (0.6%), 
 
Survival by Levels of Rurality 
In large urban areas, 82.2% of cases died from all-causes and 69.3% died from 
lung cancer during follow-up (Table 4.2). In small urban areas, 83.9% died from any 
cause compared to 70.8% for lung cancer, and for rural areas, 85.4% died from all-causes 
and 72.3% from lung cancer during follow-up. All-cause median survival was 8 months 
for large urban areas and 7 months for both small urban and rural areas.  Lung cancer-
specific median survival was 10 months for large urban areas and 9 months for both 
small urban and rural areas.  
 
The Kaplan Meier and corresponding Log rank test showed significant differences 
for both all-cause survival and lung cancer-specific survival by levels of rurality with 
p<0.01. The logrank trend test was also significant at p<0.01 by decreasing levels of 
rurality (large urban>small urban>rural). A multiple comparison test with Bonferroni 
adjustment revealed significant differences in both all-cause and lung cancer-specific 
survival with large urban vs. small urban (p<0.01) and large urban vs. rural (p<0.01). The 
unadjusted survival for small urban compared to rural was not statistically different for 




Time-Dependent Cox Proportional Hazards Model, Stratified by Race 
All covariates tested in addition to rurality (age, sex, region, marital status, 
Medicaid enrollment, year of diagnosis, stage at diagnosis, and treatment types) were 
statistically significant and retained in our final time-dependent Cox PH models, stratified 
by race.   
 
Geographic Factors 
All variables tested for inclusion in final stratified time-dependent model were 
statistically significant. We also found a significant interaction for region and rurality. 
Due to this interaction, we calculated hazard ratios for each level of rurality by Census 
regions (Table 4.3). In the South and West regions, small urban and rural areas had worse 
all-cause and lung cancer-specific survival than large urban areas, stratified by race. In 
the South, the all-cause hazard ratio was 1.07 (95%CI: 1.03-1.10) for small urban and 
1.10 (95%CI: 1.06-1.14) for rural, compared to large urban. The South lung cancer-
specific hazard ratio for small urban was 1.09 (95%CI: 1.05-1.15) and 1.10 (95%CI: 
1.06-1.15) for rural in comparison to large urban. The hazard ratios were slightly higher 
for the West small urban (All-cause HR:1.13, 95%CI: 1.10-1.16; Lung cancer-specific 
HR: 1.12, 95%CI: 1.08-1.15) and rural (All-cause HR:1.11, 95%CI: 1.06-1.15; Lung 
cancer-specific HR:1.12, 95%CI:1.07-1.18) as compared to large urban, stratified by 
race. In the Midwest, all-cause and lung cancer-specific survival was worse for only rural 
areas compared to large urban with marginal significance, stratified by race (All-cause 




Northeast, rurality was not significantly associated with all-cause or lung cancer-specific 
survival with hazard ratios either very close to or less than 1.0. 
 
Demographic Factors 
A five-year increase in age was associated with decreased all-cause and lung 
cancer-specific survival, stratified by race (All-cause HR: 1.10, 95%CI: 1.10-1.11; Lung 
cancer-specific HR:1.08, 95%CI: 1.07-1.09). Females and Medicaid enrollees had more 
favorable all-cause and lung cancer-specific survival compared to males (All-cause HR: 
0.83, 95%CI: 0.81-0.84; Lung cancer-specific HR: 0.84, 95%CI: 0.82-0.85) and those not 
on Medicaid (All-cause HR: 0.96, 95%CI: 0.94-0.99; Lung cancer-specific HR: 0.94, 
95%CI: 0.92-0.96), stratified by race. Unmarried patients had a higher risk of all-cause 
and lung cancer-specific death than their married counterparts (All-cause HR:1.12, 
95%CI:1.10-1.14; Lung cancer-specific HR: 1.12, 95%CI:1.09-1.14).  
 
Clinical factors 
Compared with localized stage, distant stage at diagnosis had the highest 
magnitude HR in our results for lung cancer-specific survival at 3.73 (95% CI: 3.62-3.83) 
and all-cause at 2.96 (95%CI: 2.29-3.03), stratifying by race. Regional stage was also 
associated with increased risk of death for both all-causes and lung cancer when 
compared to localized stage and stratifying by race (All-cause HR:1.65, 95%CI:1.61-
1.69; Lung cancer-specific HR:1.95, 95%CI:1.89-2.00). The association of comorbidities 
differed for all-cause and lung cancer-specific survival. Comorbidities showed a dose-




increase in the Charlson score corresponded with an increase in the all-cause hazard ratio 
(Table 4.3). For lung cancer-specific survival, there was a slight increase in the risk of 
death for patients with a Charlson score of 3 or higher compared to those with a score of 
0-2 (HR: 1.18, 95%CI: 1.15-1.21). Among treatment options, those not receiving surgery 
had the highest hazard ratios for both all-cause and lung cancer-specific survival (All-
cause HR:3.01, 95%CI: 2.93-3.09; Lung cancer-specific HR:3.28, 95%CI:3.18-3.38) 
compared to those who received surgery. Those who did not receive chemotherapy also 
had higher hazard ratios than those who did receive chemotherapy for both outcomes 
(All-cause HR:1.55, 95%CI:1.52-1.58; Lung cancer-specific HR:1.55, 95%CI:1.52-1.58). 
Receipt of radiation therapy was associated with significant differences in all-cause 
survival at 6 months post-diagnosis (HR:1.40, 95%CI:1.37-1.43) and marginally 
significant at 12 months post diagnosis (HR:1.04, 95%CI:1.01-1.07). The relationship 
was similar for lung cancer-specific survival at 6 months post diagnosis (HR:1.45, 
95%CI:1.42-1.49).  However, receipt of radiation therapy was not associated with 
significant differences in lung cancer-specific survival at 12 months post diagnosis 
(HR:0.97, 95%CI:0.95-1.00).  
 
There was no difference in all-cause or lung cancer-specific survival for those 
diagnosed between 2006-2008 compared to those diagnosed in 2009-2011. However, 
those diagnosed between 2003-2005 had a lower hazards ratio for both outcomes (All-






Our large-scale study to assess differences in all-cause and lung cancer-specific 
survival found significantly worse survival for rural patients when compared to those in 
large urban areas. Furthermore, the association of rurality on survival differed by region, 
with worse survival in the South and West Census regions after adjusting for 
demographic and clinical factors. These results are consistent with findings from previous 
studies.211,212 Atkins et al found a dose-response relationship between rurality and 
mortality when examining 348,002 lung cancer cases diagnosed between 2000 and 2006, 
where lung cancer mortality increased with increasing levels of rurality. Regional 
differences in access to care, screening utilization, environmental exposures, and 
smoking behavior contribute to observed regional differences in survival.24,39,187  
 
Comorbidities appears to be a stronger factor behind observed disparities in all-
cause survival. However, controlling for comorbidities did not mitigate the observed 
differences in survival by rurality in our results. Our data lacked a measurement of 
smoking status. Approximately 90% of lung cancer cases are caused by smoking.74 
Furthermore, smoking causes other chronic conditions that can make cancer treatment 
difficult for a patient to tolerate such as heart disease, chronic obstructive pulmonary 
disorder (COPD), and peripheral vascular disease. The role of smoking in rural lung 
cancer survival disparities should also be considered as the smoking prevalence among 
rural residents is higher than in urban residents183,211,78 and the South has the highest 





Similar to other studies, women also fared better for both all-cause and lung 
cancer-specific survival after adjusting for covariates in the stratified model.19,173,180,182 
Distant stage at diagnosis had a high hazard ratio (HR=3.73) compared to localized stage 
at diagnosis for lung cancer-specific survival. Early diagnosis should continue to be a 
focus of improvement in lung cancer interventions, and pursuit of equal access to LDCT 
screening may play a role in improving stage at diagnosis among rural populations, 
especially in the South with a high at-risk population based on USPSTF screening 
recommendations.39 The time-dependent relationship we observed for radiation therapy 
(with poor survival in the first year following diagnosis) fits with the standard treatment 
recommendations for distant stage cases given radiation for pain management and not for 
curative intent. Surgery is considered the most effective treatment for NSCLC when 
deemed appropriate for patients.218,219 Our findings of a high HR=3.28 for lung cancer-
specific survival in those who did not receive treatment compared to those who did is 
likely an artifact of surgery occurring more frequently in cases with early stage at 
diagnosis. Over forty percent of the cases in our sample did not receive chemotherapy 
(43.2%), associated with 55% higher risk of all-cause and lung cancer-specific death 
(HR=1.55). Except for radiation therapy received in the first year, treatment of any type 
was associated with improved all-cause and lung cancer specific survival. 
 
Strengths and Limitations 
Our study had many strengths. The use of SEER-Medicare, a large population-
based cohort of lung cancer patients, provides high quality data from areas covering 




detect small differences. The SEER component of the data provides comprehensive 
cancer registry data on patient clinical factors with follow-up of patients’ survival. 
Medicare billing data also allowed us to capture existing comorbidities before diagnosis 
with lung cancer and chemotherapy treatment after diagnosis. Expanded research on rural 
health disparities is a recognized priority of the National Cancer Institute,61 and to our 
knowledge, this is the first study assessing the relationship of rurality and region for both 
all-cause and lung cancer-specific survival.  
 
This study is not without limitations. While SEER-Medicare is the best available 
data source for our research question, it is limited it in geographic coverage of the United 
States, particularly for rural areas. Rural underrepresentation in national data is a 
documented concern for rural health research and needs improvement in the future.220–222 
Rural areas in the South, particularly in Alabama, Mississippi, and Arkansas, experience 
particularly high state-level mortality for lung cancer.39 Not representing these areas of 
documented rural disparities in our data may introduce a bias towards the null (i.e. 
underrepresent the magnitude of the rural survival disparity) as these states have some of 
the worst lung cancer mortality in the US.223 SEER data also does not contain 
information on patient smoking history.222 Approximately 90% of lung cancer cases are 
linked to smoking and the largest proportions of high-risk current and former smokers are 
in rural areas and the South.39,55,56,78 Findings that rural lung cancer patients have worse 
survival could be driven by higher smoking prevalence which is directly related to higher 
comorbidities prevalence (e.g., COPD, heart disease) and histology that is less responsive 




patients’ residence at the time of diagnosis. It is possible that patients move before 
diagnosis or following diagnosis which we were unable to measure. We also did not 
examine use of targeted therapy and immunotherapy given that our cohort was diagnosed 
between 2003-2011, before the US Food and Drug Administration (FDA) approved  such 
drugs in 2015.116 Our modeling approach, a time-dependent Cox PH model stratified by 
race, does not allow us to make direct comparisons on race, a documented disparity in 
lung cancer survival not captured here.  
 
4.6 Conclusions 
All-cause and lung cancer-specific survival were lowest among lung cancer 
patients in rural counties compared with urban residents. When examined by rurality and 
region, lung cancer cases in the South and West had the highest hazard ratios for both all-
cause and lung cancer-specific survival. Comorbidities and receipt of surgery appear to 
be driving factors behind observed survival disparities.  Future research should focus on 
identifying effective intervention strategies to improve health equity between urban and 
rural populations such as improvements in early detection, prevention and control of 
comorbid conditions, and receipt of guideline-concordant lung cancer treatment, 







Table 4.1 Demographics of Non-Small Cell Lung Cancer Cases by Urban/Rural Designation, 
 SEER-Medicare 2003-2011 
 
 Large Urban Small Urban Rural Total p-value 
Total N 77685  37920  20022  135627  
      
Age     <.01 
Mean (std) 76.5 (6.7) 76.2 (6.6) 75.6 (6.5) 76.3 (6.7)  
Sex     <.01 
Male 48.9% 51.3% 55.8% 50.6%  
Female 51.1% 48.7% 44.2% 49.4%  
Race     <.01 
White 80.4% 85.6% 90.9% 85.0%  
Black 9.7% 7.2% 6.3% 8.3%  
Asian or Pacific Islander 2.6% 2.8% 1.4% 6.2%  
Native American or 
Alaskan Native 
5.7% 3.0% 0.9% 0.3%  
Other/Unknown 1.6% 1.4% 0.5% 0.2%  
Census Region     <.01 
Midwest 11.8% 9.3% 17.2% 11.9%  
Northeast 22.2% 17.5% 3.4% 18.1%  
South 15.4% 29.6% 55.3% 25.3%  
West 50.6% 43.6% 24.1% 44.7%  
Marital Status     <.01 
Married 48.8% 50.9% 53.6% 50.1%  
Not married 47.7% 46.0% 43.2% 46.6%  
Unknown/Missing 3.5% 3.2% 3.2% 3.4%  
Medicaid Enrollment     <.01 
Yes 10.3% 9.2% 11.4%   
No 89.7% 90.8% 88.6%   
Surgery     <.01 







No 75.5% 76.8% 77.0% 76.1%  
Unknown/Missing 0.3% 0.5% 1.8% 0.6%  
Radiation     <.01 
Yes 31.4% 34.0% 32.6% 32.3%  
No 67.4% 64.8% 64.2% 66.2%  
Unknown/Missing 1.2% 1.2% 3.2% 1.5%  
Chemotherapy     <.01 
Yes 52.8% 58.9% 68.2% 56.8%  
No 47.2% 41.1% 31.8% 43.2%  
Charlson Comorbidity 
Score  
    <.01 
0 28.7% 31.8% 33.1% 30.2%  
1 22.7% 25.0% 28.1% 23.9%  
2 12.1% 13.0% 14.3% 12.7%  
3 6.2% 6.4% 7.1% 6.4%  
4 3.3% 3.4% 3.6% 3.4%  
5 1.9% 1.9% 1.9% 1.9%  
6 1.9% 1.6% 1.6% 1.8%  
Missing/Unknown 23.7% 16.9% 10.2% 19.8%  
Year of diagnosis     <.01 
2003-2005 30.8% 32.3% 32.7% 31.5%  
2006-2008 34.5% 34.1% 34.7% 34.4%  
2009-2011 34.8% 33.6% 32.6% 34.1%  
Stage at diagnosis     <.01 
Localized 22.2% 22.0% 21.9% 22.1%  
Regional 24.7% 26.1% 25.9% 25.2%  









Table 4.2 Death Rates by Levels of Rurality among SEER-Medicare NSCLC Cases, 2003-2011 
 
Among patients diagnosed with lung cancer: Large Urban Small Urban Rural 
Percentage who died from any cause 82.2%  83.9% 85.4% 
Percentage who died from lung cancer 69.3% 70.8% 72.3% 
 
 
Table 4.3 Time-Dependent Cox Proportional Hazards Results of All-Cause Survival, Stratified by Race, 
 SEER-Medicare NSCLC Cases 2003-2011 
 
 Unadjusted All-Cause Adjusted All-Cause 
 HR (95% CI) HR (95% CI) 
Geographic Factors   
Region by Rurality   
Midwest   
Large Urban 1.00 (Reference) 1.00 (Reference) 
Small Urban 1.00 (0.96-1.05) 1.02 (0.97-1.08) 
Rural 1.07 (1.03-1.12) 1.07 (1.01-1.12) 
Northeast   
Large Urban 1.00 (Reference) 1.00 (Reference) 
Small Urban 0.97 (0.94-1.00) 1.01 (0.97-1.05) 
Rural 0.98 (0.94-1.00) 0.97 (0.87-1.08) 
South   
Large Urban 1.00 (Reference) 1.00 (Reference) 
Small Urban 1.07 (1.04-1.10) 1.07 (1.03-1.10) 
Rural 1.10 (1.07-0.14) 1.10 (1.06-1.14) 
West   
Large Urban 1.00 (Reference) 1.00 (Reference) 
Small Urban 1.08 (1.06-1.10) 1.13 (1.10-1.16) 
Rural 1.08 (1.04-1.11) 1.11 (1.06-1.15) 







Age, 5-year increase 1.18 (1.18-1.19) 1.10 (1.10-1.11) 
Sex   
Male 1.00 (Reference) 1.00 (Reference) 
Female 0.85 (0.84-0.86) 0.83 (0.81-0.84) 
Marital Status   
Married 1.00 (Reference) 1.00 (Reference) 
Not married 1.21 (1.19-1.22) 1.12 (1.10-1.14) 
Medicaid Enrollment   
Yes 1.08 (1.06-1.10) 0.96 (0.94-0.99) 
No 1.00 (Reference) 1.00 (Reference) 
Clinical Factors   
Stage at Diagnosis   
Localized 1.00 (Reference) 1.00 (Reference) 
Regional 1.78 (1.75-1.81) 1.65 (1.61-1.69) 
Distant 47.45 (4.37-4.52) 2.96 (2.89-3.03) 
Charlson Comorbidity Score    
0 1.00 (Reference) 1.00 (Reference) 
1 1.07 (1.05-1.08) 1.14 (1.12-1.16) 
2 1.18 (1.15-1.20) 1.25 (1.22-1.28) 
3 1.31 (1.28-1.34) 1.35 (1.31-1.39) 
4 1.42 (1.37-1.47) 1.43 (1.38-1.49) 
5 1.53 (1.47-1.60) 1.61 (1.53-1.69) 
6 or higher 1.69 (1.62-1.77) 1.70 (1.61-1.78) 
Year of diagnosis   
2003-2005 1.02 (1.00-1.04) 0.58 (0.56-0.59) 
2006-2008 1.06 (1.05-1.08) 1.01 (0.99-1.03) 
2009-2011 1.00 (Reference) 1.00 (Reference) 
Surgery   
Yes 1.00 (Reference) 1.00 (Reference) 
No 4.647 (4.56-4.72) 3.01 (2.93-3.09) 
Chemotherapy   







No 1.37 (1.36-1.39) 1.55 (1.52-1.58) 
Radiation, less than 12 months following 
diagnosis 
  
Yes 1.00 (Reference) 1.00 (Reference) 
No 1.14 (1.12-1.16) 1.40 (1.37-1.43) 
Radiation, 12 months or more following 
diagnosis 
  
Yes 1.00 (Reference) 1.00 (Reference) 









Table 4.4 Time-Dependent Cox Proportional Hazards Results of Lung Cancer-Specific Survival, 
 Stratified by Race, SEER-Medicare NSCLC Cases 2003-2011  
 




 HR (95% CI) HR (95% CI) 
Geographic Factors   
Region by Rurality   
Midwest   
Large Urban 1.00 (Reference) 1.00 (Reference) 
Small Urban 1.03 (0.99-1.08) 1.03 (0.97-1.10) 
Rural 1.11 (1.06-1.16) 1.07 (1.01-1.14) 
Northeast   
Large Urban 1.00 (Reference) 1.00 (Reference) 
Small Urban 0.95 (0.92-0.98) 0.99 (0.95-1.03) 
Rural 0.96 (0.88-1.05) 0.94 (0.83-1.06) 
South   
Large Urban 1.00 (Reference) 1.00 (Reference) 
Small Urban 1.08 (1.05-1.12) 1.09 (1.05-1.15) 
Rural 1.10 (1.07-1.14) 1.10 (1.06-1.15) 
West   
Large Urban 1.00 (Reference) 1.00 (Reference) 
Small Urban 1.08 (1.05-1.10) 1.12 (1.08-1.15) 
Rural 1.09 (1.06-1.13) 1.12 (1.07-1.18) 







Sex   
Male 1.00 (Reference) 1.00 (Reference) 
Female 0.86 (0.85-0.87) 0.84 (0.82-0.85) 
Marital Status   







Not married 1.18 (1.17-1.20) 1.12 (1.09-1.14) 
Medicaid Enrollment   
Yes 0.98 (0.96-1.00) 0.94 (0.92-0.96) 
No 1.00 (Reference) 1.00 (Reference) 
Clinical Factors   
Stage at Diagnosis   
Localized 1.00 (Reference) 1.00 (Reference) 
Regional 2.15 (2.10-2.20) 1.95 (1.89-2.00) 
Distant 5.80 (5.69-5.92) 3.73 (3.62-3.83) 
Charlson Comorbidity Score    
0-2 1.00 (Reference) 1.00 (Reference) 
3 or higher 1.18 (1.16-1.20) 1.18 (1.15-1.21) 
Year of diagnosis   
2003-2005 1.08 (1.07-1.10) 0.56 (0.55-0.58) 
2006-2008 1.05 (1.03-1.06) 1.02 (1.01-1.04) 
2009-2011 1.00 (Reference) 1.00 (Reference) 
Surgery   
Yes 1.00 (Reference) 1.00 (Reference) 
No 5.58 (5.46-5.69) 3.28 (3.18-3.38) 
Chemotherapy   
Yes 1.00 (Reference) 1.00 (Reference) 
No 1.37 (1.36-1.39) 1.55 (1.52-1.58) 
Radiation, less than 8 months following diagnosis   
Yes 1.00 (Reference) 1.00 (Reference) 
No 1.18 (1.16-1.20) 1.45 (1.42-1.49) 
Radiation, 8 months or more following diagnosis   
Yes 1.00 (Reference) 1.00 (Reference) 




























TIME TO TREATMENT INITIATION AND LUNG CANCER 






                                                          






Rural patients must travel farther for cancer care than their urban counterparts, 
perhaps putting them at higher risk of delayed treatment initiation. The relationship 
between time to treatment initiation and survival is not well characterized and there are 
currently no standard recommendations or quality metrics for the time between diagnosis 
and treatment initiation for lung cancer patients. Our aim was to examine urban/rural 
differences in time to treatment initiation and the relationship of time to treatment 
initiation (for surgery, chemotherapy and radiation separately) and lung cancer-specific 
survival. 
Methods 
We used SEER-Medicare linked data for non-small cell lung cancer (NSCLC) 
patients diagnosed between 2003-2011. We excluded patients under age 66 (to ensure at 
least 12 months of Medicare data prior to diagnosis) and those with Medicare eligibility 
due to end-stage renal disease. We created three treatment-specific cohorts (cancer-
related surgery, chemotherapy, and radiation) using Medicare billing codes. Claims were 
used to identify the first treatment date and time from diagnosis to treatment initiation 
was examined continuously and categorized as follows: 0-4 weeks, 5-6 weeks, 7-8 
weeks, 9-12 weeks, and greater than 12 weeks. We also explored a binary comparison of 
treatment time: 0-12 weeks versus greater than 12 weeks. We used the Kaplan Meier and 
logrank test to assess the unadjusted relationship of time to treatment initiation and 
survival for each treatment type. We then used Cox Proportional Hazards (PH) models to 




assumption for all variables included. We produced univariate and adjusted Hazards 
Ratios (HR) with 95% confidence intervals (CI) based on our final models by stage at 
diagnosis. 
Results 
The majority of NSCLC patients received all treatment types in 12 weeks or less. 
The proportion of rural residents starting treatment after 12 weeks was significantly less 
than the proportion starting treatment in 0-12 weeks, and the opposite was true for urban 
residents (surgery p<0.01, chemotherapy p<0.01, radiation p<0.01). Earlier treatment 
(within 12 weeks of diagnosis) did not results in a survival advantage in the adjusted 
models for chemotherapy and radiation for any stage. In the time-dependent Cox PH 
model for surgery, those who had surgery later than 12 weeks post diagnosis had better 
survival than those who had surgery in 0-12 weeks, in the first 16 months of follow up 
time when stratifying by radiation for all stages (HR: 0.83, 95% CI: 0.75-0.91). Beyond 
16 months of follow-up, localized and regional cases who had surgery after 12 weeks had 
worse survival than those who had surgery in 0-12 weeks (localized HR:1.20, 
95%CI:1.06-1.33; regional HR:1.18, 95%CI:1.06-1.32). The difference in survival was 
not significantly different for distant cases beyond 16 months of follow-up for different 
times to surgery initiation (distant HR:0.61, 95% CI:0.46-0.82).  
Conclusions  
Lung cancer treatment decisions are complex, often requiring time for diagnostic 
testing and consultations with many specialist physicians. Time to treatment initiation 
may not be an important factor for improving lung cancer survival. However, receipt of 




all of those who received treatment, a higher proportion of rural residents initiated 
treatment within 12 weeks of diagnosis. However, rural residents had worse survival than 
urban residents. Future research is needed to better understand time to treatment initiation 
and lung cancer survival.  
 
5.2 Introduction 
Treatment approaches for lung cancer vary based upon many factors including 
stage at diagnosis, tumor histology and location, and overall health of a patient.105 Lung 
cancer treatment may include surgery, radiation, chemotherapy, or a combination thereof. 
Treatment approaches such as targeted therapies and immunotherapy are continuing to 
expand, with FDA approval starting in 2015.116 In spite of the many treatment options 
available for lung cancer, in healthy adults diagnosed before metastasis, surgery is the 
most effective treatment approach for improved survival.100 Staging, tumor size, tumor 
location(s), and patient comorbidities (i.e., medical operability) are collectively 
considered when determining if surgical resection is appropriate, yet surgery is often 
reserved for patients diagnosed in early stages.100,218,102 In late-stages and/or people with 
poor health, surgery may not be an option. Hence, chemotherapy and/or radiation are 
considered the next best treatment approaches.87 Depending on the stage at diagnosis, 
chemotherapy for lung cancer may be given prior to surgery, after surgery (adjuvant 
therapy), or at the same time as radiation treatment (concurrent therapy).87,100 Similarly to 
chemotherapy, radiation may be given before surgery, after surgery, and in some cases 
alone.87,100 Radiation prior to surgery is often an attempt to shrink tumors for easier 




the precise location of tumors.115 SBRT is mostly given to patients who are not eligible 
for surgery and have small, well differentiated tumors. Radiation alone may also be 
recommended for late-stage patients as a palliative care approach.87  
 
Timely treatment is one of six domains of health care quality recommended from 
the Institute of Medicine introduced in 2015.122 However, as choosing the appropriate 
treatment approach varies from one patient to the next, the time between diagnosis and 
treatment initiation also varies. Additionally, optimal timing of treatment initiation and 
the impact of timely treatment on lung cancer on survival is not well defined in previous 
studies.123–127,133,225 Recommendations from agencies such as the American Cancer 
Society and American Lung Association suggest starting treatment “very soon” or 
“within a few weeks” after a cancer diagnosis218,226 while other organizations recommend 
starting treatment within 14 days (Danish Lung Cancer Registry) or 6 weeks regardless of 
the stage or treatment type (RAND Corporation).126,135 The British Thoracic Society 
recommends surgical treatment in less than 8 weeks, radiation in less than 7 weeks, and 
chemotherapy in less than 4 weeks following diagnosis.126 While some view quicker 
treatment initiation as superior for patient outcomes, data supporting this stance is scarce.  
 
Timely treatment and survival outcomes 
Timely treatment and its association with lung cancer survival is not well 
understood.9–15 Publications on the topic have used a range of definitions for treatment 
itself (surgery, chemotherapy, or radiation) and timely treatment (e.g., median time from 




between timely treatment and improved survival in lung cancer patients. A study of early-
stage lung cancer patients reported an average referral time of 61.2 days following 
diagnosis.127 They found that increasing weeks from diagnosis to first surgery (measured 
continuously) predicted worse survival.127 However, these results were not statistically 
significant after adjusting for patient demographics and clinical factors. A nested case-
control study of 762 lung cancer patients found shorter time intervals between diagnosis 
and surgical treatment to be associated with improved survival through a Kaplan-Meier 
analysis.225 However, after adjusting for patient symptoms and smoking status, the results 
were no longer significant. Findings from a large, 12-year sample of stage I lung cancer 
patients from the National Cancer Database found that surgery initiation before 8 weeks 
post-diagnosis resulted in significantly higher survival rates.227 A review among 
Medicare patients found a median time-to-treatment of 27 days.124 In early-stage cases, 
treatment initiation within 35 days was associated with improved survival. There was no 
association between treatment time and survival for distant-stage cases.124  
 
Others have reported conflicting findings, showing worse survival or no 
association between for timely treatment and lung cancer. In a small sample of veterans 
(n=129) from a single health care system, the median time to treatment was 84 days.133 
Using the median, timely treatment was defined as less than 84 days. They found that 
patients receiving timely treatment were more likely to die than patients receiving care 
after 84 days, but after stratifying by disease severity (advanced stage, non-solitary 
pulmonary nodules), the results were not significantly different.133  A study of privately 




and survival when patients received treatment within 6 weeks of diagnosis.134 Likewise, 
an investigation of 482 stage I-III NSCLC patients in a single medical network in Texas 
from 2000-2005 found a median diagnosis to treatment time of 33 days.128 They defined 
timely treatment as less than 33 days and reported no association between timely 
treatment and survival using Kaplan Meier survival analysis.128  An examination of 
SEER-Medicare records from 2002-2007 showed a median time interval of 180 days with 
most patients waiting over 300 days to initiate treatment.126  Timely treatment was 
defined using guidelines published by the RAND corporation and the British Thoracic 
Society: less than 8 weeks for surgery, 7 weeks for radiation, and 4 weeks for 
chemotherapy.126,135 In their survival analysis among 16,747 patients diagnosed in 2003 
or 2004, they found worse survival in patients receiving timely care as compared to those 
receiving care after their defined time periods.126 The relationship between time to 
treatment initiation and survival in lung cancer patients remains unclear and needs further 
investigation.  
 
Disparities in Time to Treatment Initiation 
There are conflicting findings related to racial and rural disparities in the timely 
treatment of lung cancer. A study of the association between race and timely treatment of 
lung cancer among veterans found no racial differences in time to treatment, palliative 
care, or hospice referrals between black and white patients.53  Conversely, a SEER-
Medicare analysis of lung cancer patients from 2000-2002 reported delays in treatment 
were more likely among black cases than white cases.136 Other factors associated with 




being divorced or widowed (vs. married), and late-stage diagnosis (vs. early stage).136 A 
SEER analyses using records from 2002-2007 also reported differences in time to 
treatment by race where non-white patients were less likely to receive timely treatment 
compared to white patients.126 Rural residents with lung cancer are also less likely to 
receive treatment than urban residents with lung cancer.228 Thoracic surgeons are not 
widely available in rural areas, potentially resulting in unequal access  to high-quality 
surgery for rural lung cancer cases.112,113 Rurality and region may dictate patient 
experiences in navigating cancer care, influencing potential differences in survival. We 
are interested in investigating the potential contribution of time to treatment on this rural 
survival disparity. Our objective was to compare the time between diagnosis and 
treatment initiation by rurality and region, then to examine the association of time to 
treatment with lung cancer-specific survival at differing thresholds of treatment initiation 




We utilized data from the Surveillance, Epidemiology, and End Results (SEER) 
program linked with comprehensive Medicare fee-for-service (FFS) billing data (SEER-
Medicare) for cases diagnosed with non-small cell lung cancer (NSCLC) from 2003 to 
2011.199 SEER-Medicare provides population-based cancer registry data from the SEER 
registry sites covering New Jersey, Connecticut, Iowa, Wisconsin, Louisiana, Kentucky, 
Georgia, California, Hawaii, Utah, Idaho, New Mexico, Detroit (Michigan), Seattle 




months of Medicare FFS billing data prior to diagnosis. We also excluded those with 
Medicare eligibility due to end-stage renal disease, patients with a missing date of 
diagnosis, and those who did not receive cancer-directed surgery, chemotherapy, or 
radiation.  
 
Time to Treatment Initiation 
We created three separate cohorts based on treatment type (surgery, 
chemotherapy, radiation). Receipt of surgery and/or radiation was reported through SEER 
and confirmed through Medicare billing codes with the corresponding date of services. 
Chemotherapy receipt and the date of services are not reported by SEER and were pulled 
from Medicare billing codes alone. The appendix includes the list of CPT, HCPCS, and 
ICD-9 billing codes used to identify cancer-directed surgery, chemotherapy, and radiation 
from the National Cancer Institute.204 Diagnostic procedures, such as biopsy and surgical 
staging were excluded. Treatment initiation was defined by the earliest date for cancer-
directed surgery, chemotherapy, and radiation following the diagnosis date. Month of 
diagnosis and year of diagnosis are reported by SEER. The National Cancer Institute 
suggests using the first day or the fifteenth day as the day of diagnosis.229 To ensure that 
the diagnosis date always preceded the first treatment, the first of the month was assigned 
to all cases for the day of diagnosis We examined time between diagnosis and first 
treatment continuously and in five categories in an effort to identify the timing threshold 
at which survival is affected. The five categories we tested were: 0-4 weeks, 5-6 weeks, 
7-8 weeks, 9-12 weeks, and greater than 12 weeks then in two categories 0-12 weeks 




Survival and Covariates 
Lung cancer-specific survival time was assessed from SEER data using vital 
status and survival time in months. We assessed differences in time to treatment initiation 
for factors in the following categories: 1) geographic factors, 2) demographic factors, and 
3) clinical factors. Geographic factors included urban/rural residence, and Census region. 
Urban/rural status was defined by collapsing metropolitan categories and 
nonmetropolitan categories of Rural Urban Continuum Codes (RUCC) where 
metropolitan=urban and nonmetropolitan=rural.203 We grouped registry locations into 
Census regions as follows:  
1. Northeast: New Jersey, Connecticut 
2. Midwest: Iowa, Wisconsin, Detroit, Michigan  
3. South: Louisiana, Kentucky, Georgia 
4. West: Seattle, California, Utah, Idaho, New Mexico, Alaska Natives, Hawaii    
 
Demographic factors included age at diagnosis, sex, race, marital status, and 
Medicaid enrollment (yes/no). Clinical factors included stage at diagnosis (localized, 
regional, distant), Charlson comorbidity score (0-2 or 3+), year of diagnosis, and receipt 
of other treatment types. Charlson comorbidity score was calculated from Medicare 
billing codes from the 12 months prior to diagnosis using a validated SAS macro 
available from the National Cancer Institute.230 We chose our reference groups as the 
most advantaged group in terms of survival, based on existing epidemiology data (e.g., 






For each treatment type, we produced frequencies for all variables included in the 
model and performed between group comparisons by time to treatment using chi-square 
tests with =0.05 by stage at diagnosis. We tested the unadjusted relationship between 
time to treatment and lung cancer-specific survival with Kaplan Meier curves and the 
logrank test. We then tested the Proportional Hazards (PH) assumption using log-log of 
survival probability over time for all variables included in the model. We calculated 
univariate Hazards Ratios (HRs) for all variables tested for inclusion and performed a 
backwards selection with removal levels of 0.05 coupled with likelihood ratio tests to 
assess model fit. Using our final models, we produced hazards ratios with 95% 
confidence intervals for survival of NSCLC patients by categories of time to treatment. 
 
Time to Surgical Treatment Model 
For surgical treatment, two variables of interest violated the PH assumption: time 
to surgery initiation and radiation treatment. Time to surgery initiation showed a clear 
crossover in survival probability at 16 months post diagnosis. To account for these 
violations in our model, we incorporated a variable for the interaction between time to 
surgery initiation and survival time at 16 months post diagnosis and stratified by radiation 
treatment.  
 
When stratifying by a radiation in survival analysis, the stratified Cox PH models 
constructs separate partial likelihood functions for each radiation group. The multiplies 




the function. Therefore, the effect of radiation is absorbed into the time function and we 
can no longer make comparisons on this variable. Time-dependent Cox PH models allow 
us to account for the PH assumption of a variable, when deemed appropriate, and retain 
the ability to draw conclusions on that variable. Further explanations on time-dependent 
and stratified Cox PH models can be found elsewhere.206,207 
 
Time to Chemotherapy Treatment Model 
For our sample of patients who received chemotherapy treatment, the variable for 
radiation treatment also violated the PH assumption; thus, we applied a time-dependent 
PH model. Specifically, we created and incorporated a time dependent variable into the 
Cox PH model representing radiation 12 months post diagnosis or not.  
 
Time to Radiation Treatment Model 
Census region violated the PH assumption among our sample of patients who 
received radiation treatment. We chose to use a stratified Cox PH model, stratified by 
region. As described above, using a stratified Cox PH model accounts for the effect of 
region in the final model but does not allow for comparisons between regions.206   
 
5.3 Results 
Surgery Patient Characteristics  
A final sample size of 26,365 patients were identified as receiving surgical 
treatment with 22,021 (83.5%) within 12 weeks of diagnosis and 4,344 (16.5%) after 12 




(p<0.01) where 85.7% of those receiving treatment within 12 weeks were urban residents 
and 14.3% were rural residents. In those receiving surgical treatment more than 12 weeks 
after diagnosis, the proportion was higher proportion for urban residents (87.5%) and 
12.5% were rural residents. Time to surgery was significantly different by regions as well 
(p<0.01). The West was the only region that had a higher proportion of residents 
receiving surgery after 12 weeks compared to 0-12 weeks (West 0-12 weeks: 40.2%; 
West >12 weeks: 48.2%). Differences existed by age groups as well (p<0.01). Those over 
the age of 75 had higher proportions treated with surgery in 0-12 weeks compared to after 
12 weeks (75+, 0-12 weeks: 46.0% 75+, >12 weeks: 43.1%). A higher proportion of non-
white patients received surgery after 12 weeks compared with within 12 weeks (13.1% 
vs. 10.0%, p<0.01). A higher proportion of Medicaid enrollees were treated with surgery 
after 12 weeks (14.1%) than in 0-12 weeks (10.8%) (p<0.01), and a higher proportion of 
those receiving radiation received surgery after 12 weeks (21.7% vs. 8.9%, p<0.01). A 
higher proportion of married individuals received surgery after 12 weeks than 0-12 weeks 
(>12 weeks: 42.5% vs. 0-12 weeks: 37.8%, p<0.01), and a lower proportion of unmarried 
individuals received surgery after 12 weeks (55.0%) compared to those who received 
surgery within 12 weeks (59.3%, p<0.01). The majority of patients treated in 12 weeks or 
less were localized stage (55.8%) while the highest percent of those treated after 12 
weeks were regional stage (47.8%, p<0.01). Sex was not significantly different by time to 
surgery (p=0.32). However, the majority of subjects that received surgery regardless of 
time were female (0-12 weeks: 52.7%; >12 weeks: 51.8%). Chemotherapy receipt also 





Time to Surgery and Survival  
There were no significant differences in survival for time categories less than 12 
weeks (Table A.1). However, the unadjusted difference in survival with surgery initiation 
in 0-12 weeks versus greater than 12 weeks was significantly different in the first 16 
months of follow up (logrank test, p <.0001; Kaplan Meier depicted in Figure 5.1) where 
those receiving surgery in less than 12 weeks had worse survival. The median survival 
for those who received surgical treatment was greater than our follow time (greater than 
60 months), regardless of the time to initiation. Our final stratified time-dependent Cox 
PH model included time to surgery initiation, urban/rural residence, age, sex, Charlson 
comorbidity score, year of diagnosis, and stage at diagnosis, stratified by radiation. 
Medicaid enrollment (p=0.68), race (p=0.81), region (p=0.84) and chemotherapy 
(p=0.77) were dropped from the model. Surgical patient characteristics by stage at 
diagnosis are shown in Table 5.2. 
 
Based on our final model, within 16 months of follow up, those who had surgery 
later than 12 weeks post diagnosis had better survival than those who had surgery in 0-12 
weeks, when stratifying by radiation for every stage at diagnosis (localized HR:0.92, 
95%CI:0.76-1.11; regional HR:0.91, 95%CI:0.80-1.03; distant HR:0.50, 95%CI:0.39-
0.63) (Table 5.5). Beyond 16 months of follow-up, localized stage patients receiving 
surgery after 12 weeks had worse survival than localized patients receiving surgery in 0-
12 weeks, stratifying by radiation (localized HR:1.20, 95%CI:1.06-1.33). The same 
relationship was true for regional cases where after 16 months of follow-up, patients 
receiving surgery after 12 weeks had worse survival than those initiation surgical 




Among distant stage cases beyond 16 months of follow-up, surgery after 12 weeks was 
associated with improved survival when compared to distant cases who received surgery 
in 0-12 weeks, stratifying by radiation (distant HR:0.61, 95%CI:0.46-0.82).  
 
Rural residents who received surgery had worse adjusted survival than urban 
residents, stratified by radiation at localized stages (localized HR:1.20, 95%CI:1.09-
1.33). Among regional and distant stage cases who had surgery, there was no significant 
difference in survival (regional HR:1.08, 95%CI:0.99-1.18; distant HR:0.96, 
95%CI:0.79-1.18). Increasing comorbidities were associated with worse survival among 
surgery patients at every stage, though not significant among distant cases, stratifying by 
radiation (localized HR:1.36, 95%CI:1.23-1.51; regional HR:1.33, 95%CI:1.19-1.45; 
distant HR:1.19, 95%CI:0.97-1.46).  
 
Chemotherapy Patients Characteristics  
We identified 59,623 patients who received chemotherapy with 39,724 (66.6%) 
starting chemotherapy within 12 weeks following diagnosis and 19,927 (33.4%) in more 
than 12 weeks after diagnosis (Table 5.1). All geographic, demographic, and clinical 
factors differed significantly with p<0.01 by categories of time to treatment initiation. A 
higher proportion of urban residents received treatment after 12 weeks (83.5%), while a 
lower proportion of rural residents received treatment after 12 weeks (16.6%) (p<0.01). A 
higher proportion of males received chemotherapy within 12 weeks of diagnosis (53.5%), 
while a higher proportion of females received chemotherapy after 12 weeks (52.7%) 




had surgery, compared to 52.2% of those that received chemotherapy after 12 weeks 
(p<0.01). Chemotherapy patient characteristics by stage at diagnosis are shown in Table 
5.3. 
 
Time to Chemotherapy and Survival  
Our final model for time to chemotherapy initiation was a time dependent PH 
model stratified by radiation, with a crossover in survival probability at 4 months of 
follow up (Table 5.6). Region and race were not significant and dropped from the final 
model. Those who initiated chemotherapy later than 12 weeks post diagnosis had better 
survival when compared to those starting chemotherapy in 0-12 weeks at every stage at 
diagnosis (localized HR:0.61, 95%CI: 0.57-0.65; regional HR:0.69, 95%CI:0.65-0.72, 
distant HR:0.55, 95%CI:0.53-0.58). Rural residents had worse survival compared to 
urban residents at every stage, though not significantly different among regional cases 
(localized HR:1.12, 95%CI:1.04-1.20; regional HR:1.08, 95%CI:0.98-1.09, distant 
HR:1.09, 95%CI:1.05-1.15). Survival worsened with increasing Charlson comorbidity 
score at every stage of diagnosis (localized HR:1.10, 95%CI:1.02-1.19; regional HR:1.21, 
95%CI:1.14-1.28; distant HR:1.13, 95%CI:1.09-1.18). 
 
Radiation Patients Characteristics  
A total of 34,621 patients were identified as having radiation treatment. Of all 
patients who received radiation, 28,538 initiated radiation within 12 weeks of diagnosis 
and 6,083 after 12 weeks. When comparing by time to radiation initiation, patients 




marital status (p<0.01), Medicaid enrollment (p<0.01), chemotherapy (p<0.01), surgery 
(p<0.01), Charlson comorbidity score (p<0.01), and stage at diagnosis (p<0.01). A higher 
proportion of the group starting radiation after 12 weeks also received surgery (21.3%) 
and/or chemotherapy (84.5%), compared to 5.6% who received radiation within 12 weeks 
also had surgery and 75.9% also had radiation (p<0.01). Time to radiation initiation was 
not different by sex (p=0.05) and year of diagnosis (p=0.97). However, more than half of 
those who received radiation were male (53.0% at 0-12 weeks; 51.6% at >12 weeks). 
Radiation patient characteristics by stage at diagnosis are shown in Table 5.4. 
 
Time to Radiation and Survival 
Our final model for time to first radiation treatment was Cox PH model stratified 
by region (Table 5.7). Urban/rural residence, race, marital status, and Charlson 
comorbidity score were not significant and dropped from the final model. Those starting 
radiation later than 12 weeks had better survival than those starting radiation within 12 
weeks, stratified by region for every stage at diagnosis (localized HR:0.83, 95%CI:0.75-
0.91; regional HR:0.73, 95%CI:0.69-0.77; HR:0.54, 95%CI:0.52-0.57). Increasing age 
was associated with increasing hazards ratios, stratified by region at all stages. Females 
had better survival than males (localized HR:0.79, 95%CI:0.73-0.86; regional HR:0.86, 
95%CI:0.82-0.90; distant HR:0.92, 95%CI:0.89-0.95) and those on Medicaid had better 
survival than those not on Medicaid (localized HR:0.92, 95%CI:0.82-1.04; regional 
HR:0.91, 95%CI:0.84-0.98; distant HR:0.85, 95%CI:0.80-0.90), stratified by region at all 






Developing treatment plans for lung cancer is a complex process, at times 
involving multiple physicians, tumor boards, referral times, and diagnosis procedures. 
Overall, we did not find an improvement in survival probability with treatment initiation 
within 12 weeks of diagnosis except for localized and regional surgical cases after 16 
months of follow up time. For surgical treatment, the relationship between time to 
treatment initiation was not significant after 16 months of follow up. For chemotherapy 
and radiation, our results showed that those with treatment initiation after 12 weeks 
following diagnosis had better survival than those who received treatment by the 12-week 
point among all stages. We demonstrated that a higher proportion of those who had 
delayed chemotherapy treatment (>12 weeks) and a higher survival probability had also 
received surgery (52.2%) while only 15% of the early chemotherapy group (0-12 weeks) 
received surgery. The same trend held true for those receiving radiation after 12 weeks, 
where 21.3% had surgery, compared with only 5.6% of those who started radiation in 0-
12 weeks.  
 
Studies examining the time to treatment initiation of lung cancer have reported 
conflicting findings on the relationship with survival.9-17 We found that those who 
received surgery within 12 weeks of diagnosis had worse survival in the first 16 months 
following diagnosis. These findings are similar to those from Gould et al where a shorter 
wait time was associated with worse survival.133 However, these findings contrast with 
those showing shorter wait times and surgery before 8 weeks was associated with 




survival with early treatment but among all other stages there was no association between 
time to surgery and survival.124 Using SEER-Medicare data from 2000-2002, Halpern et 
al reported that late-stage patients were more likely to receive surgery quickly,136 but our 
results showed that a higher proportion of cases treated after 12 weeks (7.5%) were 
distant stage, compared to 5.5% treated within 12 weeks.  
 
Among our chemotherapy and radiation cohorts, starting chemotherapy or 
radiation within 12 weeks was associated with lower survival probability than those who 
initiated chemotherapy or radiation after 12 weeks among all stages. However, this could 
be attributed partially to the higher proportion of patients who started chemotherapy or 
radiation after 12 weeks who also had received surgery, pointing back to surgery being an 
effective treatment approach at improving survival for lung cancer. Also important to 
consider is that radiation can be given as a palliative care option for patients not eligible 
for surgery and/or chemotherapy due to comorbidities or advanced stage at 
diagnosis.87,218 Our results are similar to those examining all treatment types together 
where earlier treatment was associated with worse survival or there was no significant 
difference in survival depending on the time to treatment initiation.126,128,133,134 It may be 
informative to examine treatment types separately and sequences of treatment in future 
analyses to better characterize the relationship of each the time to initiation of each 
treatment type and survival. 
 
Low income, black race, rural residence, and living in the South are associated 




proportion receiving treatment within 12 weeks for all three treatment categories. 
However, rural residents had worse survival for surgery and chemotherapy. 4–6,10,11,13 Our 
surgery sample was nearly 90% white, and black patients have been shown to be more 
likely to decline surgery for cancer treatment than whites, even when diagnosed in early 
stages. Urban/rural, regional, and racial difference in lung cancer survival may be driven 
by disparities in access to surgical treatment as our data was restricted to only patients 
who received treatment. 
 
Our study is not without limitations. While SEER provides a large, diverse data 
source, it is limited in the geographic coverage and underrepresents rural areas.222 This 
may have underpowered our ability to detect differences between urban and rural 
settings, a recurring issue for using national data to study urban and rural 
differences.221,222,231,232 We did not examine Medicare Part D files in our analyses. 
Chemotherapy only administered outpatient and billed through Part D claims were not be 
captured. Medicare billing codes are not intended for use in research and it is possible 
that some procedure codes are incorrect or missing. While we believe our list of codes 
was thorough, it is possible that some procedure codes were missed. SEER-Medicare is 
also limited to fee-for-service claims and does not include data on Medicare Advantage 
beneficiaries. 
 
Our study has many strengths, including the large sample size from SEER-
Medicare, a multi-site data source covering 26% of the US population.199 Our analyses 




comprehensive examination of treatment options available from 2003-2011, assessing the 
differing relationships of the treatment types and survival. Our results also provide 
updated data for comparison to previous publications and future work. These results may 
also provide meaningful insight to practicing clinicians as the time between diagnosis and 
treatment initiation may not be an important factor when developing treatment protocols. 
 
We did not find evidence of a survival benefit to receiving treatment within 12 
weeks of diagnosis for chemotherapy and radiation. Time to treatment initiation may not 
be as important as factors that influence the development of personalized treatment plans 
such as confirmatory testing, surgical staging, and control of patient comorbidities. We 
did, however, observe that the median survival of those who received surgery at any time 
was higher than the overall median survival for lung cancer. We also found that surgery 
within 12 weeks of diagnosis for localized and regional patients improved survival after 
16 months of follow-up. Observed rural and racial disparities in lung cancer survival may 
be primarily driven by lower surgical utilization among these populations rather than 
differences in time to treatment initiation. Future work should focus on improving access 
to surgical treatment for lung cancer through expansion of the availability of surgeons to 
rural populations. Additional research is needed to better understand the complex 










Table 5.1. Demographics of SEER-Medicare NSCLC Patients by Time from Diagnosis to Treatment, 2003-2011 
 






 0-12 Weeks >12 Weeks 0-12 Weeks >12 Weeks 0-12 Weeks >12 Weeks 
Total (N) 22,021 4,344 39,724 19,927 28,538 6,083 
Rurality p<0.01 p<0.01 p<0.01 
Urban 85.7% 87.5% 81.9% 83.5% 83.0% 84.8% 
Rural 14.3% 12.5% 18.1% 16.6% 17.0% 15.2% 
Census Region p<0.01 p<0.01 p<0.01 
Midwest 11.7% 11.1% 13.2% 13.1% 15.2% 14.9% 
Northeast 22.0% 19.8% 19.7% 20.9% 19.5% 20.9% 
South 26.1% 20.8% 28.7% 26.6% 30.7% 24.7% 
West 40.2% 48.2% 38.4% 39.4% 34.7% 39.5% 
Demographic Factors 
Age p<0.01 p<0.01 p<0.01 
66-69 23.7% 25.9% 23.5% 23.1% 21.5% 24.7% 
70-74 30.4% 31.0% 29.6% 28.4% 27.3% 28.8% 
75-79 27.0% 26.6% 25.4% 25.1% 24.9% 25.0% 
80+ 19.0% 16.5% 21.5% 23.4% 26.3% 21.5% 
Sex p=0.32 p<0.01 p=0.05 
Male 47.3% 48.2% 53.5% 47.3% 53.0% 51.6% 
Female 52.7% 51.8% 46.5% 52.7% 47.1% 48.4% 
Race p<0.01 p<0.01 p<0.01 
White 90.0% 86.9% 86.9% 85.6% 85.0% 82.7% 
Non-White 10.0% 13.1% 13.1% 14.4% 15.0% 17.3% 
Marital Status p<0.01 p<0.01 p<0.01 
Married 37.8% 42.5% 40.3% 43.6% 54.6% 57.0% 
Not married 59.3% 55.0% 56.9% 53.6% 45.4% 43.0% 
Unknown/Missing 2.9% 2.5% 2.9% 2.9%   
Medicaid Enrollment p<0.01 p<0.01 p<0.01 
No 89.2% 85.9% 90.6% 88.0% 91.0% 89.2% 








Radiation p<0.01 p<0.01  
Yes 8.9% 21.7% 46.3% 30.5% - - 
No 90.0% 76.7% 52.0% 68.0% - - 
Unknown/Missing 1.2% 1.6% 1.7% 1.6% - - 
Chemotherapy p=0.24  p<0.01 
Yes 65.7% 66.6% - - 75.9% 84.5% 
No 34.3% 33.4% - - 24.1% 15.5% 
Surgery  p<0.01 p<0.01 
Yes - - 15.0% 52.2% 5.6% 21.3% 
No - - 85.0% 47.8% 94.4% 78.7% 
Charlson 
Comorbidity Score  
p<0.01 p<0.01 p<0.01 
0-2 75.2% 69.6% 81.1% 75.8% 78.7% 76.0% 
3 or higher 11.4% 9.5% 12.6% 13.2% 13.6% 12.7% 
Missing/Unknown 13.5% 20.9% 6.3% 11.0% 7.7% 11.3% 
Year of diagnosis p=0.03 p<0.01 p=0.97 
2003-2005 29.9% 30.3% 34.8% 37.4% 34.7% 34.6% 
2006-2008 34.9% 36.5% 36.0% 34.7% 33.3% 33.5% 
2009-2011 35.2% 33.3% 29.1% 27.9% 32.0% 32.0% 
Stage at diagnosis p<0.01 p<0.01 p<0.01 
Localized 55.8% 44.7% 12.0% 41.5% 12.2% 20.4% 
Regional 38.7% 47.8% 28.2% 33.0% 28.2% 39.3% 
Distant  5.5% 7.5% 59.8% 25.5% 59.6% 40.3% 








Table 5.2 Demographics of NSCLC Surgery Patients by Time from Diagnosis to Treatment, 








Time to Surgery 0-12 Weeks >12 Weeks 0-12 Weeks >12 Weeks 0-12 Weeks >12 Weeks 
Total  
 
12280 1943 8532 2075 1209 326 
 N (%) N (%) N (%) N (%) N (%) N (%) 
Geographic Factors 
Rurality    
Urban 10606 (86.2) 1699 (13.8) 7220 (79.9) 1815 (20.1) 1047 (78.5) 286 (21.5) 
Rural 1674 (87.3) 244 (12.7) 1312 (83.5) 260 (16.5) 162 (80.2) 40 (19.8) 
Census Region    
Midwest 1451 (85.8) 241 (14.1) 991 (82.9) 205 (17.1) 142 (79.3) 37 (20.7) 
Northeast 2808 (88.8) 356 (11.3) 1774 (79.9) 447 (20.1) 255 (81.2) 59 (18.8) 
South 3208 (88.7) 410 (11.3) 2226 (84.0) 425 (16.0) 311 (81.8) 69 (18.2) 
West 4813 (83.7) 936 (16.3) 3541 (78.0) 998 (22.0) 501 (75.7) 161 (24.3) 
Demographic Factors 
Age    
66-69 2907 (86.7) 445 (13.3) 2045 (77.8) 584 (22.2) 256 (72.5) 97 (27.5) 
70-74 3792 (86.6) 588 (13.4) 2502 (79.4) 648 (20.6) 395 (78.2) 110 (21.8) 
75-79 331 (85.9) 540 (14.1) 2345 (81.3) 541 (18.8) 305 (80.3) 75 (19.7) 
80+ 2280 (86.0) 370 (14.0) 1640 (84.5) 302 (15.6) 253 (85.20 44 (14.8) 
Sex    
Male 5515 (85.8) 910 (14.2) 4292 (80.8) 1020 (19.2) 617 (79.2) 162 (20.8) 
Female 6765 (86.8) 1033 (13.3) 4240 (80.1) 1055 (19.9) 592 (78.3) 164 (21.7) 
Race    
Caucasian 11115 (86.8) 1684 (13.2) 7619 (81.0) 1793 (19.1) 1077 (78.4) 296 (21.6) 
Non-Caucasian 1165 (81.8) 259 (18.2) 913 (76.4) 282 (23.6) 132 (81.5) 30 (18.5) 
Marital Status    
Married 7218 (87.3) 1049 (12.7) 5126 (81.7) 1146 (18.3) 723 (78.8) 195 (21.2) 
Not married 4688 (84.7) 849 (15.3) 3176 (78.4) 876 (21.6) 458 (79.4) 119 (20.6) 
Medicaid Enrollment    







No 10309 (86.8) 1570 (13.2) 6866 (80.9) 1623 (19.1) 869 (77.5) 252 (22.5) 
Clinical Factors 
Chemotherapy    
Yes 7734 (87.2) 1135 (12.8) 5908 (79.7) 1502 (20.3) 818 (76.2) 256 (23.8) 
No 4546 (84.9) 808 (15.1) 2624 (82.1) 573 (17.9) 391 (84.8) 70 (15.2) 
Radiation    
Yes 342 (71.25) 138 (28.8) 1276 (65.2) 681 (34.8) 340 (73.1) 125 (26.9) 
No 11838 (86.9) 1782 (13.1) 7121 (84.0) 1357 (16.0) 848 (81.5) 193 (18.5) 
Charlson Comorbidity Score     
0-2 9173 (87.6) 1294 (12.4) 6483 (81.3) 1487 (18.7) 892 (78.6) 243 (21.4) 
3 or higher 1516 (87.3) 221 (12.7) 841 (83.4) 168 (16.7) 151 (86.30 24 (13.7) 
Year of diagnosis    
2003-2005 3636 (86.4) 575 (13.7) 2574 (80.1) 641 (19.9) 382 (79.4) 99 (20.6) 
2006-2008 4359 (85.6) 734 (14.4) 2896 (79.8) 733 (20.2) 421 (78.3) 117 (21.80 








Table 5.3 Demographics of NSCLC Chemotherapy Patients by Time from Diagnosis to  








Time to Chemotherapy 0-12 Weeks >12 Weeks 0-12 Weeks >12 Weeks 0-12 Weeks >12 Weeks 
Total  
 
4763 8252 11192 6571 23769 5076 
 N (%) N (%) N (%) N (%) N (%) N (%) 
Geographic Factors 
Rurality    
Urban 3774 (35.5) 6853 (64.5) 9128 (62.4) 5492 (37.6) 19642 (82.2) 4261 (17.8) 
Rural 989 (41.4) 1399 (58.6) 2064 (65.7) 1079 (34.3) 4127 (83.5) 815 (16.5) 
Census Region    
Midwest 603 (35.3) 1104 (64.7) 1379 (62.2) 837 (37.8) 3253 (83.1) 663 (16.9) 
Northeast 817 (32.6) 1689 (67.4) 2329 (61.6) 1453 (38.4) 4666 (82.2) 1012 (17.8) 
South 1582 (40.0) 2417 (60.4) 3509 (66.9) 1737 (33.1) 6316 (84.7) 1142 (15.3) 
West 1761 (36.7) 3042 (63.3) 3975 (61.0) 2544 (39.0) 9534 (80.8) 2259 (19.2) 
Demographic Factors 
Age    
66-69 875 (33.3) 1752 (66.7) 2698 (63.2) 1571 (36.8) 5753 (81.9) 1269 (18.1) 
70-74 1305 (34.9) 2434 (65.1) 3453 (64.8) 1874 (35.2) 7005 (84.0) 1339 (16.1) 
75-79 1299 (37.8) 2136 (62.2) 2884 (62.6) 1725 (37.4) 5918 (83.8) 1141 (16.2) 
80+ 1284 (39.6) 1930 (60.4) 2157 (60.6) 1401 (39.4) 5093 (79.3) 1327 (20.7) 
Sex    
Male 2295 (38.5) 3668 (61.5) 6084 (65.5) 3202 (34.5) 12891 (83.5) 2545 (16.5) 
Female 2468 (35.0) 4584 (65.0) 5108 (60.3) 3369 (39.7) 10878 (81.1) 2531 (18.9) 
Race    
Caucasian 4259 (36.8) 7313 (63.2) 9851 (63.5) 5652 (36.5) 20417 (83.4) 4064 (16.6) 
Non-Caucasian 504 (34.9) 939 (65.1) 1341 (59.3) 919 (40.7) 3352 (76.8) 1012 (23.2) 
Marital Status    
Married 2543 (36.5) 4428 (63.5) 6423 (64.4) 3556 (35.6) 13624 (83.6) 2674 (16.4) 
Not married 2045 (36.3) 3582 (63.7) 4481 (61.2) 2846 (38.8) 9474 (80.9) 2244 (19.2) 
Medicaid Enrollment    








No 4232 (36.8) 7268 (63.2) 10122 (63.5) 5811 (36.5) 21646 (83.0) 4433 (17.0) 
Clinical Factors 
Surgery    
Yes 2096 (26.5) 5801 (73.5) 8014 (76.0) 2527 (24.0) 715 (57.8) 523 (42.3) 
No 2607 (51.9) 2418 (48.1) 3111 (43.6) 4021 (56.4) 22929 (83.5) 4522 (16.5) 
Radiation    
Yes 1433 (47.7) 1572 (52.3) 6338 (73.90 2241 (26.1) 12795 (82.4) 2740 (17.6) 
No 3233 (33.0) 6579 (67.1) 4637 (52.5) 4204 (47.6) 10617 (82.5) 2247 (17.5) 
Charlson Comorbidity Score     
0-2 3700 (36.7) 6388 (63.3) 9152 (64.3) 5081 (35.7) 19382 (84.3) 3610 (15.7) 
3 or higher 861 (40.7) 1254 (59.3) 1444 (65.6) 759 (34.5) 2703 (81.4) 619 (18.6) 
Year of diagnosis    
2003-2005 1648 (33.8) 3232 (66.2) 4040 (62.0) 2481 (38.1) 8145 (82.6) 1721 (17.4) 
2006-2008 1881 (39.1) 2931 (60.9) 3858 (63.7) 2198 (36.30 8579 (82.8) 1783 (17.2) 











Table 5.4 Demographics of NSCLC Radiation Patients by Time from Diagnosis to Treatment, 








Time to Radiation 0-12 Weeks >12 Weeks 0-12 Weeks >12 Weeks 0-12 Weeks >12 Weeks 
Total  
 
3483  1242 8048 2391 17007 2450 
 N (%) N (%) N (%) N (%) N (%) N (%) 
Geographic Factors 
Rurality    
Urban 2847 (73.5) 1024 (26.5) 6644 (76.5) 2040 (23.5) 14191 (87.2) 2093 (12.9) 
Rural 636 (74.5) 218 (25.5) 1404 (80.0) 351 (20.0) 2816 (88.8) 357 (11.3) 
Census Region    
Midwest 570 (72.9) 212 (27.2) 1214 (79.7) 309 (20.3) 2545 (86.9) 384 (13.1) 
Northeast 539 (70.0) 231 (30.0) 1645 (75.1) 546 (24.9) 3366 (87.2) 493 (12.8) 
South 1309 (79.3) 342 (20.7) 2661 (81.4) 609 (18.6) 4800 (89.7) 554 (10.3) 
West 1065 (70.0) 457 (30.0) 2528 (73.2) 927 (26.8) 6296 (86.1) 1019 (13.9) 
Demographic Factors 
Age    
66-69 386 (66.4) 195 (33.6) 1706 (72.9) 633 (27.1) 4051 (85.8) 673 (14.3) 
70-74 740 (69.9) 319 (30.1) 2280 (76.4) 703 (23.6) 4782 (86.7) 732 (13.3) 
75-79 913 (73.4) 331 (26.6) 2043 (76.7) 621 (23.3) 4135 (87.9) 571 (12.1) 
80+ 1444 (78.4) 397 (21.6) 2019 (82.3) 434 (17.7) 4039 (89.5) 474 (10.5) 
Sex    
Male 1614 (74.5) 533 (25.5) 4313 (77.8) 1231 (22.2) 9184 (87.2) 1353 (12.8) 
Female 1869 (73.1) 689 (26.9) 3735 (76.3) 1160 (23.7) 7823 (87.7) 1097 (12.3) 
Race    
Caucasian 3059 (74.3) 1057 (25.7) 6901 (77.7) 1978 (22.3) 14306 (87.8) 1995 (12.2) 
Non-Caucasian 424 (69.6) 185 (30.4) 1147 (73.5) 413 (26.5) 2701 (85.6) 455 (14.4) 
Marital Status    
Married 1614 (73.9) 571 (26.1) 4250 (75.60 1371 (24.4) 9293 (86.6) 1438 (13.4) 
Not married 1733 (73.5) 626 (26.5) 3595 (78.6) 979 (21.4) 7275 (88.5) 942 (11.5) 
Medicaid Enrollment    








No 3097 (74.4) 1064 (25.6) 7238 (77.2) 2138 (22.8) 
 
15623 (87.6) 2222 (12.5) 
Clinical Factors 
Chemotherapy    
Yes 2678 (73.8) 949 (26.2) 6815 (76.4) 2105 (23.6) 12171 (85.4) 2083 (14.6) 
No 805 (73.3) 293 (26.7) 1233 (81.2) 286 (18.8) 4836 (93.0) 367 (7.1) 
Surgery    
Yes 227 (48.9) 237 (51.1) 977 (52.8) 875 (47.3) 386 (68.1) 181 (31.9) 
No 3235 (76.4) 997 (23.6) 7043 (82.3) 1514 (17.7) 16575 (88.0) 2262 (12.0) 
Charlson Comorbidity Score     
0-2 2540 (74.0) 891 (26.0) 6363 (77.2) 1884 (22.8) 13541 (88.0) 1847 (12.0) 
3 or higher 826 (75.4) 269 (24.6) 1169 (82.0) 257 (18.0) 1892 (88.5) 246 (11.5) 
Year of diagnosis    
2003-2005 1040 (73.3) 378 (26.7) 2985 (77.9) 845 (22.1) 5879 (87.0) 881 (13.0) 
2006-2008 1097 (72.7) 412 (27.3) 2577 (76.4) 798 (23.6) 5826 (87.6) 825 (12.4) 











Table 5.5 Time-Dependent Cox PH Model of Time to Surgery and Lung Cancer-Specific Survival, Stratified by  
Radiation, SEER-Medicare 2003-2011 
 







Time to Surgery at time <16 months 
0-12 weeks 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
>12 weeks  0.92 (0.76-1.11)  0.91 (0.80-1.03)  0.50 (0.39-0.63)*   
Time to Surgery at time ≥ 16 months 
0-12 weeks 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
>12 weeks  1.20 (1.06-1.33)*  1.18 (1.06-1.32)*  0.61 (0.46-0.82)*  
Rurality 
Urban 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
Rural   1.20 (1.09-1.33)*  1.08 (0.99-1.18) 0.96 (0.79-1.18) 
Age 
66-69 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
70-74 1.23 (1.10-1.37)* 1.14 (1.04-1.25)* 1.01 (0.83-1.22) 
75-79 1.43 (1.28-1.59)* 1.30 (1.18-1.42)* 1.01 (0.83-1.24) 
80+ 1.76 (1.57-1.98)* 1.53 (1.38-1.69)* 1.27 (1.03-1.57)* 
Sex 
Male 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
Female 0.67 (0.62-0.73)* 0.77 (0.72-0.83)* 0.72 (0.62-0.83)* 
Marital Status 
Married 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
Not married 1.17 (1.08-1.27)* 1.13 (1.05-1.21)* 1.26 (1.09-1.46)* 
Charlson Comorbidity Score  
0-2 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
3 or higher 1.36 (1.23-1.51)* 1.33 (1.19-1.45)* 1.19 (0.97-1.46) 
Year of diagnosis 
2003-2005 1.29 (1.15-1.44)* 1.25 (1.14-1.36)* 1.27 (1.06-1.51)* 
2006-2008 1.16 (1.04-1.30)* 1.22 (1.11-1.33)* 1.03 (0.86-1.23) 
2009-2011 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 








Table 5.6 Time-Dependent Cox PH Model of Time to Chemotherapy and Lung Cancer-Specific Survival,  
SEER-Medicare 2003-2011 
 







Time to Chemotherapy 
0-12 weeks 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
>12 weeks 0.61 (0.57-0.65)* 0.69 (0.65-0.72)* 0.55 (0.53-0.57)* 
Rurality 
Urban 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
Rural 1.12 (1.04-1.20)* 1.03 (0.98-1.09) 1.09 (1.05-1.13)* 
Age 
66-69 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
70-74 1.19 (1.08-1.30)* 1.10 (1.04-1.17)* 1.04 (1.00-1.08) 
75-79 1.23 (1.12-1.35)* 1.19 (1.13-1.26)* 1.09 (1.05-1.14)* 
80+ 1.25 (1.14-1.38)* 1.28 (1.20-1.36)* 1.24 (1.19-1.29)* 
Sex 
Male 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
Female 0.69 (0.65-0.74)* 0.82 (0.78-0.85)* 0.85 (0.82-0.87)* 
Marital Status 
Married 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
Not married 1.10 (1.04-1.18)* 1.08 (1.04-1.13)* 1.12 (1.08-1.15)* 
Medicaid Enrollment 
Yes 0.87 (0.80-0.96)* 0.85 (0.80-0.91)* 0.82 (0.78-0.85)* 
No 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
Charlson Comorbidity Score  
0-2 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
3 or higher 1.10 (1.02-1.19)* 1.21 (1.14-1.28)* 1.13 (1.09-1.18)* 
Radiation, time<4 months 
Yes 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
No 1.92 (1.51-2.44)* 1.81 (1.61-2.04)* 1.20 (1.14-1.25)* 
Radiation, time≥4 months 
Yes 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 








Surgery    
Yes 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
No 4.16 (3.86-4.48)* 2.81 (2.67-2.96)* 1.84 (1.71-1.98)* 
Year of diagnosis 
2003-2005 1.23 (1.13-1.34)* 1.26 (1.19-1.33)* 1.17 (1.13-1.21)* 
2006-2008 1.06 (0.97-1.16) 1.13 (1.07-1.19)* 1.09 (1.05-1.13)* 
2009-2011 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 









Table 5.7 Cox PH Model of Time to Radiation and Lung Cancer-Specific Survival, Stratified by Region,  
SEER-Medicare 2003-2011 
 







Time to Radiation 
0-12 weeks 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
>12 weeks 0.83 (0.75-0.91)* 0.73 (0.69-0.77)* 0.54 (0.52-0.57)* 
Age 
66-69 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
70-74 1.15 (1.00-1.33) 1.11 (1.04-1.19)* 1.05 (1.01-1.10)* 
75-79 1.08 (0.94-1.24) 1.22 (1.15-1.31)* 1.10 (1.05-1.15)* 
80+ 1.17 (1.03-1.34)* 1.25 (1.16-1.34)* 1.14 (1.09-1.19)* 
Sex 
Male 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
Female 0.79 (0.73-0.86)* 0.86 (0.82-0.90)* 0.92 (0.89-0.95)* 
Medicaid Enrollment 
Yes 0.92 (0.82-1.04) 0.91 (0.84-0.98)* 0.85 (0.80-0.90)* 
No 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
Chemotherapy  
Yes 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
No 1.11 (1.01-1.22)* 1.73 (1.62-1.84)* 2.15 (2.08-2.23)* 
Surgery 
Yes 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
No 1.46 (1.26-1.68)* 1.77 (1.65-1.89)* 1.61 (1.46-1.76)* 
Year of diagnosis 
2003-2005 1.75 (1.58-1.95)* 1.25 (1.18-1.32)* 1.07 (1.03-1.11)* 
2006-2008 1.40 (1.26-1.55)* 1.11 (1.04-1.18)* 1.05 (1.01-1.09)* 
2009-2011 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 













Figure 5.1 Kaplan Meier Curve of Lung Cancer-Specific Survival by Time to Surgical Treatment  










Figure 5.2 Kaplan Meier Curve of Lung Cancer-Specific Survival by Time to Chemotherapy Treatment  










Figure 5.3 Kaplan Meier Curve of Lung Cancer-Specific Survival by Time to Radiation Treatment  
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Rural residents face a higher incidence of lung cancer, longer drive times to 
access care, and worse survival than urban lung cancer patients. Surgical resection is the 
recommended treatment approach for healthy adults diagnosed with early stages of lung 
cancer by the National Comprehensive Cancer Network and is considered the most 
effective treatment approach for improving survival among localized cases. Despite this, 
inequities in the utilization of surgical treatment exist for some minority groups, 
particularly black versus white patients. We hypothesized that observed rural survival 
disparities in early stage rural lung cancer patient may be due lower utilization of surgical 
treatment when compared to their urban counterparts, in addition to racial disparities in 
surgical utilization. To assess this, we examined patient- and county-level determinants 
of receipt of surgical treatment for non-small cell lung cancer (NSCLC), focusing on 
rural vs. urban disparities. 
Methods 
We examined patients nested within counties in a multilevel logistic regression 
model stratified by stage at diagnosis, predicting receipt of surgical treatment. Our 
sample included 63,767 localized and regional NSCLC cases diagnosed between 2003-
2011 using SEER-Medicare data across the United States. Predictors examined included 
patient demographics, clinical characteristics and county-level factors, including urban 
versus rural designation, percent of the 65 and older population in poverty, and Medically 






Less than one-half (46.1%) of patients with early stage lung cancer received 
surgical treatment. Of patients diagnosed at localized stage, 56.7% received surgery 
compared to 42.6% of patients diagnosed at regional stage. Fewer rural residents received 
surgery when compared with urban residents (42.0% vs. 46.8%), and fewer black patients 
received surgery (32.9%) than white patients (47.1%) and those of other races (48.0%). 
Rural residence was not a significant predictor of surgery at the county level for local 
stage cases (OR=0.87, 95% CI:0.74-1.03) nor regional stage cases (OR-1.09, 95% 
CI:0.95-1.26). However, the odds of surgical treatment decreased per 5% increase in 
county-level poverty for both local and regional stages (local OR=0.83, 95% CI:0.77-
0.91; regional OR=0.84, 95%CI: 0.79-0.90). Patient factors associated with lower 
likelihood of surgical treatment included increasing age, male sex, black race, those not 
married, dual Medicare/Medicaid enrollment, increasing number of comorbidities, and 
bilateral or midline location for both stages. In comparison to well-differentiated grade, 
cases with moderately differentiated grade did not have a significantly different odds of 
surgical treatment. All other grade categories (poorly differentiated, undifferentiated, and 
undetermined grade) were associated with lower odds of surgical treatment as compared 
to well differentiated grade.  
Conclusions 
  While rural residence itself was not a significant predictor of surgical treatment, 
the association between county rurality and surgery was attenuated by area poverty, 
which is observed at higher rates among rural populations. Medicaid enrollment, a proxy 




receiving surgery at both stages. While the significant predictors of surgical treatment 
were similar for local and regional stage cases, the magnitudes of the odds ratios were 
stronger among local cases for increasing age, black race, and increasing comorbidities. 
Cancer treatment decisions are complex, and this could be an indicator that patient 
demographics and comorbidities play a greater role in surgical decisions among local 
stage cases than regional cases. Future research is needed to improve our understanding 
of treatment decisions among low-income and black lung cancer patients to inform the 
development of future interventions aimed at eliminating these disparities in lung cancer 
treatment.  
 
Keywords: Non-Small Cell Lung Cancer, Healthcare Disparities, Social Determinants of 
Health  
 
6.2 Introduction  
Most rural areas in the United States have a cigarette smoking prevalence twice 
that of large urban areas, contributing to higher lung cancer incidence and mortality rates 
in rural areas.26,78,211,233 Additionally, rural residents face higher rates of late-stage lung 
cancer diagnoses than urban residents.185 The increased likelihood of late-stage diagnosis 
and limited treatment options for late-stage disease contributes to higher observed 
mortality rates for rural Americans with lung cancer 25,184,234 However, even among stage 
I patients diagnosed between 2000 and 2006, rural residents were less likely than their 
urban counterparts to receive curative surgery.48 Combined with the sheer disease burden, 
rural residents also face socioeconomic disadvantages including higher poverty rates, 




residents.48,78,183 These factors may make accessing care more difficult for rural lung 
cancer patients, particularly accessing specialist physicians who are sparse in rural 
areas.235 
 
Treatment approaches for lung cancer are highly variable depending on many 
clinical factors such as histologic type, stage at diagnosis, and patients’ health 
status.100,102 In healthy adults with earlier stage cancer that has not metastasized, surgery 
is the most favorable treatment approach in terms of improved survival.100 Staging, tumor 
characteristics, and patient comorbidities (i.e., medical operability) are collectively 
considered when determining if surgical resection is appropriate and is performed 
primarily for patients diagnosed in early stages in good health.100,102  
 
Challenges in accessing care may also be impacting treatment utilization among 
rural cancer patients.  The U.S. rural population is dispersed over 97% of the nation’s 
land area, making travel time to cancer treatment centers a barrier many rural patients 
must overcome.186,187  A geographic analysis of drive times to cancer treatment centers 
found that Native Americans, rural residents, and those living in the South had the 
longest drive times to reach any cancer treatment centers.187 A separate study of treatment 
access in Nevada found that rural residents in the state were less likely to get surgery and 
have worse survival.236  
 
Socioeconomic status (SES) also plays a role in lung cancer disparities, as lower 




patients, low SES is linked to lower likelihood of surgical resection, guideline-concordant 
treatment, and lower survival.6,51,195,197 Even after adjusting for comorbidities, patients 
with the lowest SES continue to have worse survival outcomes compared to those of 
higher SES.6 For example, among lung cancer patients in Georgia, those in segregated 
and poor neighborhoods were less likely to receive treatment for lung cancer.237 
Differences in SES may be contributing to observed cancer disparities among rural and 
black populations. While some have shown that adjusting for SES eliminates rural and 
racial disparities,53,195 others have demonstrated that these disparities are reduced, but not 
eliminated, after adjusting for SES.146,238,239  
 
Patient residence (urban vs. rural), race, and SES impact receipt of cancer 
treatment and thus survival. Improved understanding of disparities in utilization of 
surgical treatment for lung cancer is a crucial step in reducing disease mortality. Our 
objective was to examine disparities in receipt of surgical treatment for non-small cell 
lung cancer by rural residence while controlling for independent patient- and county-level 




We examined a cohort of non-small cell lung cancer (NSCLC) patients from the 
Surveillance, Epidemiology, and End Results (SEER) program cancer registry linked 
with Medicare billing data (SEER-Medicare).200,240 Our cohort included patients 




Medicare claims prior to lung cancer diagnosis. We excluded distant stage cases, as our 
interest was to assess surgical treatment with curative intent, and surgical treatment is 
primarily performed in early-stage cases. We also excluded patients with End Stage 
Renal Disease, as the prognosis and treatment recommendations for these patients greatly 
differ from cancer patients without ESRD. Our outcome, utilization of lung cancer-
related surgical treatment (yes/no) was defined from SEER records and Medicare billing 
codes.201 A full list of the billing codes used are included in the appendix, Table A.1. 
Patient demographics and clinical characteristics were also pulled from SEER data 
including age at diagnosis, race, sex, marital status, Medicaid enrollment, stage at 
diagnosis, tumor grade, and laterality. The Charlson comorbidity score was determined 
from Medicare claims from 12 months to 1 month before lung cancer diagnosis using a 
validated SAS macro from the National Institutes of Health.230  
 
We examined geographic impacts at the county level. Patients were clustered by 
county of residence at the time of diagnosis as reported by SEER. We used the 2003 
Rural Urban Continuum Codes (RUCC) from the U.S. Department of Agriculture to 
create a binary definition for rurality by collapsing county-level RUCC codes into 
Metro/urban versus Nonmetro/rural categories.203 In addition to rurality, we examined 
county fixed effects for the percent of the population over 65 in poverty (as a measure of 
socioeconomic status of the county), and county Medically Underserved Area 
designation (MUA).208 County MUAs are assigned by the Health Resources and Services 






We examined differences in the receipt of lung cancer-related surgical treatment 
by patient demographic and clinical characteristics as well as county factors using chi-
square tests for categorical variables and t-tests for continuous variables. We calculated 
the unadjusted odds ratios (OR) with 95% confidence intervals (CI) of all patient-level 
covariates with surgical treatment. All tests were assessed at the significance level 
=0.05. 
 
For the adjusted analysis, we employed a multilevel  logistic regression, 
specifically a random intercept is applied to county level, which  allows the intercept to 
vary randomly across counties, thus jointly estimating the county and patient effect in 
receipt of surgical treatment.209 We first estimated the null model predicting surgery 
utilization from only county-level random effects to measure the between-county 
variance in receipt of surgical treatment. Using this intercept-only model we then 
calculated the median odds ratio (MOR) to examine the median magnitude of the odds 
ratio between two randomly chosen counties and the intraclass correlation coefficient 
(ICC). MOR expresses the amount of individual probability of surgical utilization 
attributed to county characteristics, where a MOR not equal to (or close to) 1.0 indicates 
that the multilevel model is an appropriate statistical approach for the data.209  The ICC 
measures the proportion of the total variance in surgical treatment that can be attributed 
to the county level.210 Next, we built our level-one model with patient characteristics 
predicting surgical utilization. We stratified by the patient stage at diagnosis, as treatment 




on the literature related to our research question stayed in the models, and other patient 
characteristics were selected by backward selection based on coefficients with a p-value 
less than or equal to 0.05. 
 
We tested for the need of random slopes for race, Medicaid enrollment, and 
Charlson comorbidity score to allow for variation of these patient factors across counties. 
We assessed the fit of each model by calculating the pseudo R-squared. Using the final 
two-level model, we produced the estimated variance of the distribution of random 
effects and ORs with 95% CIs for variables associated with utilizing surgical treatment 
among early stage lung cancer patients. We also performed a post-hoc comparison of 
county-level MUAs and the percent of poverty by urban and rural designations to assess 
the representativeness of these factors in our sample covered by SEER registries in 
comparison to the overall U.S.  
 
6.4 Results 
Patient Characteristics and Surgical Treatment  
Our final cohort consisted of 63,767 NSCLC patients nested within 365 counties 
(Table 6.1). The average age was 75.9 years (std=6.4) and the majority of the sample was 
white (85.2%) and not enrolled in Medicaid (72.5%) (Table 6.1). Slightly more than half 
were female (50.7%) and married (51.6%). Over half were diagnosed at a regional stage 
(53.4%) and 46.6% at a localized stage. The majority of patients had right side laterality 
(58.2%). Undetermined tumor grade was present in 35.6% of patients and 47.8% had no 




When examining differences in surgical treatment by stage, a higher proportion of 
localized cases received surgery than regional cases (56.7% vs. 36.8%, Table 6.1).  
Among localized cases, factors associated with higher likelihood of surgery were who 
white race (57.8%) and not being married (64.2%, Table 6.2). Among regional cases, 
factors associated with a greater probability of surgery were being categorized as other 
races (41.2%) and married (42.0%) (Table 6.3). For both stages, factors associated with 
greater likelihood of surgery were urban residence, not being on Medicaid, younger age 
and having few comorbidities.  
 
County Characteristics and Surgical Treatment  
The majority of counties in which patients resided were urban (85.3%) and not 
designated MUAs (62.5%). The mean county-level percent poverty for the 65 and older 
population was 9.0%. (Table 6.1). When comparing receipt of surgical treatment, fewer 
local stage rural residents received surgery than urban residents (57.7% vs. 50.5%, 
p<0.01, Table 6.2). The same was true for comparing regional stage cases with 37.2% of 
urban cases receiving surgery and 34.7% of rural residents receiving surgery (p=0.01, 
Table 6.3). The mean county poverty for those 65 and older was similar for those who did 
not receive surgery than for other who did (9.2% vs. 8.8%). When examined by MUA 
designation, a significantly higher proportion of geographic MUA residents received 
surgery than those not living in MUAs (48.9% vs, 44.4%). The same was true when 







The intercept-only model indicated significant variation in receipt of surgical 
treatment at the county level (p<0.01) with MOR=1.34 (Table 6.4). However, a low ICC 
of 0.028 indicated that only 2.8% of the variation in surgical treatment was attributed to 
the county level. Rurality was a borderline significant county-level fixed effect (p=0.05). 
With the addition of MUA and percent of population in poverty over 65, the fixed effect 
for rurality was no longer marginally significant (p=0.77). The fixed effect for MUA was 
not significant (p=0.18) while the percent poverty fixed effect was highly significant at 
p<0.01. We considered removing rurality and MUA from the model given the non-
significant p-values (greater than 0.05) but based on significant likelihood ratio tests for 
the model including both rurality and including MUA, we retained both variables in the 
model. All patient-level demographic and clinical characteristics were significant at 
p<0.01 and kept in the model. We tested random slopes for race, comorbidities, and 
Medicaid enrollment, all of which were not significant and therefore not retained in the 
model. The final model’s MOR for the random effect at the county-level was 1.38 and 
the ICC increased slightly to 0.033. The pseudo R-squared improved from 0.01 in the 
model with only county-level rurality to 0.51 in the final model for localized cases and 






Multilevel Logistic Regression Results 
In our final multilevel model stratified by stage, the county-level fixed effect for 
the percent of poverty in the over 65 population was significant where the odds of 
receiving surgical treatment decreased by 17% with each 5% increase in poverty among 
localized stage cases (OR=0.83, 95% CI: 0.77-0.91) and by 16% for regional cases 
(OR=0.84, 95%CI: 0.79-0.90) (Table 6.4). At the patient-level, a 5-year increase in age 
also resulted in lower odds of surgical treatment for localized cases (OR=0.58, 95% CI: 
0.56-0.59) and for regional cases (OR=0.74, 95%CI: 0.72-0.75). Men had lower odds of 
receiving surgery when compared to women at both localized and regional stages. Black 
patients had 43% lower odds of receiving surgery than white patients for localized stage 
(OR=0.60, 95% CI: 0.56-0.66) and 37% lower odds for regional cases (OR=0.63, 95%CI: 
0.56-0.70). For localized cases, those of other races also had lower odds of surgical 
treatment than whites (OR=0.83, 95%CI: 0.73-0.95) while there was no significant 
difference for regional stage patients categorized as other races compared with whites 
(OR=1.04, 95% CI: 0.93-1.16). For both stages, non-married patients had lower odds of 
surgery than married patients (localized OR=0.65, 95% CI:0.61-0.69; regional OR=0.70 
95% CI:0.66-0.75), and those enrolled in Medicaid had lower odds of surgery compared 
to those on Medicare alone (localized OR=0.83, 95% CI:0.73-0.95; regional OR=0.85, 
95%CI:). An increasing number of comorbid conditions was associated with decreasing 
odds of surgical treatment for both localized and regional cases. In terms of laterality, 
when compared with right primary location the left location of tumors in localized cases 
had slightly lower odds of surgery (OR=0.93, 95% CI:0.88-0.99), but regional cases had 




1.26). Bilateral or midline locations had much lower odds of surgery for both stages 
(localized OR=0.11, 95% CI:0.03-0.43; regional OR=0.09, 95% CI:0.04-0.17). Over one-
third of the sample had undetermined tumor grade, which was associated with the lowest 
odds of receiving surgery compared to well-differentiated grade for both stages (localized 
OR=0.07, 95% CI:0.06-0.07; regional OR=0.05, 95%CI:0.05-0.06). Moderately 
differentiated grade was not significantly different from well differentiated for either 
stage. Poorly differentiated (localized OR=0.50, 95% CI:0.45-0.55; regional OR=0.54, 
95%CI: 0.48-0.61) and undifferentiated (localized OR=0.54, 95% CI:0.43-0.67; regional 
OR=0.56, 95%CI: 0.46-0.68) grades had similarly low odds of surgery in comparison to 
well differentiated grade. 
 
6.5 Discussion 
In our examination of a large, national sample of local and regional stage NSCLC 
patients, only 46.1% (n=29,381) received surgical treatment, with 57.4% of those 
diagnosed at localized stage and 42.6% diagnosed at regional stage. In unadjusted 
examination of surgical utilization, a lower proportion of rural residents received surgery 
when compared to urban residents. When rurality was examined as a county-level fixed 
effect, it was a borderline significant predictor of surgical treatment utilization (p=0.05), 
where rural residents had decreased odds of surgical treatment. However, the relationship 
of rurality and surgical treatment was attenuated with the addition of fixed effects for 
county-level MUAs and percent poverty in the 65 and older population. The unadjusted 
association of patient race and surgical treatment showed that black patients had lower 




stages. This relationship held true for black race in the adjusted multilevel model 
controlling for patient demographic and clinical characteristics as well as county-level 
effects. While both had lower odds of surgical treatment, the magnitude of the odds ratios 
for black race and comorbidities were stronger among those diagnosed at localized stages 
when compared with regional stage.    
 
A higher percentage of rural residents living in poverty may be driving disparities 
in treatment and furthermore a primary factor contributing to observed lower survival 
among rural patients.233,241 When examining county-level fixed effects for surgical 
treatment, poverty in the 65 and older population was highly significant (p<0.01) with 
increasing poverty associated with lower odds of receiving surgical treatment. In our 
sample, only 14.7% the of counties were rural, compared to 19.3% of the U.S.242 
Furthermore, our data does not provide a representative sample of rural MUAs, as 54.6% 
of the total MUAs in the U.S. are rural and another 9.3% are partially rural.208 In a post-
hoc comparison of county-level MUAs and poverty by urban/rural designation, rural 
counties had a significantly higher percent of the 65 and older population living in 
poverty at 11.3% compared to 8.7% for urban counties (p<0.01). Conversely, only 6.9% 
of the rural counties in our sample were MUAs. In our multilevel model, MUA had a 
positive but non-significant association with surgical utilization (OR=1.10, 95% CI: 0.97-
1.25). Like rurality, the association between MUA and surgical utilization may be driven 
by poverty levels, because MUA counties in our sample had a significantly lower mean 
percent of the population over 65 living in poverty at 8.7% compared to 9.2% in non-




Our analysis revealed that adjusting for county-level poverty eliminated the 
significance of rurality and MUA. On the contrary, race remained a significant factor in 
our adjusted analysis, with black patients having lower odds of surgical treatment when 
compared to whites. Black cases of other cancer types are less likely to receive surgery as 
well, citing fatalism and distrust in the medical community.243,244 Our results were similar 
to those previously showing that black cancer patients diagnosed at early stages are less 
likely to receive surgery than any other racial or ethnic group.5,6,10–12,245 Also like other 
studies, 146,238,246 our results showed a reduction in racial disparities in surgical treatment 
after adjusting for demographics including SES via county-level poverty, though the 
reduction in the association was minimal when comparing black vs white cases (localized 
unadjusted OR=0.55 vs. localized adjusted OR=0.57; regional unadjusted OR=0.58 vs. 
regional adjusted OR=0.63). 
 
While individual income is not available in SEER-Medicare data, we were able to 
include Medicaid enrollment as a covariate. With Medicaid enrollment functioning as a 
measure of individual income in our multilevel model, were able to conclude that those 
enrolled in Medicaid (those with low incomes) had lower odds of receiving surgical 
treatment than those not enrolled in Medicaid. This relationship should be reevaluated 
with future data to examine the potential association of Medicaid expansion under the 
Affordable Care Act on surgical receipt among Medicaid enrollees.  
 
All patient-level demographic and clinical characteristics in our adjusted analysis 




stage NSCLC. Increasing age and number of comorbidities were both associated with 
decreasing odds of surgical treatment. Older age and comorbidities can create challenges 
when deciding treatment plans for cancer patients as both are also related to worse 
survival among lung cancer patients.247 Risk of surgery, recovery and quality of life 
following surgery must be considered when treatment recommendations are made to 
patients.247 We did not assess the physician’s recommendation of surgery; therefore, it is 
possible that older patients and those with multiple comorbidities were not considered 
eligible for surgical treatment.  
 
Our results are limited by some aspects of the data source. SEER-Medicare data is 
restricted to Fee-for-Service beneficiaries only and does not include those enrolled in 
Medicare Advantage plans (approximately 25% of total Medicare beneficiaries in 
2011).248 Individual smoking history is also not available, preventing us from controlling 
for the potential effect of smoking on surgical treatment. Smoking has been cited as 
reason for delay in treatment initiation,125 although not all current smoker patients who 
attempt to quit are successful. This could potentially be an additional contributor for 
some patients not receiving surgery. We also measured rurality at the county-level. 
Counties vary greatly in both population sizes and geographic area across the U.S. Using 
a county-level measure may have contributed to our null results. Granularity in rurality 






Our study is strengthened by the large sample size, that although limited in rural 
representation, still covers approximately 26% of cancer cases in the U.S. Our results 
provide an updated analysis the urban vs. rural comparison of lung cancer treatment since 
the 2017 publication of Atkins et al. based on patients diagnosed between 2000-2006.211 
We also accounted for rurality in a multilevel model as a contextual effect rather than a 
patient-level variable, portraying a more accurate depiction of geographic impacts on 
health care utilization.249  
 
6.6 Conclusions 
While rural residence itself was not a significant predictor of surgical treatment, 
the association of rurality was attenuated by area poverty, which is observed at higher 
rates among rural populations. Area deprivation, measured by the percent of the 
population age 65 and over living in poverty, appears to be a stronger driving factor in 
surgical treatment utilization than rurality itself. Medicaid enrollment, a measure of 
patient-level poverty, and black race were also associated with a reduced likelihood of 
receiving surgery. We have documented lower utilization of surgical care for local and 
regional lung cancer among lower socioeconomic status and black populations. The 
reasons for these inequities are likely complex and multifaceted. Future research is 
needed to understand the causes of these disparities in surgical treatment of lung cancer 






Table 6.1 Patient and County Level Characteristics by Receipt of Surgical 








Level 1 Patient Demographics  
Total 63,767  34386 (53.9) 29381 (46.1)  
Age    <.01 
Mean (std) 75.9 (6.4) 77.4 (6.8) 74.2 (5.5)  
Sex     
Male 31,411  17,141 (54.6) 14,270 (45.4) <.01 
Female 32,356  17,245 (53.3) 15,111 (46.7)  
Race     
White 54,313  28,718 (52.9) 25,595 (47.1) <.01 
Black 4,979  3,341 (67.1)  1,638 (32.9)   
Other 4,475  2,327 (52.0)  2,148 (48.0)  
Marital Status     
Married 32,870  15,685 (47.7) 17,185 (52.3) <.01 
Not Married 28,850  17,475 (60.6) 11,375 (39.4)  
Unknown/Missing 2,047  1,226 (59.9) 821 (40.1)  
Medicaid Enrollment     
Yes 6,456  4,124 (63.9) 2,332 (36.1) <.01 
No  57,311  30,262 (52.8) 27,049 (47.2)  
Level 1 Patient Clinical Characteristics 
Stage at Diagnosis    <.01 
Localized 29,743  12,888 (43.3) 16,855 (56.7)  
Regional 34,024  21,498 (63.2) 12,526 (36.8)  
Comorbidities    <.01 
0 30,465  14,928 (49.0) 15,537 (51.0)  
1 15,951  8,622 (54.0) 7,329 (46.0)  
2 3,535  5,022 (58.7) 3,535 (41.3)  
3 or higher 2,980  5,814 (66.1) 2,980 (33.9)  
Laterality    <.01 
Right: origin of 
primary 
37,106  20,061 (54.1) 17,045 (45.9)  
Left: origin of primary 26,203  13,884 (53.0) 12,319 (47.1)  
Bilateral, Midline, or 
Unspecified 
458  441 (96.3) 17 (3.7)  
Grade    <.01 
I, well differentiated 5,220  1,328 (25.4) 3,892 (74.6)  
II, moderately 
differentiated 
11,621  4,521 (28.0) 11,621 (72.0)  
III, poorly 
differentiated 
10,175  8,203 (44.6) 10,175 (55.4)  
IV, undifferentiated 740  562 (43.2) 740 (13.0)  
Undetermined 2,953  19,772 (87.0) 2,953 (13.0)  




Rurality    <.01 
Urban 54,393  28,946 (53.2) 25,447 (46.8)  
Rural 9,374  5,440 (58.0) 3,934 (42.0)  
Percent Poverty in 
over 65 Population 
   <.01 
Mean (std) 9.0 (3.2) 9.2 (3.3) 8.8 (3.0)  
Medically 
Underserved Areas 
   <.01 
Yes 23,927  12,224 (51.1) 11,703 (48.9)  






Table 6.2 Patient and County Level Characteristics by Receipt of Surgical 
Treatment among NSCLC Localized Stage Cases, SEER-Medicare 2003-2011 










Level 1 Patient Demographics  
Total 29,743 12,888 (43.3) 16,855 (56.7)  
Age    <0.01 
Mean (std) 76.1 (6.5) 78.6 (6.8) 74.3 (5.5)  
Sex    0.47 
Male 13,789 5,944 (43.1) 7,845 (56.9)  
Female 15,954 6,944 (43.5) 9,010 (56.5)  
Race    <0.01 
White 25,659 10,829 (42.2) 14,830 (57.8)  
Black 2,067 1,177 (56.9) 890 (43.0)  
Other 2,017 882 (43.7) 1,135 (56.3)  
Marital Status    <0.01 
Married 13,489 6,899 (51.2) 6,590 (48.9)  
Not Married 15,212 5,443 (35.8) 9,769 (64.2)  
Unknown/Missing 1,042 546 (52.4) 496 (47.6)  
Medicaid 
Enrollment 
    
<0.01 
No 26,682 11,164 (41.8) 15,518 (58.2)  
Yes 3,061 1,724 (56.3) 1,337 (43.7)  
Level 1 Patient Clinical Characteristics 
Comorbidities    <0.01 
0 13,508 4,862 (36.0) 8,646 (64.0)  
1 7,577 3,335 (44.0) 4,242 (56.0)  
2 4,158 2,086 (49.8) 2,099 (50.2)  
3 or higher 4,473 2,605 (58.2) 1,868 (41.8)  
Laterality    <0.01 
Right: origin of 
primary 
17,346 7,339 (42.3) 10,007 (57.7)  
Left: origin of 
primary 
12,329 5,487 (44.5) 6,842 (55.5)  
Bilateral, Midline, or 
Unspecified 
68 62 (91.2) 6 (8.8)  
Grade    <0.01 
I, well differentiated 3,730 764 (20.5) 2,966 (79.5)  
II, moderately 
differentiated 
8,338 1,686 (20.2) 6,652 (79.8)  
III, poorly 
differentiated 
7,513 2,543 (33.9) 4,970 (67.8)  
IV, undifferentiated 534 172 (32.2) 362 (67.8)  
Undetermined 9628 7723 (80.2) 1905 (19.8)  
Level 2 County Characteristics 
Rurality    <0.01 




Rural 4,295 2,125 (49.5) 2,170 (50.5)  
Percent Poverty in 
over 65 Population 
    
<0.01 
Mean (std) 9.0 (3.2) 9.3 (3.3) 8.8 (3.0)  
Medically 
Underserved Areas 
    
<0.01 
No 18,614 8379 (45.0) 10,235 (55.0)  





Table 6.3 Patient and County Level Characteristics by Receipt of Surgical 
Treatment among NSCLC Regional Stage Cases, SEER-Medicare 2003-2011 










Level 1 Patient Demographics  
Total 34,024 21,498 (63.2) 12,526 (36.8)  
Age    <0.01 
Mean (std) 75.7 (6.4) 76.7 (6.6) 74.1 (5.5)  
Sex    0.16 
Male 17,622 11,197 (63.5) 6,425 (36.5)  
Female 16,402 10,301 (62.8) 6,101 (37.2)  
Race    <0.01 
White 28,654 17,889 (62.4) 10,765 (37.6)  
Black 2,912 2,164 (74.3) 748 (25.7)  
Other 2,458 1,445 (58.8) 1,013 (41.2)  
Marital Status    <0.01 
Married 15,361 10,242 (58.0) 7,416 (42.0)  
Not Married 17,658 10,576 (68.9) 4,785 (31.2)  
Unknown/Missing 1,005 680 (67.7) 325 (32.3)  
Medicaid 
Enrollment 
    
<0.01 
No 30,629  19,098 (62.4) 11,531 (37.7)  
Yes  3,395 2,400 (70.7) 995 (29.3)  
Level 1 Patient Clinical Characteristics 
Comorbidities    <0.01 
0 16,957 10,066 (59.4) 6,891 (40.6)  
1 8,374 5,287 (63.1) 3,087 (36.9)  
2 4,372 2,936 (67.2) 1,436 (32.9)  
3 or higher 4,321 3,209 (74.3) 1,112 (25.7)  
Laterality    <0.01 
Right: origin of 
primary 
19,760 12,722 (64.4) 7,0.8 (35.6)  
Left: origin of 
primary 
13,874 8,397 (60.5) 5,477 (39.5)  
Bilateral, Midline, or 
Unspecified 
390 379 (97.2) 11 (2.8)  
Grade    <0.01 
I, well differentiated 1,490 564 (37.9) 926 (62.2)  
II, moderately 
differentiated 
7,804 2,835 (36.3) 4,969 (63.7)  
III, poorly 
differentiated 
10,865 5,660 (52.1) 5,205 (47.9)  
IV, undifferentiated 768 390 (50.8) 378 (49.2)  
Undetermined 13,097 12,049 (92.0) 1,048 (8.00)  
Level 2 County Characteristics 
Rurality    0.01 




Rural 5,079 3,315 (65.3) 1,764 (34.7)  
Percent Poverty in 
over 65 Population 
    
Mean (std) 9.0 (3.2) 9.2 (3.3) 8.9 (3.1) <0.01 
Medically 
Underserved Areas 
    
<0.01 
No 21,226 13,783 (64.9) 7,443 (35.1)  






Table 6.4 Unadjusted Associations between Patient Characteristics and Surgical 
Treatment of NSCLC, SEER-Medicare 2003-2011 
 Local Stage Regional Stage 
OR (95% CI) OR (95% CI) 
Patient Fixed Effects 
Age    
5-year increase 0.89 (0.89-0.90) 0.93 (0.93-0.94) 
Sex   
Male  1.00 (Reference) 1.00 (Reference) 
Female 0.98 (0.94-1.03) 1.03 (0.99-1.08) 
Race   
White 1.00 (Reference) 1.00 (Reference) 
Black 0.55 (0.50-0.60) 0.58 (0.53-0.63) 
Other  0.94 (0.86-1.03) 1.17 (1.07-1.27) 
Marital Status   
Married 1.00 (Reference) 1.00 (Reference) 
Not Married 0.98 (0.94-1.03) 1.03 (0.99-1.08) 
Medicaid Enrollment   
No 1.00 (Reference) 1.00 (Reference) 
Yes 0.56 (0.52-0.60) 0.69 (0.64-0.74) 
Comorbidities   
0 1.00 (Reference) 1.00 (Reference) 
1 0.72 (0.68-0.76) 0.85 (0.81-0.90) 
2 0.57 (0.53-0.61) 0.71 (0.67-0.77) 
3 or more 0.40 (0.38-0.43) 0.51 (0.47-0.55) 
Laterality   
Right 1.00 (Reference) 1.00 (Reference) 
Left 0.91 (0.87-0.96) 1.18 (1.13-1.23) 
Bilateral, Midline, or Unspecified  0.07 (0.03-0.16) 0.05 (0.02-0.10) 
Grade   
I, well differentiated 1.00 (Reference) 1.00 (Reference) 
II, moderately differentiated 1.02 (0.92-1.12) 1.07 (0.95-1.30) 
III, poorly differentiated 0.50 (0.46-0.55) 0.56 (0.50-0.63) 
IV, undifferentiated 0.54 (0.45-0.66) 0.59 (0.50-0.70) 









Table 6.5 Results Summary of Multilevel Logistic Mixed Models for Surgical Treatment of NSCLC,  
SEER-Medicare 2003-2011 
 



























Pseudo R2  0.00 0.05 0.51 0.44 
County Random Effect 
MOR 1.49 1.34 1.33 1.38 1.38 
County Fixed Effects 
  OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) 
Rurality      
Urban  1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 




     
No   1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
Yes   1.14 (1.02-1.26) 1.05 (0.88-1.25) 1.14 (1.01-1.29) 
Percent 
Poverty in over 
age 65 
     
5% increase   0.85 (0.81-0.89) 0.83 (0.77-0.91) 0.84 (0.79-0.90) 
Patient Fixed Effects 
    OR (95% CI) OR (95% CI) 
Age       







Sex      
Male     1.00 (Reference) 1.00 (Reference) 
Female    0.85 (0.80-0.91) 0.82 (0.78-0.87) 
Race      
White    1.00 (Reference) 1.00 (Reference) 
Black    0.57 (0.51-0.65) 0.63 (0.56-0.70) 
Other     0.83 (0.73-0.95) 1.04 (0.93-1.16) 
Marital Status      
Married    1.00 (Reference) 1.00 (Reference) 
Not Married    0.65 (0.61-0.69) 0.70 (0.66-0.75) 
Medicaid 
Enrollment 
     
No    1.00 (Reference) 1.00 (Reference) 
Yes     0.85 (0.76-0.94) 
Comorbidities      
0    1.00 (Reference) 1.00 (Reference) 
1    0.75 (0.69-0.80) 0.91 (0.85-0.97) 
2    0.64 (0.58-0.70) 0.86 (0.79-0.94) 
3 or more    0.46 (0.42-0.51) 0.67 (0.61-0.73) 
Laterality      
Right    1.00 (Reference) 1.00 (Reference) 




   0.11 (0.03-0.43) 0.09 (0.04-0.17) 
Grade      
I, well 
differentiated 
   1.00 (Reference) 1.00 (Reference) 
II, moderately 
differentiated 









   0.50 (0.45-0.55) 0.54 (0.48-0.61) 
IV, 
undifferentiated 
   0.54 (0.43-0.67) 0.56 (0.46-0.68) 






 The goals for this dissertation were to investigate rural and racial disparities in 
lung cancer survival and treatment. The results provided updated U.S. estimates of 
survival by rurality and region, examined the potential association between time to 
treatment initiation and lung cancer survival, and identified inequities in surgical 
treatment for lung cancer. These results enhance the understanding of lung cancer 
survival disparities and identified lines of inquiry for future research.  
 
The lung cancer landscape has evolved in many ways in recent years, with the 
National Lung Screening Trial results and subsequent recommendations from the 
USPSTF in 2013 to screen high risk patients annually. The Affordable Care Act has also 
changed the national healthcare environment of the country since its inception. Our 
results include patients diagnosed between 2003-2011, providing a useful baseline of 
lung cancer survival differences by rurality that can be compared to future data 
examining the impact of annual LDCT screening and ACA coverage.  
 
The findings of our three papers provide additional insight into disparities in lung 
cancer survival. Our first paper showed that both all cause and lung cancer specific 
survival was lower among lung cancer patient residing in rural versus urban counties at 




surgical treatment were strongly associated with the observed survival differences. These 
results motivated the second research topic, examining if urban vs. rural differences in 
time to treatment initiation could be a factor impacting the observed differences in 
survival. In the second paper, having lung cancer surgery within 12 weeks of being 
diagnosed was associated with greater survival benefit among localized and regional 
stage lung cancer cases compared with distant cases when examined beyond 16 months 
of follow-up. Conversely, in the first 16 months post-diagnosis, surgery initiation after 12 
weeks was associated with better survival among all stages. Similarly, chemotherapy and 
radiation initiation after 12 weeks post diagnosis was associated with lower risk of death 
at all stages. Combinations of treatment types and differing sequences of treatments may 
be contributing to our results. Delays in chemotherapy may be due to surgery or 
procedures to confirm diagnosis, leading to a survival advantage. Further investigation 
accounting in a more refined fashion for patterns of care within stage of diagnosis is 
needed to better understand these observed differences.  
 
The third paper, investigating racial and rural differences in the utilization of 
surgical treatment of lung cancer, also identified potential factors contributing to 
disparities in lung cancer survival. Among early stage cases, county-level poverty in the 
aged 65 and older population was more strongly associated than rurality with the 
likelihood of surgical treatment for lung cancer. Individual poverty (measured by 
Medicaid enrollment) and black race were also associated with a lower likelihood of 




disparities in surgical treatment of lung cancer so strategies to eliminate them may be 
developed.  
 
 Overall, these findings advance understanding of the existing disparities in lung 
cancer treatment and survival, especially for the urban versus rural comparisons that had 
not previously been so thoroughly investigated. This includes the refined examination of 
rural vs. urban residence across regions of the United States; to our knowledge, our 
results are the first to also make urban vs. rural lung cancer survival comparisons by 
region and they revealed that the association varied by region. As expected, a greater 
comorbidity burden and not receiving surgical treatment were associated with worse 
survival. Future research that examinations the potential benefits of effective 
management of preexisting conditions during lung cancer treatment is warranted.  For 
example, uncontrolled diabetes could lessen survival independently and via worsening 
response to lung cancer treatments. The evidence generated on time to treatment 
initiation and survival needs to be further refined, but in the long run this evidence could 
inform recommendations for timely surgical treatment in early stage cases. Consistent 
with prior evidence, we observed that black race continues to have a lower likelihood of 
surgery for lung cancer, indicating that black lung cancer patients may benefit from 
targeted interventions addressing patient and provider education aimed at improving 
utilization of surgery, when appropriate, in this population. The body of evidence 
presented in this document contributes an advance in understanding disparities in lung 
cancer survival, but this research area needs continued focus to further improve 
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CPT, HCPCS, ICD CODES FOR LUNG CANCER TREATMENT 
Table A.1 CPT, HCPCS, ICD Codes for Lung Cancer Treatment 
Code Type Code Treatment Type Description 
HCPCS C9216 Chemotherapy ABARELIX 
HCPCS J9216 Chemotherapy ABARELIX 
HCPCS J0128 Chemotherapy ABARELIX 
HCPCS S0165 Chemotherapy ABARELIX 
HCPCS J3490 Chemotherapy ABATACEPT 
HCPCS C9230 Chemotherapy ABATACEPT 
HCPCS J0129 Chemotherapy ABATACEPT 
HCPCS J9354 Chemotherapy ADO-TRASTUZUMAB EMTANSINE 
HCPCS C9131 Chemotherapy ADO-TRASTUZUMAB EMTANSINE 
HCPCS J0178 Chemotherapy AFLIBERCEPT 
HCPCS Q2046 Chemotherapy AFLIBERCEPT 
HCPCS J9400 Chemotherapy AFLIBERCEPT 
HCPCS J9015 Chemotherapy ALDESLEUKIN 
HCPCS S0087 Chemotherapy ALEMTUZUMAB 
HCPCS J9010 Chemotherapy ALEMTUZUMAB 
HCPCS J0202 Chemotherapy ALEMTUZUMAB 
HCPCS C9110 Chemotherapy ALEMTUZUMAB 
HCPCS J9215 Chemotherapy ALFERON 




HCPCS S0170 Chemotherapy ANASTROZOLE 
HCPCS J9017 Chemotherapy ARSENIC 
HCPCS C9012 Chemotherapy ARSENIC 
HCPCS J9019 Chemotherapy ASPARAGINASE 
HCPCS J9020 Chemotherapy ASPARAGINASE 
HCPCS J9025 Chemotherapy AZACITIDINE 
HCPCS C9416 Chemotherapy BCG LIVE 
HCPCS J9031 Chemotherapy BCG LIVE 
HCPCS Q2044 Chemotherapy BELIMUMAB 
HCPCS J0490 Chemotherapy BELIMUMAB 
HCPCS J9034 Chemotherapy BENDAMUSTINE 
HCPCS J9033 Chemotherapy BENDAMUSTINE 
HCPCS S0116 Chemotherapy BEVACIZUMAB 
HCPCS C9257 Chemotherapy BEVACIZUMAB 
HCPCS Q2024 Chemotherapy BEVACIZUMAB 
HCPCS J9035 Chemotherapy BEVACIZUMAB 
HCPCS C9214 Chemotherapy BEVACIZUMAB 
HCPCS J9040 Chemotherapy BLEOMYCIN 
HCPCS C9417 Chemotherapy BLEOMYCIN 
HCPCS S0115 Chemotherapy BORTEZOMIB 
HCPCS J9041 Chemotherapy BORTEZOMIB 
HCPCS C9207 Chemotherapy BORTEZOMIB 
HCPCS J9042 Chemotherapy BRENTUXIMAB 
HCPCS J8510 Chemotherapy BUSULFAN 
HCPCS C1178 Chemotherapy BUSULFAN 
HCPCS J0594 Chemotherapy BUSULFAN 




HCPCS J8521 Chemotherapy CAPECITABINE 
HCPCS J9045 Chemotherapy CARBOPLATIN 
HCPCS J9047 Chemotherapy CARFILZOMIB 
HCPCS J9050 Chemotherapy CARMUSTINE 
HCPCS C9437 Chemotherapy CARMUSTINE 
HCPCS J9055 Chemotherapy CETUXIMAB 
HCPCS C9215 Chemotherapy CETUXIMAB 
HCPCS G0360 Chemotherapy CHEMOTHERAPY 
HCPCS C8954 Chemotherapy CHEMOTHERAPY 
HCPCS C8955 Chemotherapy CHEMOTHERAPY 
HCPCS G9029 Chemotherapy CHEMOTHERAPY 
HCPCS G9031 Chemotherapy CHEMOTHERAPY 
HCPCS G9030 Chemotherapy CHEMOTHERAPY 
HCPCS G9032 Chemotherapy CHEMOTHERAPY 
HCPCS G9021 Chemotherapy CHEMOTHERAPY 
HCPCS G9022 Chemotherapy CHEMOTHERAPY 
HCPCS G9023 Chemotherapy CHEMOTHERAPY 
HCPCS G9024 Chemotherapy CHEMOTHERAPY 
HCPCS G9025 Chemotherapy CHEMOTHERAPY 
HCPCS G9026 Chemotherapy CHEMOTHERAPY 
HCPCS G9027 Chemotherapy CHEMOTHERAPY 
HCPCS G9028 Chemotherapy CHEMOTHERAPY 
HCPCS G8372 Chemotherapy CHEMOTHERAPY 
HCPCS G0359 Chemotherapy CHEMOTHERAPY 
HCPCS G8373 Chemotherapy CHEMOTHERAPY 
HCPCS G8374 Chemotherapy CHEMOTHERAPY 




HCPCS C8953 Chemotherapy CHEMOTHERAPY 
HCPCS S5019 Chemotherapy CHEMOTHERAPY 
HCPCS S5020 Chemotherapy CHEMOTHERAPY 
HCPCS Q0085 Chemotherapy CHEMOTHERAPY 
HCPCS Q0084 Chemotherapy CHEMOTHERAPY 
HCPCS Q0083 Chemotherapy CHEMOTHERAPY 
HCPCS G0358 Chemotherapy CHEMOTHERAPY 
HCPCS G0362 Chemotherapy CHEMOTHERAPY 
HCPCS G0357 Chemotherapy CHEMOTHERAPY 
HCPCS S9329 Chemotherapy CHEMOTHERAPY 
HCPCS S9330 Chemotherapy CHEMOTHERAPY 
HCPCS S9331 Chemotherapy CHEMOTHERAPY 
HCPCS G0361 Chemotherapy CHEMOTHERAPY 
HCPCS J9999 Chemotherapy CHEMOTHERAPY 
HCPCS J8999 Chemotherapy CHEMOTHERAPY 
HCPCS J7150 Chemotherapy CHEMOTHERAPY 
HCPCS J3590 Chemotherapy CHEMOTHERAPY 
HCPCS S0172 Chemotherapy CHLORAMBUCIL 
HCPCS J9062 Chemotherapy CISPLATIN 
HCPCS C9418 Chemotherapy CISPLATIN 
HCPCS J9060 Chemotherapy CISPLATIN 
HCPCS 209622 Chemotherapy CISPLATIN 
HCPCS C9419 Chemotherapy CLADRIBINE 
HCPCS J9065 Chemotherapy CLADRIBINE 
HCPCS J9027 Chemotherapy CLOFARABINE 
HCPCS J9091 Chemotherapy CYCLOPHOSPHAMIDE 




HCPCS J9092 Chemotherapy CYCLOPHOSPHAMIDE 
HCPCS J9080 Chemotherapy CYCLOPHOSPHAMIDE 
HCPCS J9090 Chemotherapy CYCLOPHOSPHAMIDE 
HCPCS C9420 Chemotherapy CYCLOPHOSPHAMIDE 
HCPCS J9096 Chemotherapy CYCLOPHOSPHAMIDE 
HCPCS J9093 Chemotherapy CYCLOPHOSPHAMIDE 
HCPCS J9097 Chemotherapy CYCLOPHOSPHAMIDE 
HCPCS J9094 Chemotherapy CYCLOPHOSPHAMIDE 
HCPCS J9095 Chemotherapy CYCLOPHOSPHAMIDE 
HCPCS C9421 Chemotherapy CYCLOPHOSPHAMIDE 
HCPCS J8530 Chemotherapy CYCLOPHOSPHAMIDE 
HCPCS C9438 Chemotherapy CYCLOSPORINE 
HCPCS J9098 Chemotherapy CYTARABINE 
HCPCS J9100 Chemotherapy CYTARABINE 
HCPCS J9110 Chemotherapy CYTARABINE 
HCPCS C9422 Chemotherapy CYTARABINE 
HCPCS C1166 Chemotherapy CYTARABINE 
HCPCS J9130 Chemotherapy DACARBAZINE 
HCPCS J9140 Chemotherapy DACARBAZINE 
HCPCS C9423 Chemotherapy DACARBAZINE 
HCPCS J9120 Chemotherapy DACTINOMYCIN 
HCPCS J9145 Chemotherapy DARATUMUMAB 
HCPCS J9151 Chemotherapy DAUNORUBICIN 
HCPCS J9150 Chemotherapy DAUNORUBICIN 
HCPCS C9424 Chemotherapy DAUNORUBICIN 
HCPCS J0894 Chemotherapy DECITABINE 




HCPCS C1084 Chemotherapy DENILEUKIN 
HCPCS J9160 Chemotherapy DENILEUKIN 
HCPCS C9272 Chemotherapy DENOSUMAB 
HCPCS J0897 Chemotherapy DENOSUMAB 
HCPCS J8540 Chemotherapy DEXAMETHASONE 
HCPCS J1094 Chemotherapy DEXAMETHASONE 
HCPCS J1100 Chemotherapy DEXAMETHASONE 
HCPCS J1190 Chemotherapy DEXRAZOXANE 
HCPCS J9165 Chemotherapy DIETHYLSTILBESTROL 
HCPCS J9170 Chemotherapy DOCETAXEL 
HCPCS J9171 Chemotherapy DOCETAXEL 
HCPCS J9000 Chemotherapy DOXORUBICIN 
HCPCS J9001 Chemotherapy DOXORUBICIN 
HCPCS C9415 Chemotherapy DOXORUBICIN 
HCPCS J9002 Chemotherapy DOXORUBICIN 
HCPCS Q2049 Chemotherapy DOXORUBICIN 
HCPCS Q2048 Chemotherapy DOXORUBICIN 
HCPCS Q2050 Chemotherapy DOXORUBICIN 
HCPCS J9180 Chemotherapy EPIRUBICIN 
HCPCS J9178 Chemotherapy EPIRUBICIN 
HCPCS C1167 Chemotherapy EPIRUBICIN 
HCPCS J9181 Chemotherapy ETOPOSIDE 
HCPCS J9182 Chemotherapy ETOPOSIDE 
HCPCS C9425 Chemotherapy ETOPOSIDE 
HCPCS C9414 Chemotherapy ETOPOSIDE 
HCPCS J8560 Chemotherapy ETOPOSIDE 




HCPCS J8561 Chemotherapy EVEROLIMUS 
HCPCS S0156 Chemotherapy EXEMESTANE 
HCPCS J9200 Chemotherapy FLOXURIDINE 
HCPCS C9426 Chemotherapy FLOXURIDINE 
HCPCS J9185 Chemotherapy FLUDARABINE 
HCPCS C9262 Chemotherapy FLUDARABINE 
HCPCS J8562 Chemotherapy FLUDARABINE 
HCPCS J9190 Chemotherapy FLUOROURACIL 
HCPCS S0175 Chemotherapy FLUTAMIDE 
HCPCS J9395 Chemotherapy FULVESTRANT 
HCPCS C9434 Chemotherapy GALLIUM 
HCPCS J1457 Chemotherapy GALLIUM 
HCPCS J8565 Chemotherapy GEFITINIB 
HCPCS J9201 Chemotherapy GEMCITABINE 
HCPCS C9004 Chemotherapy GEMTUZUMAB 
HCPCS J9300 Chemotherapy GEMTUZUMAB 
HCPCS J1620 Chemotherapy GONADORELIN 
HCPCS J9202 Chemotherapy GOSERELIN 
HCPCS J9226 Chemotherapy HISTRELIN 
HCPCS J9225 Chemotherapy HISTRELIN 
HCPCS J1675 Chemotherapy HISTRELIN 
HCPCS Q2020 Chemotherapy HISTRELIN 
HCPCS G0356 Chemotherapy HORMONE 
HCPCS S0176 Chemotherapy HYDROXYUREA 
HCPCS A9522 Chemotherapy IBRITUMOMAB 
HCPCS J9211 Chemotherapy IDARUBICIN 




HCPCS C9427 Chemotherapy IFOSFAMIDE 
HCPCS J9208 Chemotherapy IFOSFAMIDE 
HCPCS S0088 Chemotherapy IMATINIB 
HCPCS S2107 Chemotherapy IMMUNOTHERAPY 
HCPCS J9213 Chemotherapy INTERFERON ALFA-2A 
HCPCS S0146 Chemotherapy INTERFERON ALFA-2B 
HCPCS J9214 Chemotherapy INTERFERON ALFA-2B 
HCPCS J9212 Chemotherapy INTERFERON ALFACON 
HCPCS J1826 Chemotherapy INTERFERON BETA-1A 
HCPCS J9228 Chemotherapy IPILIMUMAB 
HCPCS J9206 Chemotherapy IRINOTECAN 
HCPCS J9207 Chemotherapy IXABEPILONE 
HCPCS J1930 Chemotherapy LANREOTIDE 
HCPCS C9237 Chemotherapy LANREOTIDE 
HCPCS J0640 Chemotherapy LEUCOVORIN 
HCPCS J1950 Chemotherapy LEUPROLIDE 
HCPCS J9217 Chemotherapy LEUPROLIDE 
HCPCS J9219 Chemotherapy LEUPROLIDE 
HCPCS J9218 Chemotherapy LEUPROLIDE 
HCPCS S0177 Chemotherapy LEVAMISOLE 
HCPCS J0641 Chemotherapy LEVOLEUCOVORIN 
HCPCS S0178 Chemotherapy LOMUSTINE 
HCPCS J9230 Chemotherapy MECHLORETHAMINE 
HCPCS J1050 Chemotherapy MEDROXYPROGESTERONE 
HCPCS J1051 Chemotherapy MEDROXYPROGESTERONE 
HCPCS S0179 Chemotherapy MEGESTROL 




HCPCS J8600 Chemotherapy MELPHALAN 
HCPCS S0108 Chemotherapy MERCAPTOPURINE 
HCPCS J9209 Chemotherapy MESNA 
HCPCS J9250 Chemotherapy METHOTREXATE 
HCPCS J9260 Chemotherapy METHOTREXATE 
HCPCS J8610 Chemotherapy METHOTREXATE 
HCPCS J9290 Chemotherapy MITOMYCIN 
HCPCS J9291 Chemotherapy MITOMYCIN 
HCPCS J9280 Chemotherapy MITOMYCIN 
HCPCS C9432 Chemotherapy MITOMYCIN 
HCPCS J9293 Chemotherapy MITOXANTRONE 
HCPCS J0340 Chemotherapy NANDROLONE 
HCPCS J2320 Chemotherapy NANDROLONE 
HCPCS J2321 Chemotherapy NANDROLONE 
HCPCS J2322 Chemotherapy NANDROLONE 
HCPCS J2323 Chemotherapy NATALIZUMAB 
HCPCS Q4079 Chemotherapy NATALIZUMAB 
HCPCS J9261 Chemotherapy NELARABINE 
HCPCS J9299 Chemotherapy NIVOLUMAB 
HCPCS J9301 Chemotherapy OBINUTUZUMAB 
HCPCS J2352 Chemotherapy OCTREOTIDE 
HCPCS J2353 Chemotherapy OCTREOTIDE 
HCPCS J2354 Chemotherapy OCTREOTIDE 
HCPCS J9302 Chemotherapy OFATUMUMAB 
HCPCS C9297 Chemotherapy OMACETAXINE 
HCPCS J9262 Chemotherapy OMACETAXINE 




HCPCS C9205 Chemotherapy OXALIPLATIN 
HCPCS J9264 Chemotherapy PACLITAXEL 
HCPCS J9267 Chemotherapy PACLITAXEL 
HCPCS J9265 Chemotherapy PACLITAXEL 
HCPCS C9431 Chemotherapy PACLITAXEL 
HCPCS J2430 Chemotherapy PAMIDRONATE 
HCPCS C9235 Chemotherapy PANITUMUMAB 
HCPCS J9303 Chemotherapy PANITUMUMAB 
HCPCS J9266 Chemotherapy PEGASPARGASE 
HCPCS C9027 Chemotherapy PEMBROLIZUMAB 
HCPCS J9271 Chemotherapy PEMBROLIZUMAB 
HCPCS J9305 Chemotherapy PEMETREXED 
HCPCS C9213 Chemotherapy PEMETREXED 
HCPCS J9268 Chemotherapy PENTOSTATIN 
HCPCS J9306 Chemotherapy PERTUZUMAB 
HCPCS J9270 Chemotherapy PLICAMYCIN 
HCPCS J9600 Chemotherapy PORFIMER 
HCPCS J9307 Chemotherapy PRALATREXATE 
HCPCS S0182 Chemotherapy PROCARBAZINE 
HCPCS J2675 Chemotherapy PROGESTERONE 
HCPCS J9308 Chemotherapy RAMUCIRUMAB 
HCPCS 214693 Chemotherapy RITUXIMAB 
HCPCS J9310 Chemotherapy RITUXIMAB 
HCPCS J9315 Chemotherapy ROMIDEPSIN 
HCPCS C9265 Chemotherapy ROMIDEPSIN 
HCPCS A9604 Chemotherapy SAMARIUM 




HCPCS Q2043 Chemotherapy SIPULEUCEL 
HCPCS J9320 Chemotherapy STREPTOZOCIN 
HCPCS A9600 Chemotherapy STRONTIUM-89 
HCPCS S0187 Chemotherapy TAMOXIFEN 
HCPCS J9328 Chemotherapy TEMOZOLOMIDE 
HCPCS C1086 Chemotherapy TEMOZOLOMIDE 
HCPCS J8700 Chemotherapy TEMOZOLOMIDE 
HCPCS J9330 Chemotherapy TEMSIROLIMUS 
HCPCS Q2017 Chemotherapy TENIPOSIDE 
HCPCS J1070 Chemotherapy TESTOSTERONE 
HCPCS J1080 Chemotherapy TESTOSTERONE 
HCPCS J1090 Chemotherapy TESTOSTERONE 
HCPCS J1060 Chemotherapy TESTOSTERONE 
HCPCS J3120 Chemotherapy TESTOSTERONE 
HCPCS J3130 Chemotherapy TESTOSTERONE 
HCPCS J0900 Chemotherapy TESTOSTERONE 
HCPCS J3150 Chemotherapy TESTOSTERONE 
HCPCS J3140 Chemotherapy TESTOSTERONE 
HCPCS J9340 Chemotherapy THIOTEPA 
HCPCS C9433 Chemotherapy THIOTEPA 
HCPCS J3262 Chemotherapy TOCILIZUMAB 
HCPCS J9351 Chemotherapy TOPOTECAN 
HCPCS J9350 Chemotherapy TOPOTECAN 
HCPCS J8705 Chemotherapy TOPOTECAN 
HCPCS C9480 Chemotherapy TRABECTEDIN 
HCPCS J9355 Chemotherapy TRASTUZUMAB 




HCPCS J9357 Chemotherapy VALRUBICIN 
HCPCS J9360 Chemotherapy VINBLASTINE 
HCPCS J9370 Chemotherapy VINCRISTINE 
HCPCS J9375 Chemotherapy VINCRISTINE 
HCPCS J9380 Chemotherapy VINCRISTINE 
HCPCS J9371 Chemotherapy VINCRISTINE 
HCPCS C9440 Chemotherapy VINORELBINE 
HCPCS J9390 Chemotherapy VINORELBINE 
ICD-9 9928 Chemotherapy CHEMOTHERAPY 
ICD-9 9925 Chemotherapy CHEMOTHERAPY 
ICD-9 9929 Chemotherapy CHEMOTHERAPY 
ICD-9 177 Chemotherapy CLOFARABINE 
CPT C9287 Chemotherapy BRENTUXIMAB 
CPT J9043 Chemotherapy CABAZITAXEL 
CPT 4180F Chemotherapy CHEMOTHERAPY 
CPT 36640 Chemotherapy CHEMOTHERAPY 
CPT 96446 Chemotherapy CHEMOTHERAPY 
CPT 96445 Chemotherapy CHEMOTHERAPY 
CPT 96440 Chemotherapy CHEMOTHERAPY 
CPT 96450 Chemotherapy CHEMOTHERAPY 
CPT 96423 Chemotherapy CHEMOTHERAPY 
CPT 96425 Chemotherapy CHEMOTHERAPY 
CPT 96422 Chemotherapy CHEMOTHERAPY 
CPT 96420 Chemotherapy CHEMOTHERAPY 
CPT 96415 Chemotherapy CHEMOTHERAPY 
CPT 96417 Chemotherapy CHEMOTHERAPY 




CPT 96413 Chemotherapy CHEMOTHERAPY 
CPT 96410 Chemotherapy CHEMOTHERAPY 
CPT 96408 Chemotherapy CHEMOTHERAPY 
CPT 96402 Chemotherapy CHEMOTHERAPY 
CPT 96401 Chemotherapy CHEMOTHERAPY 
CPT 96400 Chemotherapy CHEMOTHERAPY 
CPT 96406 Chemotherapy CHEMOTHERAPY 
CPT 96405 Chemotherapy CHEMOTHERAPY 
CPT 96411 Chemotherapy CHEMOTHERAPY 
CPT 96409 Chemotherapy CHEMOTHERAPY 
CPT 219583 Chemotherapy CHEMOTHERAPY 
CPT 96542 Chemotherapy CHEMOTHERAPY 
CPT 203682 Chemotherapy CHEMOTHERAPY 
CPT 96414 Chemotherapy CHEMOTHERAPY 
CPT 96412 Chemotherapy CHEMOTHERAPY 
CPT 242226 Chemotherapy CHEMOTHERAPY 
CPT 61517 Chemotherapy CHEMOTHERAPY 
CPT 219687 Chemotherapy CHEMOTHERAPY 
CPT 0519F Chemotherapy CHEMOTHERAPY 
CPT 96545 Chemotherapy CHEMOTHERAPY 
CPT 206820 Chemotherapy CHEMOTHERAPY 
CPT 206929 Chemotherapy CHEMOTHERAPY 
CPT 96549 Chemotherapy CHEMOTHERAPY 
CPT J9179 Chemotherapy ERIBULIN 
CPT 81350 Chemotherapy IRINOTECAN 
CPT 83520 Chemotherapy METHOTREXATE 




ICD-9 9221 Radiation Beam  
ICD-9 9222 Radiation Beam  
ICD-9 9223 Radiation Beam  
ICD-9 9224 Radiation Beam  
ICD-9 9225 Radiation Beam  
ICD-9 9226 Radiation Beam  
ICD-9 9227 Radiation Brachytherapy  
ICD-9 9228 Radiation Isotopes  
ICD-9 9229 Radiation General  
ICD-9 923 Radiation Beam  
ICD-9 9231 Radiation Beam  
ICD-9 9232 Radiation Beam  
ICD-9 9233 Radiation Beam  
ICD-9 9239 Radiation Beam  
ICD-9 9241 Radiation Beam  
ICD-9 9220 Radiation Brachytherapy  
ICD-9 9230 Radiation Beam  
CPT 0073T Radiation Beam  
CPT 0082T Radiation Beam  
CPT 0083T Radiation Beam  
CPT 0182T Radiation Brachytherapy  
CPT 0190T Radiation Brachytherapy  
CPT 0197T Radiation Beam  
CPT 19296 Radiation Brachytherapy  
CPT 19297 Radiation Brachytherapy  
CPT 19298 Radiation Brachytherapy  




CPT 20660 Radiation Beam  
CPT 31463 Radiation Brachytherapy  
CPT 32553 Radiation General  
CPT 41019 Radiation Brachytherapy  
CPT 49411 Radiation General  
CPT 49412 Radiation General  
CPT 52250 Radiation Brachytherapy  
CPT 55859 Radiation Brachytherapy  
CPT 55860 Radiation Brachytherapy  
CPT 55875 Radiation Brachytherapy  
CPT 55876 Radiation General  
CPT 55920 Radiation Brachytherapy  
CPT 57155 Radiation Brachytherapy  
CPT 57156 Radiation Brachytherapy  
CPT 58346 Radiation Brachytherapy  
CPT 61720 Radiation Beam  
CPT 61735 Radiation Beam  
CPT 61770 Radiation Beam  
CPT 61781 Radiation Beam  
CPT 61782 Radiation Beam  
CPT 61783 Radiation Beam  
CPT 61793 Radiation Beam  
CPT 61795 Radiation Beam  
CPT 61796 Radiation Beam  
CPT 61797 Radiation Beam  
CPT 61798 Radiation Beam  




CPT 61800 Radiation Beam  
CPT 63620 Radiation Beam  
CPT 63621 Radiation Beam  
CPT 73670 Radiation Beam  
CPT 76950 Radiation Beam  
CPT 76965 Radiation Brachytherapy  
CPT 77014 Radiation Beam  
CPT 77261 Radiation Beam  
CPT 77262 Radiation Beam  
CPT 77263 Radiation Beam  
CPT 77280 Radiation Beam  
CPT 77285 Radiation Beam  
CPT 77290 Radiation Beam  
CPT 77295 Radiation Beam  
CPT 77299 Radiation Beam  
CPT 77300 Radiation Beam  
CPT 77301 Radiation Beam  
CPT 77305 Radiation Beam  
CPT 77306 Radiation Beam  
CPT 77307 Radiation Beam  
CPT 77310 Radiation Beam  
CPT 77315 Radiation Beam  
CPT 77321 Radiation Beam  
CPT 77326 Radiation Brachytherapy  
CPT 77326 Radiation Brachytherapy  
CPT 77327 Radiation Brachytherapy  




CPT 77328 Radiation Brachytherapy  
CPT 77328 Radiation Brachytherapy  
CPT 77331 Radiation General  
CPT 77332 Radiation General  
CPT 77333 Radiation General  
CPT 77334 Radiation General  
CPT 77336 Radiation General  
CPT 77338 Radiation Beam  
CPT 77370 Radiation Beam  
CPT 77370 Radiation General  
CPT 77371 Radiation Beam  
CPT 77372 Radiation Beam  
CPT 77373 Radiation Beam  
CPT 77380 Radiation Beam  
CPT 77381 Radiation Beam  
CPT 77385 Radiation Beam  
CPT 77386 Radiation Beam  
CPT 77387 Radiation Beam  
CPT 77399 Radiation General  
CPT 77400 Radiation Beam  
CPT 77401 Radiation Beam  
CPT 77402 Radiation Beam  
CPT 77403 Radiation Beam  
CPT 77404 Radiation Beam  
CPT 77405 Radiation Beam  
CPT 77406 Radiation Beam  




CPT 77408 Radiation Beam  
CPT 77409 Radiation Beam  
CPT 77410 Radiation Beam  
CPT 77411 Radiation Beam  
CPT 77412 Radiation Beam  
CPT 77413 Radiation Beam  
CPT 77414 Radiation Beam  
CPT 77415 Radiation Beam  
CPT 77416 Radiation Beam  
CPT 77417 Radiation Beam  
CPT 77418 Radiation Beam  
CPT 77419 Radiation General  
CPT 77420 Radiation General  
CPT 77421 Radiation General  
CPT 77422 Radiation Beam  
CPT 77423 Radiation Beam  
CPT 77425 Radiation General  
CPT 77427 Radiation General  
CPT 77430 Radiation General  
CPT 77431 Radiation General  
CPT 77432 Radiation Beam  
CPT 77435 Radiation Beam  
CPT 77469 Radiation Beam  
CPT 77470 Radiation Beam  
CPT 77499 Radiation General  
CPT 77520 Radiation Beam  




CPT 77523 Radiation Beam  
CPT 77525 Radiation Beam  
CPT 77750 Radiation Isotopes  
CPT 77761 Radiation Brachytherapy  
CPT 77762 Radiation Brachytherapy  
CPT 77763 Radiation Brachytherapy  
CPT 77776 Radiation Brachytherapy  
CPT 77777 Radiation Brachytherapy  
CPT 77778 Radiation Brachytherapy  
CPT 77781 Radiation Brachytherapy  
CPT 77782 Radiation Brachytherapy  
CPT 77783 Radiation Brachytherapy  
CPT 77784 Radiation Brachytherapy  
CPT 77785 Radiation Brachytherapy  
CPT 77786 Radiation Brachytherapy  
CPT 77787 Radiation Brachytherapy  
CPT 77789 Radiation Brachytherapy  
CPT 77790 Radiation Brachytherapy  
CPT 77799 Radiation Brachytherapy  
CPT 79005 Radiation Isotopes  
CPT 79030 Radiation Isotopes  
CPT 79035 Radiation Isotopes  
CPT 79100 Radiation Isotopes  
CPT 79101 Radiation Isotopes  
CPT 79200 Radiation Isotopes  
CPT 79300 Radiation Isotopes  




CPT 79403 Radiation Isotopes  
CPT 79420 Radiation Isotopes  
CPT 79440 Radiation Isotopes  
CPT 79445 Radiation Isotopes  
CPT 79900 Radiation Isotopes  
CPT 79999 Radiation Isotopes  
HCPCS  A9606 Radiation Isotopes  
HCPCS  A9699 Radiation Isotopes  
HCPCS  C1715 Radiation Brachytherapy  
HCPCS  C1716 Radiation Brachytherapy  
HCPCS  C1717 Radiation Brachytherapy  
HCPCS  C1718 Radiation Brachytherapy  
HCPCS  C1719 Radiation Brachytherapy  
HCPCS  C1720 Radiation Brachytherapy  
HCPCS  C1728 Radiation Brachytherapy  
HCPCS  C2616 Radiation Brachytherapy  
HCPCS  C2633 Radiation Brachytherapy  
HCPCS  C2634 Radiation Brachytherapy  
HCPCS  C2635 Radiation Brachytherapy  
HCPCS  C2636 Radiation Brachytherapy  
HCPCS  C2637 Radiation Brachytherapy  
HCPCS  C2638 Radiation Brachytherapy  
HCPCS  C2639 Radiation Brachytherapy  
HCPCS  C2640 Radiation Brachytherapy  
HCPCS  C2641 Radiation Brachytherapy  
HCPCS  C2642 Radiation Brachytherapy  




HCPCS  C2698 Radiation Brachytherapy  
HCPCS  C2699  Radiation Brachytherapy  
HCPCS  C9726 Radiation Brachytherapy  
HCPCS  C9728 Radiation Brachytherapy  
HCPCS  G0173 Radiation Beam  
HCPCS  G0174 Radiation Beam  
HCPCS  G0242 Radiation Beam  
HCPCS  G0243 Radiation Beam  
HCPCS  G0251 Radiation Beam  
HCPCS  G0338 Radiation Beam  
HCPCS  G0339 Radiation Beam  
HCPCS  G0340 Radiation Beam  
HCPCS  G6003 Radiation Beam  
HCPCS  G6004 Radiation Beam  
HCPCS  G6005 Radiation Beam  
HCPCS  G6006 Radiation Beam  
HCPCS  G6007 Radiation Beam  
HCPCS  G6008 Radiation Beam  
HCPCS  G6009 Radiation Beam  
HCPCS  G6010 Radiation Beam  
HCPCS  G6011 Radiation Beam  
HCPCS  G6012 Radiation Beam  
HCPCS  G6013 Radiation Beam  
HCPCS  G6014 Radiation Beam  
HCPCS  G6015 Radiation Beam  
HCPCS  G6016 Radiation Beam  




HCPCS  S2270 Radiation Brachytherapy  
HCPCS  S8049 Radiation Beam  
HCPCS  C1325 Radiation Brachytherapy  
HCPCS  C1348 Radiation Isotopes  
HCPCS  C1350 Radiation Brachytherapy  
HCPCS  C1700  Radiation Brachytherapy  
HCPCS  C1701 Radiation Brachytherapy  
HCPCS  C1702 Radiation Brachytherapy  
HCPCS  C1703 Radiation Brachytherapy  
HCPCS  C1704 Radiation Brachytherapy  
HCPCS  C1705 Radiation Brachytherapy  
HCPCS  C1706 Radiation Brachytherapy  
HCPCS  C1707 Radiation Brachytherapy  
HCPCS  C1708 Radiation Brachytherapy  
HCPCS  C1709 Radiation Brachytherapy  
HCPCS  C1710 Radiation Brachytherapy  
HCPCS  C1711 Radiation Brachytherapy  
HCPCS  C1712 Radiation Brachytherapy  
HCPCS  C1790 Radiation Brachytherapy  
HCPCS  C1791 Radiation Brachytherapy  
HCPCS  C1792 Radiation Brachytherapy  
HCPCS  C1793 Radiation Brachytherapy  
HCPCS  C1794 Radiation Brachytherapy  
HCPCS  C1795 Radiation Brachytherapy  
HCPCS  C1796 Radiation Brachytherapy  
HCPCS  C1797 Radiation Brachytherapy  




HCPCS  C1799 Radiation Brachytherapy  
HCPCS  C1800 Radiation Brachytherapy  
HCPCS  C1801 Radiation Brachytherapy  
HCPCS  C1802 Radiation Brachytherapy  
HCPCS  C1803 Radiation Brachytherapy  
HCPCS  C1804 Radiation Brachytherapy  
HCPCS  C1805 Radiation Brachytherapy  
HCPCS  C1806 Radiation Brachytherapy  
HCPCS  C2632 Radiation Brachytherapy  
HCPCS  C9714 Radiation Brachytherapy  
HCPCS  C9715 Radiation Beam  
HCPCS  G0178 Radiation Beam  
HCPCS  G0256 Radiation Brachytherapy  
HCPCS  G0273 Radiation Isotopes  
HCPCS  G0274 Radiation Isotopes  
HCPCS  G0338 Radiation Beam  
HCPCS  G0339 Radiation Beam  
HCPCS  G0340 Radiation Beam  
HCPCS  G0458 Radiation Brachytherapy  
HCPCS  C2644 Radiation Brachytherapy  
HCPCS  C2645 Radiation Brachytherapy  
CPT 3220 Surgery 
 
CPT 3229 Surgery 
 
CPT 3230 Surgery 
 
CPT 3239 Surgery 
 
CPT 3241 Surgery 
 





CPT 3250 Surgery 
 
CPT 3259 Surgery 
 
CPT 3260 Surgery 
 
CPT 32095 Surgery 
 
CPT 32096 Surgery 
 
CPT 32097 Surgery 
 
CPT 32098 Surgery 
 
CPT 32100 Surgery 
 
CPT 32124 Surgery 
 
CPT 32140 Surgery 
 
CPT 32141 Surgery 
 
CPT 32150 Surgery 
 
CPT 32402 Surgery 
 
CPT 32440 Surgery 
 
CPT 32445 Surgery 
 
CPT 32480 Surgery Lobectomy 
CPT 32480 Surgery 
 
CPT 32482 Surgery 
 
CPT 32484 Surgery Segmentectomy 
CPT 32486 Surgery 
 
CPT 32488 Surgery 
 
CPT 32491 Surgery 
 
CPT 32500 Surgery Wedge Resection 
CPT 32503 Surgery 
 
CPT 32504 Surgery 
 
CPT 32505 Surgery 
 





CPT 32507 Surgery 
 
CPT 32601 Surgery 
 
CPT 32602 Surgery 
 
CPT 32603 Surgery 
 
CPT 32605 Surgery 
 
CPT 32607 Surgery 
 
CPT 32608 Surgery 
 
CPT 32609 Surgery 
 
CPT 32610 Surgery 
 
CPT 32657 Surgery VATS Wedge Resection 
CPT 32657 Surgery 
 
CPT 32660 Surgery 
 
CPT 32663 Surgery Thoracoscopy 
CPT 32663 Surgery 
 
CPT 32663 Surgery 
 
CPT 32666 Surgery 
 
CPT 32667 Surgery 
 
CPT 32668 Surgery 
 
CPT 32669 Surgery 
 
CPT 32670 Surgery 
 
CPT 32671 Surgery 
 
CPT 32672 Surgery 
 
CPT 32673 Surgery 
 
CPT 32674 Surgery 
 
CPT 38746 Surgery 
 
 
